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ABSTRACT 
Types of Co-existing Chronic Physical Conditions and Newly-diagnosed Depression, its 
Treatment and Economic Outcomes among Medicaid Beneficiaries with Type 2 Diabetes 
Rituparna Bhattacharya, B. Pharm., M.S. 
Diabetes is a widely prevalent metabolic condition. Adults with type 2 diabetes mellitus (T2DM) 
also have many coexisting chronic physical conditions. Coexisting chronic physical conditions 
among individuals with T2DM may be concordant (conditions that overlap with T2DM in their 
pathogenesis and management plans such as cardiovascular diseases) or discordant (conditions 
with unrelated pathogenesis or management plans such as musculoskeletal disorders) or 
dominant (conditions whose severity eclipses all other illness management plans such as 
metastatic cancer). There is documented evidence on the negative consequences of depression in 
adults with T2DM. However, there is only limited knowledge on how the types of coexisting 
chronic physical conditions (defined as concordant, discordant or dominant conditions) influence 
the risk for developing depression, subsequent depression treatment patterns and economic 
consequences of depression treatment, among adults with T2DM. Therefore the aims of this 
dissertation were to examine (1) the association of risk of newly-diagnosed depression with types 
of coexisting chronic physical conditions among adults with T2DM (2) the association between 
types of coexisting chronic physical conditions and depression treatment among adults with 
T2DM and newly-diagnosed depression was analyzed and (3) whether the relationship between 
depression treatment and total and T2DM-related healthcare care expenditures vary by types of 
coexisting chronic physical conditions among non-elderly adult Medicaid beneficiaries with 
T2DM and newly-diagnosed depression. A retrospective longitudinal cohort study design was 
used. Patient-level data were obtained from multi-year, multi-state Medicaid claims. Non-elderly 
(ages 18-64), fee-for-service Medicaid beneficiaries with T2DM who were depression free were 
followed for a period of 12 months to identify newly-diagnosed depression. The final study 
population consisted of 59,857 Medicaid beneficiaries of whom N=5,974 had newly diagnosed 
depression. After controlling for other risk factors, those with dominant conditions were at 17% 
higher risk (p=0.0006) and those with both concordant and discordant conditions were found to 
be at 30% higher risk (p<.0001) to develop newly-diagnosed depression as compared to those 
with concordant conditions only. Individuals with dominant conditions (p<0.05) were less likely 
to receive depression treatment with only antidepressants compared to those with discordant 
conditions only. Individuals with dominant conditions were more likely to receive depression 
treatment with only psychotherapy (p<.01) as compared to those with discordant conditions only. 
No statistically significant associations were observed between types of coexisting chronic 
physical conditions and receipt of adequate depression treatment. As compared to no depression 
treatment, treating depression reduced total healthcare expenditures. As compared to no 
depression treatment, treatment with only antidepressants was associated with 17% reduction in 
total healthcare expenditures, treatment with only psychotherapy was associated with 22% 
reduction in total healthcare expenditures and treatment with both antidepressants and 
psychotherapy was associated with 28% reductions in total healthcare expenditures. As 
compared to no depression treatment, treatment with both antidepressants and psychotherapy 
was associated with reductions in total healthcare expenditures among all types of coexisting 
chronic physical condition groups. In summary, these results indicate that among adults with 
T2DM, newly-diagnosed depression rates, its treatment and economic benefits vary by types of 
coexisting chronic physical conditions. 
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CHAPTER 1: Background and Significance 
 
Epidemiology of Type 2 Diabetes and Depression 
 
Diabetes is a widely prevalent metabolic condition. According to a World Health 
Organization report recently updated in 2014, 347 million people around the world suffer from 
diabetes [1].  In the US, based on 2005-2008 National Health and Nutrition Examination Survey, 
25.6 million individuals i.e. 11.3% of the US population who were 20 years or older had diabetes 
[2]. It has been estimated that among adults with a diagnosis of diabetes, 90%-95% suffer from 
type 2diabetes mellitus (T2DM) [2, 3].  
Depression is a highly disabling, yet very commonly prevalent psychiatric condition with 
worldwide new diagnosis (i.e. incidence) rates of 3%. Depression has been reported to be the 
second leading cause of disability as defined by years lived with disability (YLD) estimates [4]. 
In the US, over a period of 12 months, 5.28% of the population has been found to be affected by 
depression [5]. Coexisting depression leads to significant disease burden in terms of impaired 
cognition, reduced quality of life, increased mortality risk, social dysfunction and financial 
burden [6]. Presence of depression among adults with chronic medical illnesses is associated 
with high risk of mortality, increased disability and poor adherence to self-care regimens. 
Adults with T2DM are considered to be a high risk of developing depression. Pooled 
estimates from two  previous meta-analyses [7, 8] examining the association of T2DM and 
depression have found that the risk of developing depression among individuals with T2DM, 
range from 15% (Relative Risk (RR): 1.15; 95% CI 1.02–1.30) [8]  to 24% (RR: 1.24; 95% CI 
1.09–1.40) [7]. 
 
[3] 
 
Coexisting chronic physical conditions, T2DM and Depression 
 
Among adults with T2DM, coexisting chronic physical conditions are often the norm 
rather than exception and presence of such conditions affect the management of T2DM. Adults 
with T2DM and coexisting chronic physical conditions often experience confusion, frustration 
and feelings of being overwhelmed, perhaps due to several different and sometimes conflicting 
recommendations from clinicians with regard to management of their conditions [9]. Therefore, 
adults with T2DM and coexisting chronic physical conditions are at risk for developing 
depression. Using the Canadian National Population Health Survey (NPHS), a study found that 
as compared to the 2.8% (95% Confidence Interval (CI):2.2–3.4) rate of new major depressive 
episodes among those no long term medical condition, those with any long term medical 
condition had a 4% (95% CI: 3.3–4.7) rate of major depressive episode; long term medical 
conditions included hypertension, food allergies, other allergies, asthma, arthritis/„rheumatism‟, 
back problems, migraine headaches, sinusitis, diabetes, heart disease, peptic ulcers/gastritis and 
chronic bronchitis/emphysema [10]. Another study conducted in the US examined the risk of 
development of significant depressive symptoms after a new diagnosis of several different 
chronic conditions [11]. This study found that within 2 years of initial diagnosis, those with 
cancer were 3.55 times (Hazards Ratio (HR): 3.55; 95% CI: 2.79-4.52), those with chronic lung 
disease had 2.21times (HR: 2.21; 95% CI:1.64-2.97) and those with heart disease had 1.45 times 
(HR:1.45; 95% CI: 1.09-1.93) higher risk of developing depressive symptoms [11]. 
Relationship between types of physical conditions and risk of depression  
 
It is plausible that adults with T2DM and coexisting chronic physical conditions with 
similar disease management strategies may be at a lower risk for developing depression 
compared to those with coexisting chronic physical conditions that may require contradicting 
[4] 
 
clinical and self-management strategies. Only six these studies, controlled for types of coexisting 
chronic physical conditions while estimating the risk of developing depression among adults 
with T2DM [12-17] as compared to adults with no T2DM. Some of these studies [13] [17] found 
that coexisting chronic physical conditions were significantly associated with risk of depression, 
while other studies [12] [14] found that coexisting chronic physical conditions were not 
significantly associated with risk of depression. De Jonge et al., [16] controlled for the 
interaction of T2DM and coexisting chronic conditions in their model, but this interaction was 
not significantly associated with risk of newly diagnosed depression (p-value=0.26). Maraldi et 
al., [15] article did not report the estimates on the association between coexisting chronic 
conditions and newly diagnosed depression, but found that controlling for coexisting conditions, 
the significant association between T2DM and incident depression disappeared. Therefore, 
except the one study by De Jonge et al., [16] which controlled for an interaction term, no other 
study has examined the association between coexisting conditions and newly diagnosed 
depression among adults with T2DM. However, in this study coexisting conditions were 
measured by counting the number of medication classes prescribed. Therefore, no existing study 
has examined whether among individuals with T2DM, types of coexisting chronic physical 
conditions affect the risk of depression. As a majority of individuals with T2DM live with 
multiple other coexisting chronic physical conditions, it is essential to examine whether 
individuals with different types of coexisting chronic physical conditions are at higher risk of 
developing depression as compared to other groups. 
Relationship between types of chronic physical conditions and treatment of depression  
 
A handful of studies have indirectly examined the association between types of 
coexisting chronic physical conditions and depression treatment patterns among individuals with 
[5] 
 
T2DM. However, coexisting chronic physical conditions in these studies were measured using 
either comorbidity indices [18, 19] or number of coexisting conditions [20]. Two of these studies 
found that the number of coexisting chronic condition variable or the comorbidity index variable 
was not significantly associated with receipt of depression treatment [18, 20]. On the contrary, in 
the study among Medicaid beneficiaries with T2DM by Sambamoorthi et al.,[19]  it was reported 
that individuals with higher burden from coexisting conditions, were more likely to receive 
antidepressants compared to those with no burden from coexisting conditions. However, since 
these studies used comorbidity indices or number of chronic condition variable in their analyses, 
there is an existing knowledge gap regarding how different types of coexisting conditions may 
effect depression treatment among individuals with T2DM and coexisting chronic physical 
conditions. 
Additionally, no study has examined the relationship between adequate depression 
treatment and types of chronic physical conditions, among non-elderly adults with T2DM. 
Coexisting chronic physical conditions may be associated with whether an individual received 
adequate depression treatment. For example, many adults with T2DM also have coexisting 
cardiovascular diseases, physicians may be cautious in prescribing adequate antidepressant 
treatment for adults with T2DM and coexisting chronic physical conditions such as hypertension 
and heart disease. As depression treatment often competes with treatment for other conditions, 
among individuals with multiple coexisting conditions, it is possible that even those who start 
depression treatment may not get the “adequate” treatment as per guidelines for depression 
treatment. Adequate depression treatment is one of the quality measures included in National 
Committee for Quality Assurance's (NCQA) Healthcare Effectiveness Data and Information Set 
(HEDIS). These quality measures are used by various health plans including Medicaid and other 
[6] 
 
organizations in the US for the purpose of accreditation, accountability and quality improvement.  
Therefore, there is a need to analyze the association of adequate depression treatment with type 
coexisting chronic physical conditions, among individuals with T2DM and a newly diagnosed 
depression. 
Economic benefits of treating depression and its association with types of chronic physical 
conditions 
 Studying the economic benefits of treating depression among adults with T2DM has 
become a necessity because of rising healthcare expenditures of T2DM and policy efforts 
towards cost-containment strategies. According to the American Diabetes Association, the direct 
medical care expenditures of diagnosed diabetes has increased from $245 billion in 2012 from 
$174 billion in 1997[21]. Among adults with diabetes, healthcare expenditures in specific 
populations are higher than others. For example, among individuals with diabetes, those with 
coexisting depression could have mean total annual healthcare expenditures 4.5 times higher 
($247,000,000) compared to those without depression ($55,000,000) [22]. Healthcare payers 
need to understand if depression management is associated with reduced healthcare expenditures 
in presence of T2DM and multiple coexisting conditions. Randomized controlled trials [23-25]  
have shown that among individuals with T2DM, depression treatment with pharmacotherapy 
and/or psychotherapy using stepped care or algorithm based approach in collaborative care 
settings are cost-effective. However, the economic benefits of treating depression among adults 
with T2DM in real-world practices and how the relationship varies by types of coexisting 
chronic physical conditions are not known.  
Need for Using Non-Elderly Medicaid Population 
It is particularly important to study this association in non-elderly population given that, 
in recent years, the prevalence of multiple coexisting chronic conditions, which has traditionally 
[7] 
 
been thought of as a problem in the elderly population, has been increasing among non-elderly 
adults. In the US, among adults in the age group 45-64 years, the prevalence of multiple 
coexisting chronic conditions has grown from 24.5% in 2004 to 28.1% in in 2010 [26]. In the 
US, State Medicaid Plans are a major provider of health insurance among non-elderly adults. As 
of 2010, 27% of US adults, 20-64 years of age were covered by Medicaid [16]. Adults with 
diabetes are disproportionately covered by Medicaid and four out of five Medicaid beneficiaries 
with diabetes suffer from a coexisting chronic physical condition. It has been reported that 
among Medicaid enrollees, those with diabetes spend 2.5 times more than those without diabetes 
[27]; 20% of Medicaid enrollees are diagnosed with depression [28, 29]. According to Agency of 
Healthcare Research and Quality 2011 statistical brief, mood disorders which includes 
depression ranks top most among the ten conditions for 30 day readmission in Medicaid resulting 
in 41,600 readmissions and costing $286 million [30]. Depression is also a major driver for poor 
health outcomes and future healthcare expenditures in T2DM [31]. Given such compelling 
statistics, it is apparent that Medicaid data provides a rich opportunity to conduct research of 
both depression and T2DM, and can lead to important findings that might influence clinical 
practice and policy. Therefore, delineating relationship between depression, its treatment and 
healthcare expenditures among Medicaid enrollees with T2DM and understanding how types of 
coexisting chronic physical conditions impact this association is necessary in the high risk 
Medicaid population. 
Theoretical Framework Used to Categorize Types Of Coexisting Chronic Physical Conditions 
 
Existing theoretical framework developed by Piette and Kerr has categorized forty-four 
different chronic physical illnesses commonly coexisting with T2DM into concordant, discordant 
and dominant conditions using ICD-9-CM codes [44]. Piette and Kerr had developed this novel 
[8] 
 
theoretical framework for categorizing coexisting chronic physical conditions based on how 
these conditions had an impact on the medical care, self-management, and healthcare outcomes 
of an individual with T2DM. This framework suggested that studies which used one-dimensional 
scores or number of coexisting conditions to assess the impact of coexisting conditions on T2DM 
care, implicitly assumed that all conditions have similar impact on T2DM care. However, such 
studies fail to identify whether characteristics specific to coexisting conditions impact patient 
priorities for T2DM care. Based on typologies of coexisting conditions, the theoretical 
framework developed by Piette and Kerr identified coexisting conditions among individuals with 
T2DM as: dominant (conditions whose severity eclipses all other conditions‟ management plans 
such as metastatic cancer), concordant (conditions that overlap with T2DM in their 
pathophysiology and management plans such as cardiovascular diseases) and discordant 
(conditions with unrelated pathophysiology or management plans such as musculoskeletal 
disorders) [32].  
Though this study does not assess outcomes related to T2DM, the same theory may be 
applied to development of newly-diagnosed depression. Based on disease pathophysiology 
pathophysiology and similarity or differences with T2DM management, dominant, concordant 
and discordant conditions may have different risks associated with development of newly-
diagnosed depression, its treatment and economic outcomes of depression treatment. Therefore, 
based on Piette and Kerr‟s framework, a hierarchical classification [33]  was used to categorize 
forty four physical conditions which are found commonly coexisting with. Dominant conditions 
were given priority in the hierarchical classification because such conditions eclipse the 
management of other health conditions. Among those without dominant conditions, concordant 
and discordant conditions were identified. The types of coexisting chronic physical conditions 
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were classified as: 1) Dominant Conditions, 2) Concordant only, 3) Discordant only and 4) Both 
concordant and discordant. The conditions were identified using ICD-9-CM codes and are 
presented in Appendix A. 
Research Objectives and Hypotheses 
 
Aim 1: Among non-elderly (18-64 years) Medicaid beneficiaries with T2DM, examine whether 
risk of newly-diagnosed depression vary by types of coexisting chronic physical conditions. 
Hypothesis 1.1: Adults with dominant, both concordant and discordant conditions and 
discordant conditions only would have higher risk of newly-diagnosed depression as compared 
to individuals with concordant conditions only 
Aim 2: Objective 1.1: Examine the association between types of coexisting chronic physical 
conditions and depression treatment (antidepressants only, psychotherapy only, both 
antidepressants and psychotherapy and none), after adjusting for other covariates among non-
elderly (18-64 years) fee-for-service Medicaid beneficiaries with T2DM and newly-diagnosed 
depression, 
Aim2: Hypothesis 1.1: As compared to individuals with discordant conditions only, those with 
concordant conditions would be less likely to receive treatment with antidepressants.   
Aim 2: Objective 1.2: Evaluate the association between types of coexisting chronic physical 
conditions and receipt of adequate depression treatment (yes, no), after adjusting for other 
covariates among non-elderly (18-64 years) fee-for-service Medicaid beneficiaries with T2DM 
and newly-diagnosed depression who received either antidepressants or psychotherapy. 
Aim 2: Hypothesis 1.2: As compared to individuals with discordant conditions only, those with 
dominant conditions would be less likely to receive adequate depression treatment. 
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Aim 3: Objective 3.1: Among non-elderly Medicaid beneficiaries with T2DM and newly-
diagnosed depression, examine the association depression treatment categories and total and 
T2DM-related healthcare care expenditures.  
Hypothesis 3.1: As compared to those with no depression treatment, those with depression 
treatment with only antidepressants, only psychotherapy or both, will have negative associations 
with total and T2DM-related healthcare expenditures as compared no depression treatment. 
Aim 3.2: Among non-elderly Medicaid beneficiaries with T2DM and newly-diagnosed 
depression, examine whether the association between depression treatment and total and T2DM-
related medical care expenditures vary by types of coexisting chronic physical conditions.  
Hypothesis 3.2.1: As compared to no depression treatment, treatment within both 
antidepressants and psychotherapy will reduce total and T2DM related healthcare expenditures 
across all conditions.  
Hypothesis 3.2.2: Depression treatment with only antidepressants will not be associated with 
T2DM related healthcare expenditures among those with concordant conditions only.  
[11] 
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CHAPTER 2: Type of Coexisting Chronic Physical Conditions and the Risk of Newly-
diagnosed Depression among Medicaid Beneficiaries with Type 2 Diabetes 
Introduction 
Epidemiology of Diabetes 
 
Diabetes is a widely prevalent metabolic condition. According to a World Health 
Organization report recently updated in 2014, 347 million people around the world suffer from 
diabetes [1].  In the US, based on 2005-2008 National Health and Nutrition Examination Survey, 
25.6 million individuals i.e. 11.3% of the US population who were 20 years or older had diabetes 
[2]. It has been estimated that among adults with a diagnosis of diabetes, 90%-95% suffer from 
type 2diabetes mellitus (T2DM) [2, 3].  
Epidemiology of Depression 
Depression is a highly disabling, yet very commonly prevalent psychiatric condition with 
worldwide new diagnosis (i.e. incidence) rates of 3%. Depression has been reported to be the 
second leading cause of disability as defined by years lived with disability (YLD) estimates [4]. 
In the US, over a period of 12 months, 5.28% of the population has been found to be affected by 
depression [5].  With the elimination of “bereavement exclusion” for clinical diagnosis of 
depression under Diagnostic and Statistical Manual-5 (DSM-5), the rates of new diagnosis of 
depression is expected to rise further [6]. 
T2DM and Risk of Newly-diagnosed Depression  
Adults with T2DM are at a high risk of developing depression.  Prospective and 
retrospective studies have examined the risk of developing depression among adults with T2DM 
by comparing them to those without T2DM [7-20].  These studies were  based on data from 
different countries; four were from the Netherlands [7, 8, 10, 20], one each from Norway [9], 
Korea [11], Canada [12] and Taiwan[13] and six from the US [14-19] . Rates of newly-
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diagnosed depression in these studies varied because of differences in study design, lengths of 
follow-up, settings and measurement of depression. The minimum length of follow-up was 2 
years [11] and the maximum was 12 years [12]. Twelve [7-11, 14-18, 20] of these studies had a 
prospective design and the remaining three were retrospective observational in design [12, 13, 
19]; two studies assessed rates of newly-diagnosed depression after combining data from two 
different time points (years 2 and 5) to [7, 8]. Some studies identified depression using diagnosis 
scales such as the Center for Epidemiologic Studies Depression Scale (CES-D) [7, 16, 17], 
Edinburgh Depression Scale (EDS) [20], Beck Depression Inventory (BDI)[14], Mental Health 
Index (MHI-5), a five-item subscale of the Short-Form 36 Health Status [18], Hospital Anxiety 
and Depression Scale - Depression (HADS-D) [9], Geriatric Mental State B3 Diagnostic 
Schedule with application of the Automated Geriatric Examination for Computer-Assisted 
Taxonomy algorithm (GMS-AGECAT) [8]; others used inpatient or outpatient diagnosis codes 
for depression as identified by physicians [13], alone or in conjunction with  antidepressant drug 
use [12, 19], to identify newly-diagnosed depression.  
The adjusted odds ratio (AOR) and 95% confidence interval (CI) estimates for newly-
diagnosed depression in studies using diagnosis scales varied from (AOR: 0.73; 95% CI: 0.41–
1.30) [14] to (AOR: 1.54; 95% CI: 1.13–2.09) [17] and the estimates ranged from (AOR: 1.10; 
95% CI: 1.01–1.19) [12] to (AOR:1.48; 95% CI: 1.35–1.63) [19] for studies using diagnosis 
codes. Meta-analyses that have included majority of these studies have concluded that the risk of 
developing depression among individuals with T2DM, ranged from 15% (Adjusted Relative Risk 
(ARR): 1.15; 95% Confidence Interval: 1.02–1.30) [21]  to 24% (ARR: 1.24; 95% CI 1.09–1.40) 
[22]. The Mezuk et al., meta-analysis [23] included 7 studies and the other meta-analysis by 
Nouwen et al., which was published later, included 11 studies [22].  
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Many of the above-mentioned studies did not differentiate between depressive symptoms 
and major depression. Often self-reported depression based on diagnostic scales was used [7, 9, 
14-17]; newly-diagnosed depression was identified as appearance of “depressive symptoms”, 
defined by a pre-validated cut-off score on the diagnosis scales, e.g. >=16 on CES-D scale, >=12 
on EDS, >=8 on HADS-D,  <=52 on MHI-5.  Self-reports may overestimate the extent of 
depressive symptoms and there is discordance between rates of newly-diagnosed depression 
identified by scores on self-reported depression scales and depression identified by diagnostic 
schedules such as Diagnostic Statistical Manual (DSM-IV) [24]. On the other hand, the study by 
Brown et al., [12] identified depression by including use of antidepressants along with physician 
recognized clinical diagnosis code for depression. However, studies have reported that  two 
thirds of individuals with depression is often not treated [25]. Therefore, use of antidepressants 
as a criterion for identifying depression may lead to underestimated rates. Additionally, these 
studies compared risk of depression among those with T2DM as compared to those without 
T2DM. None of them examined whether risk of depression differed among subgroups of 
individuals with T2DM and coexisting conditions. 
Coexisting Chronic Physical Conditions among Adults withT2DM 
Among adults with T2DM coexisting chronic physical conditions are often the norm 
rather than the exception and presence of such conditions affect the management of T2DM. 
According to Medical Expenditure Panel Survey data, majority of adults (88.6%) with T2DM in 
the United States (US) have at least one chronic condition and 15% have reported having four or 
more chronic conditions [26]. Based on similarity or difference from T2DM management and 
pathophysiology, types of coexisting chronic physical conditions among individuals with T2DM 
may be concordant (conditions that overlap with T2DM in their pathophysiology and 
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management plans such as cardiovascular diseases), discordant (conditions with unrelated 
pathophysiology or management plans such as musculoskeletal disorders), or dominant 
(conditions whose severity eclipses all other conditions‟ management plans such as metastatic 
cancer) [27]. Among 42,826 Veterans with T2DM, it has been found that 12% had dominant 
conditions, 13% had concordant only, 30% had discordant only and 25% had both concordant 
and discordant [28].There is evidence that types of coexisting chronic physical conditions affect 
T2DM management [28] 
Coexisting Chronic Physical Conditions and Risk of Depression 
Coexisting depression in adults with chronic physical conditions often lead to impaired 
cognition, reduced quality of life, increased mortality, social dysfunction and financial burden 
[29].  Therefore, individuals with coexisting chronic physical conditions are at particularly high 
risk of developing depression. Using the Canadian National Population Health Survey, a study 
found that rates of new major depressive episodes among those with no long term medical 
conditions were lower as compared to those with any long term medical condition (2.8% (95% 
CI:2.2–3.4) vs 4% (95% CI: 3.3–4.7); long term medical conditions included hypertension, food 
allergies, other allergies, asthma, arthritis/„rheumatism‟, back problems, migraine headaches, 
sinusitis, diabetes, heart disease, peptic ulcers/gastritis and chronic bronchitis/emphysema [30]. 
Another study conducted in the US examined the risk of development of significant depressive 
symptoms after a new diagnosis of several different chronic conditions [15]. This study found 
that within 2 years of initial diagnosis, the risk of developing depressive symptoms was, 3.55 
times higher among with cancer (Hazards Ratio (HR): 3.55; 95% CI: 2.79-4.52), 2.21 times 
higher among those with chronic lung disease had (HR: 2.21; 95% CI:1.64-2.97) and 1.45 times 
higher among those with heart disease (HR:1.45; 95% CI: 1.09-1.93) [15].  
[18] 
 
Coexisting Chronic Physical Conditions among Adults with T2DM and Risk of Depression 
 Adults with T2DM and coexisting chronic physical conditions often experience 
confusion, frustration and feelings of being overwhelmed, perhaps due to several different and 
sometimes conflicting recommendations from clinicians with regard to management of their 
conditions [31]. Such feelings may eventually lead to poor emotional health and development of 
depression. To the best of our knowledge no study has evaluated the risk of newly-diagnosed 
depression by types of coexisting chronic physical conditions among adults with T2DM.   
Therefore, available evidence from studies that have examined the risk of newly-diagnosed 
depression after controlling for coexisting conditions, among adults with T2DM as compared to 
those without T2DM, has been parsed.  
Only six of the fifteen studies that examined the risk of depression among adults with 
T2DM  controlled for types of co-existing chronic physical conditions in their multivariable 
analyses [8, 10, 12, 16, 17, 19]. Some of these studies [12] [19] found that coexisting chronic 
physical conditions were significantly associated with an increased risk of depression, while 
other studies [10] [17] found that coexisting chronic physical conditions were not significantly 
associated with risk of depression. Maraldi et al., [16] did not report the estimates of the 
association between coexisting conditions and newly-diagnosed depression, but found that 
controlling for coexisting conditions, the significant association between T2DM and newly-
diagnosed depression disappeared.  The study by de Jonge et al., [8] controlled for the interaction 
of T2DM and coexisting conditions, but this interaction was not significantly associated with risk 
of newly-diagnosed depression (p-value=0.26). This may indicate that the risk of newly-
diagnosed depression does not vary by coexisting conditions. However, in this study coexisting 
conditions were measured by counting the number of medication classes prescribed. Therefore, 
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except the one study by de Jonge et al., [8] which controlled for an interaction term, no other 
study has examined the association between coexisting conditions and newly-diagnosed 
depression among adults with T2DM.  
Need for the Study 
Presence of depression among adults with chronic medical illnesses is associated with 
high risk of mortality, increased disability, poor adherence to self-care regimens and high health 
care expenditures [32]. Identification of groups of individuals at high risk of depression can help 
in prevention, timely diagnosis and management of the disease. From the literature discussed, it 
is apparent that individuals with T2DM are at increased risk of developing depression. Presence 
of coexisting conditions may also increase the risk of depression. Since, majority of individuals 
with T2DM live with multiple other coexisting chronic physical conditions [26], it is essential to 
examine whether subgroups of individuals with T2DM and particular types of coexisting chronic 
physical conditions are at higher risk of developing depression as compared to other groups. 
However, with the conspicuous absence of studies relating to association between types of 
coexisting chronic physical conditions in adults with T2DM and risk of depression, a significant 
knowledge gap exists in this area. Therefore, this study intends to fill this knowledge gap by 
examining the risk of depression for different types of coexisting chronic physical conditions 
among adults with T2DM.  
This study focused on adults with T2DM whose healthcare expenses are covered by state 
Medicaid programs. There are several reasons to examine this association among Medicaid 
enrollees. In the US, State Medicaid Plans are a major provider of health insurance among non-
elderly adults. As of 2010, 27% of US adults, 20-64 years of age were covered by Medicaid 
outlaying 68% of federal spending [8]. Adults with diabetes are disproportionately covered by 
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Medicaid and four out of five Medicaid beneficiaries with diabetes suffer from a coexisting 
chronic physical condition. Medicaid enrollees with diabetes spend more than 2.5 times 
compared to those without diabetes [33] and 20% of Medicaid enrollees are diagnosed with 
depression [34, 35]. Mood disorders including depression ranks top most among the ten 
conditions for 30 day readmission in Medicaid programs and costs $286 million [36]. 
Additionally, depression contributes heavily towards poor health outcomes and future healthcare 
costs in T2DM [37]. Based on these statistics, it can be seen that Medicaid data provides a rich 
opportunity to conduct research of both depression and T2DM, and can lead to important 
findings that might influence clinical practice and policy.  
This study identified newly-diagnosed depression from International Classification of 
Diseases 9
th
 Revision ie.ICD-9-CM codes and mainly focused on new diagnoses of major 
depression. The focus on major depression was because, specific treatment guidelines are 
available for major depression, while treatment guidelines for minor depression are not clear 
[38]. Additionally, depression diagnosis from administrative claims data is cheaper compared to 
resource intensive prospective data collection. Additionally, these diagnosis codes have been 
identified by Healthcare Effectiveness Data and Information Set, a tool used by 90% of US 
healthcare plans including Medicaid [23].  
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RESEARCH AIM AND HYPOTHESIS 
 
Aim 1: Among non-elderly (18-64 years) Medicaid beneficiaries with T2DM, examine whether 
risk of newly-diagnosed depression vary by types of coexisting chronic physical conditions.  
Hypothesis 1.1: Adults with dominant, both concordant and discordant conditions and 
discordant conditions only would have higher risk of newly-diagnosed depression as compared 
to individuals with concordant conditions only 
[22] 
 
CONCEPTUAL FRAMEWORK 
An adapted version of the conceptual framework on Determinants of Health Model was 
used to study the risk factors contributing to chronic diseases. In this framework, a variety of 
factors may influence the health and well-being of individuals including development of 
diseases. These factors include environmental factors, geographical location, socioeconomic 
characteristics, knowledge, attitudes and beliefs, health behaviors, psychological factors, safety 
factors, biomedical factors and individual physical and psychological makeup. This study 
focused on biomedical factors i.e. types of coexisting chronic physical condition as risk factor 
disease i.e. newly-diagnosed depression, after controlling for other factors which were chosen 
based on the this framework and the availability of variables in the dataset. The following figure 
presents the adapted theoretical framework used in this study.  
Community Resources  
County level median income,  
Whether the percentage 
below poverty is < national 
average of 11.1% 
Whether the percentage with 
4 year college education is < 
national average of county 
Geographical Location 
Metro Status of County 
 
Socio-economic 
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Access to Care 
Presence of community 
mental health clinic,  
Presence of federally 
quality health care clinic 
Whether county was a 
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shortage area for mental 
health  
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Measured by 
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behaviors; History of 
use of health care 
services such as: 
Outpatient visits, 
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visits, Inpatient 
hospitalizations 
Psychological 
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Presence of other 
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Biological Risk 
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Medication Use 
Use of oral 
antidiabetic 
medication, insulin 
and polypharmacy 
Disease- Newly-
diagnosed 
Depression 
Individual Physical Make-up:  
Age, gender, race 
[23] 
 
METHODS 
Study Design 
A retrospective cohort study design was used for this study. A cohort of Medicaid 
beneficiaries with T2DM who were free of depression during baseline were identified. This 
cohort was then followed in to the following calendar year. Those who received a diagnosis of 
depression in the following year were considered as having newly-diagnosed depression. 
Therefore, individuals classified as having a newly-diagnosed depression had at least a 365 day 
period free of any history of depression diagnosis or antidepressant use.  
  Among those with newly-diagnosed depression, the date of diagnosis was the “index 
date”. Among individuals with no newly-diagnosed depression, the index date was randomly 
chosen from the dates of inpatient and outpatient services received by an individual during the 
calendar year. Baseline period was defined as 12 months prior to the index date. Coexisting 
chronic physical conditions and health care utilization variables were identified during this 
baseline period.  
Data Sources 
Medicaid Analytic Extract (MAX) Files:  
The Centers for Medicare and Medicaid Services prepares the MAX files. These files 
comprise of enrollment (“personal summary”), inpatient claims, other therapy medical claims, 
and pharmacy claims files of Medicaid beneficiaries. These files were linked by beneficiaries‟ 
unique identification number. Information on Medicaid eligibility and demographics 
characteristics were extracted from the personal summary files. Information on diagnoses, use of 
services and Medicaid payments were identified from the other claims files. This study used 8 
years Medicaid data (2000-2007) from three states: New York (NY), Texas (TX), Illinois (IL). 
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Medicaid data use agreement policy specifies that cell sizes less than eleven cannot be displayed 
and percentages or other mathematical formulas may not be used if the result in display has cell 
sizes less than eleven [39]. To ensure that dependent and all independent variable categories had 
enough sample sizes, multiple years of Medicaid data were combined.   
Area Health Resource File (AHRF):  
The AHRF is a publicly available data file provided by Department of Health and Human 
Services [40] which contains county level information on more than six thousand variables. The 
Medicaid files were linked with ARF files with five digit county identification variable. This 
study used AHRF variables such as median household income, percent below poverty level and 
percent with college education in a county, whether the county of residence of the enrollee had 
been designated as a health professional shortage area (HPSA) for mental health services, metro 
status of the county, presence of a Community Mental Health Clinic (CMHC) and a Federally 
Qualified Healthcare Clinic (FQHC) in the county. 
Identification of Study Cohort: Individuals with T2DM and Free of Depression at Baseline  
Using Medicaid data from 2000-2007, seven 2-year cohorts (2000-01, 2001-02, 2002-03, 
2003-04, 2004-05, 2005-06, 2006-07) were identified. Those with at least one inpatient visit or 
two or more physician outpatient visits (which were at least 30 days apart) with a primary or 
secondary diagnosis of International Classification of Diagnosis Codes 9th Revision (ICD-9-
CM) codes: 250.x0 or 250.x2, were identified as having T2DM. The study population excluded 
individuals with a diagnosis for depression and antidepressant medication use, in the calendar 
year. The eligible study population was then followed into the subsequent calendar year to 
identify newly-diagnosed depression.  
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Exclusion criteria for the study cohort were: (1) not having a diagnosis of at least one of the 
forty-four coexisting chronic physical conditions as identified by ICD-9-CM codes included in 
the appendix, during the baseline (2) no use of any inpatient or outpatient services during the 
subsequent calendar year i.e. the calendar year in which newly-diagnosed depression was 
identified (2) no continuous Medicaid eligibility and (3) enrollment in Medicare managed care at 
any point during the observation period; and (4) died during the study period. 
Dependent Variable  
Newly-Diagnosed Depression:  
Among individuals with T2DM, no diagnosis of depression and no  antidepressant use in 
a calendar year, those with at least one inpatient or outpatient diagnosis [41] corresponding to 
ICD9 CM codes: 296.2 (major depressive disorder, single episode), 296.3 (major depressive 
disorder, recurrent episode), 311 (depression not elsewhere classified), 309.1 (prolonged 
depressive reaction), 300.4 (neurotic depression) and 298.0 (depressive type psychosis) in the 
subsequent calendar year, were identified as having newly-diagnosed depression [42, 43] . These 
ICD-9-CM codes were recommended by National Committee for Quality Assurance and had 
been used in previous studies to identify depression among Medicaid enrollees [42-44].  These 
diagnosis codes are also widely used by health plans to identify depression [38].  
Independent Variables 
Key Independent Variable: Types of coexisting chronic physical Conditions:  
Piette and Kerr had developed a novel theoretical framework for categorizing coexisting 
chronic physical conditions based on how these conditions had an impact on the medical care, 
self-management, and healthcare outcomes of an individual with T2DM. This framework 
suggested that studies which used one-dimensional scores or number of coexisting conditions to 
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assess the impact of coexisting conditions on T2DM care, implicitly assumed that all conditions 
have similar impact on T2DM care. However, such studies fail to identify whether characteristics 
specific to coexisting conditions impact patient priorities for T2DM care. Based on typologies of 
coexisting conditions, the theoretical framework developed by Piette and Kerr identified 
coexisting conditions among individuals with T2DM as: dominant (conditions whose severity 
eclipses all other conditions‟ management plans such as metastatic cancer), concordant 
(conditions that overlap with T2DM in their pathophysiology and management plans such as 
cardiovascular diseases) and discordant (conditions with unrelated pathophysiology or 
management plans such as musculoskeletal disorders) [27].  
Though this study does not assess outcomes related to T2DM, the same theory may be applied to 
development of newly-diagnosed depression. Based on disease pathophysiology 
pathophysiology and similarity or differences with T2DM management, dominant, concordant 
and discordant conditions may have different risks associated with development of newly-
diagnosed depression. Therefore, based on Piette and Kerr‟s framework, a hierarchical 
classification [28]  was used to categorize forty four physical conditions which are found 
commonly coexisting with T2DM and this variable was to examine the association between 
types of coexisting chronic physical conditions and risk of newly-diagnosed depression. These 
conditions were identified using ICD-9-CM codes and are presented in Appendix A. Dominant 
conditions were given priority in the hierarchical classification because such conditions eclipse 
the management of other health conditions. Among those without dominant conditions, 
concordant and discordant conditions were identified. The types of coexisting chronic physical 
conditions were classified as: 1) Dominant Conditions, 2) Concordant only, 3) Discordant only 
and 4) Both concordant and discordant.  
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Other independent variables:  
The other independent variables were selected based on the Determinants of Health Model. 
Individual Physical Make-up: The variables included were: age, sex, race/ethnicity [Whites, 
African Americans, Hispanics or other races]); 
Psychological Factors: Defined by presence of other mental health conditions in the baseline. 
The other mental health conditions included bipolar disorder, schizophrenia, post-traumatic 
stress disorder, and alcohol and drug abuse. 
Medication Use: The variables included were: number of oral antidiabetic medication classes 
and insulin use as identified by national drug codes (NDC), presence of polypharmacy identified 
by use of 6 or more drug classes in the 90 days prior to index date; 
Healthcare Seeking Behavior: The variables included were: baseline healthcare utilization 
factors (number of emergency room visits in 180 days prior to index date, inpatient 
hospitalization, number of outpatient visits measured in quartiles); 
Community Level Access to Care: The variables included were: whether county of residence had 
a community mental health clinic (CMHC) and federally qualified health clinic (FQHC), 
whether county of residence designated as urban area and Health Professional Shortage area 
(HPSA) for mental health;  
Community Resources: The variables included were: median income in the county, whether 
percent below poverty level and percent with college education greater than national average 
based on US census estimates [45, 46]. 
Additionally, the model also controlled for year of observation. 
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Statistical Analysis  
Unadjusted Analyses: 
Descriptive analysis using frequency and mean and standard errors were conducted. Chi-square 
tests were used to examine unadjusted association between baseline characteristics and types of 
coexisting chronic physical conditions. Unadjusted associations between types of coexisting 
chronic physical conditions and newly-diagnosed depression were also examined with chi-square 
tests.  Chi-square tests were also used to examine the associations between types of coexisting 
chronic physical conditions and newly-diagnosed depression for each group of the categorical 
independent variables. 
Adjusted Analyses: 
Multivariable complementary log-log regressions were performed used to examine the risk of 
newly-diagnosed depression associated with types of coexisting conditions. As the authors 
intended to estimate “risk” of newly-diagnosed depression instead of “odds”, the complementary 
log-log regressions were used instead of logistic regression, which are in general used to estimate 
the associations between independent variables and binary dependent variable. It has been shown 
that odds ratio often fail to give approximation of risk, especially when disease rates are close to 
10% or more  [47]. Complementary log-log regression has been shown to be an alternative 
statistical model to estimate risk [48] and has been used in previous studies [49]. Regression 
coefficients from complementary log-log regressions were exponentiated to derive the risk ratios 
(RR) and adjusted risk ratios (ARR) of newly-diagnosed depression associated with types of 
coexisting conditions; 95% upper and lower confidence intervals for RRs and ARRs were 
calculated by respectively adding and subtracting 1.96 from the exponentiated standard errors 
from complementary log-log regressions. 
[29] 
 
Self-management of conditions are especially difficult when coexisting conditions have widely 
varying modes of management; individuals with concordant conditions which have similar mode 
of management as T2DM may therefore may be at lesser risk of developing depression as 
compared to discordant or dominant conditions. Thus, “concordant conditions only” was used as 
the reference group in regression analyses. Multiple regression models were examined. In model 
1, only types of coexisting conditions were included; in model 2 individual physical make-up 
and year of observation were included; in model 3 the presence of other psychological factors, 
medication use and healthcare seeking behavior were added and the final model 4 consisted of 
all the variables in model 3 and additionally included community level access to care and 
community resources variables. All analyses were done using Statistical Analytic Software 
(SAS) version 9.3. 
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RESULTS 
Characteristics of the Study Population 
The study population consisted of 59,857 non-elderly, fee-for-service and continuously 
enrolled Medicaid beneficiaries with T2DM who were depression free during baseline, not 
dually eligible for Medicare and alive during the study period. Description of the study 
population is presented in Table 1. Majority of the study population were older adults (53.2%) 
between 55 and 64 years and females (62.9%); 25.2% were Whites and 30.4% were African 
Americans and 44.4% were other races. Majority of the counties of residence were metro areas 
(86.9%); 84.4% of counties had shortage of mental health professionals and 53.3% of counties 
did not have a CMHC.  
Study Population Characteristics by Types of Coexisting Chronic Physical Conditions 
Table 1 also presents a description of study population by types of coexisting conditions. 
In the study population, 11.2% had dominant conditions, 35.9% had concordant conditions only, 
17.7% had discordant conditions only and 35.2% had both concordant and discordant conditions. 
All study characteristics differed significantly among the types of coexisting condition 
subgroups. For example, a greater percentage of individuals with dominant conditions were older 
i.e.55-64 years (12.8% vs 6.7% in 18-44 years age-group), males (12.7% vs 10.3% in females), 
had presence of other mental health conditions (17.6% vs 10.1% with absence of other mental 
health conditions), inpatient hospitalizations (19.6% vs 6.7% in those without) and higher 
number of outpatient visits (19.6% in 4
th
 vs 4.6% in 1
st
 quartile).  
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Unadjusted Associations between Types of Coexisting Chronic Physical Conditions and 
Newly-Diagnosed Depression 
Overall, 10% of Medicaid enrollees with T2DM had newly-diagnosed depression during 
the follow up year. The rate of newly-diagnosed depression was highest among those with 
dominant conditions (13.1%) followed by both concordant and discordant conditions (12.2%), 
discordant conditions only (8.7%) and concordant conditions only (7.5%). Chi-square analysis 
showed that newly-diagnosed depression rates significantly differed by types of coexisting 
chronic physical conditions (P<0.001). This significant association between types of coexisting 
chronic physical conditions and newly-diagnosed depression was observed among all categories 
of independent variables.  
Relationships between Types of Coexisting Chronic Physical Conditions and Newly-
Diagnosed Depression 
Model 1, adjusted for the type of coexisting chronic physical conditions.  In this model,  
as compared to Medicaid beneficiaries with concordant conditions, those with dominant 
conditions were at 81% higher risk (Adjusted Risk Ratio (ARR): 1.81; 95% Confidence Interval 
(CI): 1.67,1.96; p<0.001), those with both concordant and discordant conditions were at 67% 
higher risk (AOR: 1.67; 95% CI: 1.57, 1.77; p<0.001) and those with discordant conditions were 
at 18% (ARR: 1.18; 95% CI: 1.09,1.28; p<0.001)  higher risk to develop newly-diagnosed 
depression.  
This statistically significant higher risk of newly-diagnosed depression among those with 
dominant, both discordant and concordant conditions and discordant conditions only as 
compared to those with concordant conditions only persisted in Model 2 which controlled for 
individual physical make-up such as age, sex and race and year of observation. In model 3, the 
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significant association between discordant conditions and newly-diagnosed depression 
disappeared, after additionally controlling for other psychological factors, medication use and 
healthcare seeking behaviors such as inpatient, outpatient and emergency room visits. After 
controlling for county level variables such as community level access to care and community 
resources variables in the fully adjusted model 4, those with dominant conditions were at were at 
17% higher risk (ARR: 1.17; 95% CI: 1.07, 1.20; p=0.0006) and those with both concordant and 
discordant conditions were found to be at 30% higher risk (ARR: 1.30; 95% CI: 1.22, 1.39; 
p<.0001) to develop newly-diagnosed depression as compared to those with concordant 
conditions only. Results of multivariable complementary log-log regression analyses are 
presented in Table 3. Appendix B presents ARRs and 95% CIs of all independent variables 
controlled in the models. 
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DISCUSSION 
 This study examined whether the risk of newly-diagnosed depression differed by types of 
coexisting chronic physical conditions among non-elderly fee-for-service Medicaid beneficiaries 
with T2DM. Overall, 10% of the study population had newly-diagnosed depression. Even after 
controlling for all baseline variables, it was found that Medicaid beneficiaries with T2DM and 
dominant conditions and also those with both concordant and discordant conditions were at 
higher risk of developing newly-diagnosed depression as compared to those with concordant 
conditions only.  
The dominant conditions in our study included diseases such as cancer, Alzheimer‟s and 
Parkinson‟s diseases. These diseases carry very high burden in terms of mortality and disability 
[50, 51].   Therefore, it is not surprising that individuals with T2DM and dominant conditions 
were at higher risk of developing newly-diagnosed depression, as compared to those with 
concordant conditions only. Coexisting life threatening illnesses such as cancer can negatively 
impact self-management behaviors among individuals with T2DM. For example, among those 
with both cancer and T2DM, Hershey et al., observed that, after 8 weeks of chemotherapy, 
individuals were able to perform significantly lower number of T2DM self-management 
behaviors; the most affected behaviors were exercising, ability to eat and drink, and blood sugar 
monitoring [52]. Neurological conditions such as Parkinson‟s diseases has been said to cause 
changes in brain chemistry that may lead to depression [53].  
Presence of discordant conditions such as respiratory problems and arthritis are also 
highly disabling [54]. When such discordant conditions are present along with other concordant 
conditions, individuals may feel overwhelmed. It has been found that about one third of 
individuals with both T2DM and arthritis never or rarely exercise owing to reasons such as 
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concerns about aggravating arthritis pain, fear about causing further joint damage, uncertainty 
about which types and amounts of activity are safe for their joints [55]. In general, among 
individuals with chronic obstructive pulmonary disease (COPD), dyspnoea i.e. breathlessness 
triggered by exercise severely limits physical activity [56, 57]. However, regular exercise is 
essential for management of concordant conditions such as hypertension and cardiovascular 
conditions. Thus coexistence of such conditions may be overwhelming and may cause poor self-
management of conditions. It has been observed that among adults with diabetes, higher number 
of macro- and micro-vascular and non-diabetes related coexisting conditions are associated with 
poor self-management [58].  Inability to manage conditions effectively may lead to feelings of 
frustration and guilt, subsequently leading to depression.  
Implications 
The study results have important clinical and policy implications. As a part of the Patient 
Protection and Affordable Care Act (PPACA) passed in 2010, many states have expanded their 
Medicaid coverage to individuals at or below 138% of the Federal poverty level. Therefore, a 
greater number of individuals who were previously uninsured are now covered by state Medicaid 
programs. Illinois and New York are among the twenty-eight states that decided to expand their 
Medicaid programs as of 2014. It is expected that with the new expansion, 571,000 individuals in 
Illinois and 631,000 individuals in New York may gain access to Medicaid [59]. An analysis of 
the 2009 Medical Expenditure Panel Survey data showed that 5% of uninsured individuals at or 
below 138% of Federal poverty level, who may become newly eligible for Medicaid as a result 
of the expansion had diabetes and 64% of these individuals had at least one coexisting chronic 
physical condition [33]. Based on the results of the current study, it may be speculated that these 
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individuals, if they already do not have prevalent depression, may be at high risk of developing 
newly-diagnosed depression.  
Challenges of coexisting depression among those with T2DM are many and include 
increased risk of complications, increased health care expenditures and also increased risk of 
mortality [32]. Individuals with T2DM are considered to be at higher risk for newly-diagnosed 
depression [21]. Coexisting chronic physical conditions which may aggravate this risk should be 
closely monitored and screened for depression. Given the higher risk of newly-diagnosed 
depression among individuals with dominant and among those with both concordant and 
discordant conditions, such individuals should be regularly screened for depression in primary 
care settings.  The U.S. Preventive Services Task Force (USPSTF) recommends depression 
screening in all adults and the recommendation has also been supported by American College of 
Preventive Medicine. Depression screening among adults with T2DM has also been 
recommended by American Diabetes Association [60]. However, these recommendation only 
applies to clinical settings with that have systems in place with care management and staff 
assistance for depression care as in absence of such systems, appropriate diagnosis, treatment 
plan and follow-up of depression may not be feasible [61], thereby  rendering screening efforts 
ineffective.   
The PPACA promotes such integrated care through patient centered medical homes 
(PCMH) and Accountable Care Organizations (ACO). The PCMH model promotes team based 
approaches to patient care. Such settings can form teams with primary care physicians, mental 
health care specialists and a care managers so as to regularly screen for depression among 
individuals with varying types of coexisting chronic physical conditions and do appropriate 
follow-up with care managers in case a diagnosis for depression is made [62]. Performance 
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measures for Accountable Care Organizations also include screening for depression [63].  
Provision of such novel health care systems may go a long way in timely diagnosis of depression 
among individuals with T2DM and coexisting chronic physical conditions. 
Strengths and Limitations 
The study has many advantages. The use of administrative claims data allowed for the 
identification of T2DM, depression and a wide array of physical and other mental conditions and 
additionally, helped in establishing a 365 day depression free period. Unlike previous studies 
which have used a 120 day depression free period to define newly-diagnosed depression [64], 
using a greater look-back period of 365 days may minimize the misclassification of an episodic 
manifestation of chronic depression (where depression symptoms last for two or more years) as 
newly-diagnosed depression. The availability of healthcare encounters across a variety of 
providers enabled us to control for a comprehensive set of variables such polypharmacy, 
antidiabetes medication use, and propensity to seek healthcare. The use of a theoretical 
framework enabled us to summarize the forty-four coexisting conditions into four categories. To 
the best of the authors‟ knowledge this is the first study to assess the risk of newly-diagnosed 
depression among different types of coexisting chronic physical conditions in adults with T2DM, 
using such framework.  
However, this study also had some limitations. Depression was identified using diagnosis codes. 
Therefore there is a potential for underestimating newly-diagnosed depression rates owing to 
undiagnosed depression and under-coding of depression. However, the use of diagnoses codes 
that are recommended by HEDIS and extensively used by health plans in order to identify 
depression claims and the ability to identify  physician/psychologist diagnoses of depression, 
offer a particularly attractive alternative to the substantial cost and complications associated with 
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prospective surveys supplemented with medical record data. T2DM and other coexisting 
conditions were also identified using diagnosis codes in medical claims. Incomplete or erroneous 
records submitted by healthcare providers, limited clinical detail in the ICD-9-CM codes and 
inaccurate demographic information might limit the accuracy of administrative data. As the 
study population was restricted to only fee-for-service Medicaid beneficiaries, the results are not 
generalizable to beneficiaries who are enrolled in managed care.  In addition, we used only three 
states and results cannot be extrapolated to other states due to differing Medicaid eligibility and 
enrollment criteria.  
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CONCLUSION 
One in ten Medicaid beneficiaries with T2DM developed depression. The risk of developing 
depression among those with T2DM varied by types of coexisting conditions; Medicaid 
beneficiaries with T2DM and dominant conditions and those with both concordant and 
discordant conditions were at higher risk of developing newly-diagnosed depression. This 
research built on previous research studies that indicated that individuals with T2DM may have 
high risk of depression and successfully identified non-elderly adults with T2DM who may even 
be at a higher risk of developing depression.  The study findings suggest that to reduce this 
increased risk of newly-diagnosed depression, those with dominant conditions and combinations 
of concordant and discordant conditions need to be under constant surveillance. However, in 
order for surveillance to be effective, in case such individuals get diagnosed with depression, 
appropriate treatment and follow-up must be provided. Future research may examine specific 
dominant conditions and combinations of concordant and discordant conditions that may result 
in high risk of newly diagnosed depression among adults with T2DM. 
[39] 
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TABLES & APPENDICES 
Table 1: Description of the Study Population by Types of Coexisting Chronic Physical Conditions among Medicaid 
Beneficiaries with Type 2 Diabetes Mellitus, Multi State Medicaid Claims – 2000 – 2008 
    
All Dominant Concordant 
Only 
Discordant Only Both 
Concordant 
& Discordant Sig 
    N % N % N % N % N %   
ALL 
 
59,857 
 
6,708 11.2 21,477 35.9 10,603 17.7 21,069 35.2 
 Individual Physical Make-up 
Age 
           
*** 
 
18-44  11,676 19.5 777 6.7 4,896 41.9 2,494 21.4 3,509 30.1 
 
 
45-54  16,314 27.3 1,847 11.3 5,496 33.7 3,184 19.5 5,787 35.5 
 
 
55-64  31,867 53.2 4,084 12.8 11,085 34.8 4,925 15.5 11,773 36.9 
 Sex 
           
*** 
 
Female 37,635 62.9 3,892 10.3 12,625 33.5 7,231 19.2 13,887 36.9 
 
 
Male 22,222 37.1 2,816 12.7 8,852 39.8 3,372 15.2 7,182 32.3 
 Race 
           
*** 
 
Whites 15,090 25.2 1,625 10.8 5,339 35.4 2,837 18.8 5,289 35.0 
 
 
African 
Americans 18,200 30.4 2,088 11.5 6,223 34.2 3,337 18.3 6,552 36.0 
 
 
Others 26,567 44.4 2,995 11.3 9,915 37.3 4,429 16.7 9,228 34.7 
 Psychological Factors 
Other Mental Health 
Conditions 
          
*** 
 
Yes 8,883 14.8 1,560 17.6 2,616 29.4 1,526 17.2 3,181 35.8 
 
 
No 50,974 85.2 5,148 10.1 18,861 37.0 9,077 17.8 17,888 35.1 
 Medication Use 
Oral Antidiabetic Drugs (OADs) 
        
*** 
 
1   OAD 17,996 30.1 1,890 10.5 6,288 34.9 3,511 19.5 6,307 35.0 
 
 
2   OADs 14,890 24.9 1,255 8.4 5,685 38.2 2,747 18.4 5,203 34.9 
 
 
3+ OADs 5,292 8.8 344 6.5 2,257 42.6 831 15.7 1,860 35.1 
 
 
No OAD 21,679 36.2 3,219 14.8 7,247 33.4 3,514 16.2 7,699 35.5 
 Insulin Use 
          
*** 
 
Yes 18,885 31.6 2,362 12.5 7,098 37.6 1,791 9.5 7,634 40.4 
 
 
No 40,972 68.4 4,346 10.6 14,379 35.1 8,812 21.5 13,435 32.8 
 Polypharmacy 
          
*** 
 
Yes 18,774 31.4 2,475 13.2 4,892 26.1 2,931 15.6 8,476 45.1 
 
 
No 41,083 68.6 4,233 10.3 16,585 40.4 7,672 18.7 12,593 30.7 
              
          continued 
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Table 1: Description of the Study Population by Types of Coexisting Chronic Physical Conditions among Medicaid 
Beneficiaries with Type 2 Diabetes Mellitus, Multi State Medicaid Claims – 2000 – 2008 
    
All Dominant Concordant 
Only 
Discordant Only Both 
Concordant 
& Discordant Sig 
    N % N % N % N % N %   
ALL 
 
59,857 
 
6,708 11.2 21,477 35.9 10,603 17.7 21,069 35.2 
 Healthcare Seeking Behavior 
Inpatient Hospitalization 
         
*** 
 
Yes 20,960 35.0 4,106 19.6 5,027 24.0 1,726 8.2 10,101 48.2 
 
 
No 38,897 65.0 2,602 6.7 16,450 42.3 8,877 22.8 10,968 28.2 
 Outpatient Visits 
          
*** 
 
1st Q 14,503 24.2 665 4.6 7,595 52.4 3,462 23.9 2,781 19.2 
 
 
2nd Q 14,973 25.0 1,134 7.6 5,833 39.0 3,125 20.9 4,881 32.6 
 
 
3rd Q 15,081 25.2 1,907 12.6 4,557 30.2 2,341 15.5 6,276 41.6 
 
 
4th Q 15,300 25.6 3,002 19.6 3,492 22.8 1,675 10.9 7,131 46.6 
 
  
Mean + SE Mean + SE Mean + SE Mean + SE Mean + SE 
 Number of T2DM 
related office visits 
5.70±0.04 6.85±0.12 5.29 ± 0.06 4.10 ± 0.05 6.56 ± 0.07  
Number of ER Visits 0.61±0.01 1.03± 0.03 0.35 ± 0.01 0.42 ± 0.01 0.85 ± 0.01   
Access to Care 
HPSA- Mental Health Care          ** 
 
Yes 50,518 84.4 5,720 11.3 18,119 35.9 8,842 17.5 17,837 35.3 
 
 
No 9,339 15.6 988 10.6 3,358 36.0 1,761 18.9 3,232 34.6 
 Metro 
           
*** 
 
Yes 51,996 86.9 5,988 11.5 18,798 36.2 9,011 17.3 18,199 35.0 
 
 
No 7,861 13.1 720 9.2 2,679 34.1 1,592 20.3 2,870 36.5 
 CMHC 
           
*** 
 
Yes 27,941 46.7 3,159 11.3 10,450 37.4 4,659 16.7 9,673 34.6 
 
 
No 31,916 53.3 3,549 11.1 11,027 34.6 5,944 18.6 11,396 35.7 
 FQHC 
           
*** 
 
Yes 48,625 81.2 5,596 11.5 17,565 36.1 8,396 17.3 17,068 35.1 
 
 
No 11,232 18.8 1,112 9.9 3,912 34.8 2,207 19.6 4,001 35.6 
 Community Resources 
Median Income 
          
*** 
 
1st  Q 14,958 25.0 1,526 10.2 5,271 35.2 2,489 16.6 5,672 37.9 
 
 
2nd Q 14,984 25.0 1,721 11.5 5,524 36.9 2,708 18.1 5,031 33.6 
 
 
3rd Q 14,951 25.0 1,737 11.6 5,319 35.6 2,846 19.0 5,049 33.8 
 
 
4th Q 14,964 25.0 1,724 11.5 5,363 35.8 2,560 17.1 5,317 35.5 
              
          (continued) 
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Table 1: Description of the Study Population by Types of Coexisting Chronic Physical Conditions among Medicaid 
Beneficiaries with Type 2 Diabetes Mellitus, Multi State Medicaid Claims – 2000 – 2008 
    
All Dominant Concordant 
Only 
Discordant Only Both 
Concordant 
& Discordant Sig 
    N % N % N % N % N %   
ALL 
 
59,857 
 
6,708 11.2 21,477 35.9 10,603 17.7 21,069 35.2 
 % with GT 4yr college 
education >  16%
ⱡ
 
         
*** 
 
Yes 47,072 78.6 5,435 11.5 16,964 36.0 8,535 18.1 16,138 34.3 
 
 
No 12,785 21.4 1,273 10.0 4,513 35.3 2,068 16.2 4,931 38.6 
 % below poverty level GT 
11.1%
ⱡⱡ
 
         
** 
 
Yes 53,092 88.7 5,968 11.2 19,060 35.9 9,307 17.5 18,757 35.3 
 
 
No 6,765 11.3 740 10.9 2,417 35.7 1,296 19.2 2,312 34.2 
 State            *** 
 Illinois 15,674 26.2 1,659 10.6 5,525 35.2 2,895 18.5 5,595 35.7  
 New York 26,342 44.0 3,134 11.9 9,470 36.0 5,022 19.1 8,716 33.1  
 Texas 17,841 29.8 1,915 10.7 6,482 36.3 2,686 15.1 6,758 37.9  
 
Note: Study sample comprised of adults with type 2 diabetes mellitus aged 18-64 years and with at least one 
coexisting concordant, discordant or dominant chronic physical condition and who were alive, not dually eligible for 
Medicare and continuously enrolled in fee-for-service Medicaid for at least 24 months( N=59,857); includes 
Medicaid data from three states: Illinois, Texas, New York 
 
Asterisks (*) represent significant differences in study population characteristics and  coexisting chronic physical 
conditions categories i.e. Dominant, Concordant Only, Discordant Only and Both Concordant and Discordant, 
derived from chi-square statistics and univariate ordinary least square regressions. 
***P < .001; **.001 ≤ P < .01; *.01 ≤ P < .05. 
 
ⱡ 16% Cut off was chosen based on 2000 Census Education attainment results 
ⱡⱡ 11.1% Cut off was chosen based on 1999 Census Poverty in 18-64 year results  
 
HPSA: health professional shortage area; CMHC: Community Mental Health Clinic; FQHC: Federally qualified 
health clinic; GT: Greater Than; Q: Quartile 
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Table 2: Percentages of Newly-diagnosed Depression by Types of Coexisting Chronic Physical 
Conditions among Medicaid Beneficiaries with Type 2 Diabetes Mellitus, Multi-state Medicaid Claims 
data – 2000 – 2008 
  
  
  Percent with Newly-diagnosed depression 
 
  ALL Dominant 
Concordant  
Only 
Discordant  
Only 
Both 
 Concordant 
 & Discordant   
    % % % % % Sig 
ALL 
 
10.0 13.1 7.5 8.7 12.2 *** 
Individual Physical Make-up 
Age 
       
 
18-44 years 12.6 17.1 9.8 11.2 16.7 *** 
 
45-54 years 13.0 16.5 9.3 11.0 16.5 *** 
 
55-64 years 7.5 10.8 5.6 6.0 8.7 *** 
Sex 
       
 
Female 10.6 13.3 8.3 9.4 12.6 *** 
 
Male 8.9 12.9 6.3 7.3 11.3 *** 
Race 
      
 
Whites 10.6 14.2 7.8 9.6 12.8 *** 
 
African 
Americans 9.9 13.5 7.1 8.1 12.4 *** 
 
Others 9.7 12.3 7.6 8.6 11.6 *** 
Psychological Factors 
Other Mental Health Conditions 
     
 
Yes 23.4 24.8 19.8 21.2 26.8 *** 
 
No 7.6 9.6 5.8 6.6 9.6 *** 
Medication  Use 
Oral Antidiabetic Drugs (OADs) 
     
 
1   OAD 9.4 11.0 7.4 8.5 11.4 *** 
 
2   OADs 9.2 13.3 6.7 8.9 11.1 *** 
 
3+ OADs 9.4 11.6 7.6 8.3 11.7 *** 
 
No OAD 11.1 14.4 8.1 8.9 13.6 *** 
Insulin Use 
      
 
Yes 11.1 13.9 8.2 9.0 13.4 *** 
 
No 9.5 12.7 7.1 8.7 11.4 *** 
Polypharmacy 
      
 
Yes 11.6 14.4 8.0 11.0 13.0 *** 
 
No 9.2 12.4 7.3 7.9 11.6 *** 
       
     (continued) 
      
[47] 
 
Table 2: Percentages of Newly-diagnosed Depression by Types of Coexisting Chronic Physical 
Conditions among Medicaid Beneficiaries with Type 2 Diabetes Mellitus, Multi-state Medicaid Claims 
data – 2000 – 2008 
  
  
  Percent with Newly-diagnosed depression 
 
  ALL Dominant 
Concordant  
Only 
Discordant  
Only 
Both 
 Concordant 
 & Discordant   
    % % % % % Sig 
ALL 
 
10.0 13.1 7.5 8.7 12.2 *** 
Health Seeking Behavior 
Inpatient Hospitalization 
     
 
Yes 14.2 15.6 11.8 15.2 14.7 *** 
 
No 7.7 9.3 6.2 7.5 9.8 *** 
Outpatient Visits 
      
 
1st  Q 4.6 5.9 4.2 4.2 5.7 ** 
 
2nd Q 8.2 7.4 7.8 8.1 8.9 
 
 
3rd Q 11.3 12.7 9.1 11.4 12.5 *** 
 
4th Q 15.6 17.2 12.0 15.5 16.7 *** 
Access to Care 
HPSA- Mental Health Care 
     
 
Yes 9.9 13.3 7.5 8.6 11.8 *** 
 
No 10.5 12.0 7.5 9.4 13.9 *** 
Metro 
      
 
Yes 10.3 13.7 7.7 9.0 12.4 *** 
 
No 8.1 8.6 6.0 7.2 10.4 *** 
CMHC 
      
 
Yes 10.3 13.5 7.5 9.2 12.7 *** 
 
No 9.7 12.8 7.5 8.4 11.7 *** 
FQHC 
      
 
Yes 10.1 13.5 7.6 9.0 12.2 *** 
 
No 9.3 11.1 6.7 7.9 12.0 *** 
Community Resources 
Median Income 
      
 
1st  Q 8.3 9.8 6.2 7.4 10.1 *** 
 
2nd Q 11.7 14.7 8.5 11.0 14.5 *** 
 
3rd Q 11.3 15.3 8.6 9.3 13.9 *** 
 
4th Q 8.6 12.3 6.5 7.0 10.4 *** 
% with GT 4yr college education >  16%ⱡ 
    
 
Yes 10.6 14.1 7.9 9.2 12.9 *** 
 
No 7.8 9.0 5.9 6.8 9.6 *** 
        
      continued 
% below poverty level GT 11.1%
ⱡⱡ
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Table 2: Percentages of Newly-diagnosed Depression by Types of Coexisting Chronic Physical 
Conditions among Medicaid Beneficiaries with Type 2 Diabetes Mellitus, Multi-state Medicaid Claims 
data – 2000 – 2008 
  
  
  Percent with Newly-diagnosed depression 
 
  ALL Dominant 
Concordant  
Only 
Discordant  
Only 
Both 
 Concordant 
 & Discordant   
    % % % % % Sig 
ALL 
 
10.0 13.1 7.5 8.7 12.2 *** 
 
Yes 10.0 13.2 7.5 8.7 12.0 *** 
 
No 10.2 12.6 7.4 8.9 13.0 *** 
State  
      
 
Illinois 10.4 13.9 7.6 9.5 12.6 *** 
 
New York 11.0 15.1 8.5 9.2 13.3 *** 
 
Texas 8.1 9.2 5.9 7.1 10.3 *** 
        
 
 Note: Study population comprised of adults with type 2 diabetes mellitus aged 18-64 years and with at least one co-
existing concordant, discordant or dominant chronic physical condition and who were alive, not dually eligible for 
Medicare and continuously enrolled in fee-for-service Medicaid for at least 24 months( N=59,857). 
Asterisks (*) represent significant differences in developing newly-diagnosed depression among coexisting chronic 
physical conditions categories i.e. Dominant, Concordant Only, Discordant Only and Both Concordant and 
Discordant for each of the categorical independent variable subgroups 
***P< .001; **.001 ≤ P < .01; *.01 ≤ P < .05. 
 
ⱡ 16% Cut off was chosen based on 2000 Census Education attainment results 
ⱡⱡ 11.1% Cut off was chosen based on 1999 Census Poverty in 18-64 year results  
 
HPSA: health professional shortage area; CMHC: Community Mental Health Clinic; FQHC: Federally qualified 
health clinic; GT: Greater Than; Q: Quartile 
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Table 3:  Adjusted Risk Ratios and 95% Confidence Intervals  of Types of Coexisting chronic physical Conditions 
from Complementary Log-Log  Regression  on  Newly-Diagnosed Depression among Medicaid Beneficiaries with 
Type 2 Diabetes Mellitus, Multistate Medicaid Claims 2000- 2008 (Reference Group: Concordant only) 
    
Dominant Discordant Conditions 
Only 
Both Concordant and 
Discordant 
Newly-Diagnosed  
Depression 
Model 1: Adjusted for Types of Coexisting chronic physical Conditions 
  
RR 95% CI Sig RR 95% CI Sig RR 95% CI Sig 
 
Yes (Ref :No) 1.81 [1.67,1.96] *** 1.18 [1.09,1.28] *** 1.67 [1.57,1.77] *** 
   
  
ARR 95% CI Sig ARR 95% CI Sig ARR 95% CI Sig 
  
Model 2:Adjusted for: Model 1+Individual Physical Make-up 
 
Yes (Ref: No) 1.92 [1.76,2.08] *** 1.09 [1.01,1.19] * 1.73 [1.63,1.84] *** 
          
 
 
Model 3: Adjusted for: Model 1+ Model 2+Medication Use and Healthcare Seeking Behavior 
 
Yes (Ref: No) 1.18 [1.08,1.29] *** 1.06 [0.98,1.16] 
 
1.29 [1.21,1.38] *** 
           
 
 
Model 4: Model 1+ Model 2+Model 3+Community level Access to Care, Community Resources 
 
Yes (Ref: No) 1.17 [1.07,1.27] *** 1.06 [0.98,1.15] 
 
1.30 [1.22,1.39] *** 
           
 
Note: Study sample comprised of adults with type 2 diabetes mellitus aged 18-64 years and with at least one 
coexisting concordant, discordant or dominant chronic physical condition and who were alive, not dually eligible for 
Medicare and continuously enrolled in fee-for-service Medicaid for at least 24 months( N=59,857); includes 
Medicaid data from three states: Illinois, Texas, New York 
 
Model 1: adjusted for types of coexisting chronic physical conditions.  
Model 2 adjusted for gender, age, race/ethnicity and years of observation;  
Model 3: Additionally Adjusted for adjusts for presence of other mental health conditions, , number of oral antidiabetic 
medication classes and insulin use as identified by NDC codes, presence of polypharmacy number of emergency room 
visits, inpatient hospitalization,  number of total and T2DM related office visits;  
Model 4: Additionally adjusts for state of residence, whether county of residence had a community mental health clinic 
and FQHC, CMHC, metro and HPSA-mental health status of county, median income in the county, whether percent 
below poverty level and percent with college education greater than national average 
 
Asterisks (*) indicate statistical significances are based on complementary log-log regressions with concordant 
conditions as reference group for types of coexisting chronic physical conditions. ***P < 0.001; **.001 ≤ P < .01; 
*.01 ≤ P < .05. 
 
T2DM: type 2 diabetes mellitus; HPSA: health professional shortage area; CMHC: Community Mental Health Clinic; 
FQHC: Federally qualified health clinic; Ref: Reference Group
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Appendix A : ICD-9-CM Codes for Identifying  Types of Coexisting chronic physical Conditions 
Conditions ICD-9-CM Codes 
Concordant conditions 
 
 
Coronary Artery Disease 410,4100,4101,4102,4103,4104,4105,4106,4107,4108,4109,411,4110,
4111,4118,41181,41189,412,413,4130,4131,4139,414,4140,41400,414
01,41402,41403,41404,41405, 4141,41410,41411, 41419,4148,4149 
 
Congestive Heart Failure 40201,40211,40291,40401,40411,40491,428,4280,4281,4289 
 
Arrhythmia 423,4230,4231,4232,4238,4239,42731 
 
Stroke 431,43301,43311,43321,43331,43381,43391,43401,43411,43491,435,
4350,4351,4352,4353,4358,4359,438,4380,4381,43811,43812,4382,43
83,4384,4385,43850,4385,43852,43853,4388,43881, 
43882,43889,4389 
 
Peripheral Vascular Disease 2507,4402,44020,44021,44022,44023,44024,44029,4408,4409,4422,4
423,443,4430, 4431,4438,44381, 44389,4439,44422,44481 
 
Peripheral Vascular Disease-gangrene 7854 
 
Renal  
Chronic Renal Failure 
Chronic Pathophysiology 
40311,40391,40412,40413,40492,40493, 585,586,587, 
2741,27410,27411,27419, 
40310,40390,40410,40411,40490,40491, 
581,5810,5811,5812,5813,5818,5819, 
582,5820,5821,5822,5824,5828,58281,58289,5829,583,5830,5831,583
2,5834,5836, 
5837, 5838,58381,58389,5839,  5900,59000,59001,5936,5939, 
75312,75313,75314 
 
Diabetic Nephropathy 2504,25040,25041,25042,25043 
 
Acute Renal Failure and Disease 
 
40300,40301,40400,40401,40402,40403,40501,4533,584,5845,5846,5
847,5848,5849, 
580,5800,5804,5808,58081,58089,5809,5901,59010,59011,5902,5903,
5908,59080, 
59081,59381,866,8660,86600,86601,86602,86603,8661,86610,86611,
86612,86613 
 
Retinopathy 
(excludes advanced retinopathy, blindness) 
3620,36201,25050,25051,25052,25053 
 
Ulcer 700,68110,68111,6827,7071,73076,73077 
 
Other Diabetes Related Complications 
Uncontrolled Diabetes 
Short Term Diabetes 
25002,25003,25010,25011,25012,25013,25020,25021,25022,25023,25
030,25031, 
25032,25033 
Discordant Conditions  
 
Gastro Intestinal Tract Related Disorders: 
GERD/Esophagitis 
Peptic ulcers 
Inflammatory Bowel Disease 
Diverticulitis 
Gall Bladder disease and stone 
Viral hepatitis 
5301,5302,5303,53081,531,532,533,534,555,556,56211,56213,574 
575,576,070 
 
Chronic Obstructive Pulmonary Disease 490,491,492,493,495,496,500,501,502,503,504,505,5064  
 
Gout 274,712 
 
Hip problem 71905,71915,71925,71935,71945,71955,71965,71975,71985,71995,72
65,73314,73315,73342,820 
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Appendix A : ICD-9-CM Codes for Identifying  Types of Coexisting chronic physical Conditions 
Conditions ICD-9-CM Codes 
 
Low back pain 720,7213,72142,72210,72252,72273,72283, 
72293,72402,7242,7243,7244,7245,7246,7247,7248,7249 
 
Osteoarthritis  715 
 
Other Arthritis 716 
 
Rheumatoid arthritis  714 
 
Connective tissue rheumatological disease 7100,7101,7104,725 
 Blindness Single Eye 3696,3697,3698,3699 
Dominant Conditions  
 
End Stage Renal Disease E8791,V51,V56,V560,V5631,V5632,V568 
 
End Stage Liver Disease 5722,5723,5724,5728,4560,4561, 4562,45620,45621, 571 
 
Blindness Both Eyes/ Advanced Retinopathy 36202,3690,3691,3692,3693,3694 
 
Cancer 140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,1
56,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,17
2,174,175,176,177,178,179,180,181,182,183,184,186,187,188,189,190
,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,
207,208 
 
Pre-dementia Cognitive Impairment 294 ,2941, 29283, 2949 ,33183,78093,438,3330,3334,3315 
 
Dementia and Related Conditions 2900,29010,29011,29012,29013,2902,29021,2903,29040,29041,29042
,29043,2912, 
29410,29411,2948,3310,3311,3312,3317,33182,33189,3319,3320,046
1,0463,0941, 
29282,3109 
 
Multiple Sclerosis  340 
 
Hemiplegia Hemiparesis and Paraplegia 342,3441 
 
Parkinson‟s Disease  332 
 
Muscular dystrophy 359 
 
Spinal cord injury 80600,80601,80602,80603,80604,80605,80606,80607,80608,80609,80
61, 9520, 
 34400,34401,34402,34403,34404,34409 
 
Epilepsy 345 
 
Gastropareis  5363 
 
AIDS 042 
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Appendix B:  Adjusted Risk Ratios and 95% Confidence Intervals from Complementary Log-Log Regression on Newly-diagnosed 
Depression among Medicaid Beneficiaries with Type 2 Diabetes Mellitus, Multistate Medicaid Claims 2000-2007 
    Model 1 Model 2 Model 3 Model 4 
    ARR 95% CI Sig ARR 95% CI Sig ARR 95% CI Sig ARR 95% CI Sig 
Biological Risk Factors 
 Types of Coexisting chronic physical conditions 
         
 
Dominant 1.81 [1.67,1.96] *** 1.92 [1.76,2.08] *** 1.18 [1.08,1.29] *** 1.17 [1.07,1.27] *** 
 
Concordant  
Conditions Only  Reference 
 
Discordant  
Conditions Only  1.18 [1.09,1.28] *** 1.09 [1.01,1.19] * 1.06 [0.98,1.16] 
 
1.06 [0.98,1.15] 
 
 
Both 1.67 [1.57,1.77] *** 1.73 [1.63,1.84] *** 1.29 [1.21,1.38] *** 1.30 [1.22,1.39] *** 
Individual Physical Make-up   
Age 
            
 
18-44 years Reference 
 
45-54 years 
   
0.99 [0.92,1.06] 
 
1.00 [0.93,1.07] 
 
1.01 [0.95,1.08] *** 
 
55-64 years 
   
0.52 [0.48,0.55] *** 0.57 [0.54,0.61] *** 0.59 [0.55,0.63] 
 Sex 
           
*** 
 
Female 
   
1.24 [1.18,1.31] *** 1.41 [1.33,1.49] *** 1.42 [1.34,1.50] 
 
 
Male Reference 
Race 
           
*** 
 
Whites 
   
1.15 [1.07,1.23] *** 1.24 [1.15,1.32] *** 1.34 [1.25,1.44] 
 
 
African Americans Reference 
 
Others 
   
1.02 [0.96,1.08] 
 
1.14 [1.07,1.21] *** 1.26 [1.18,1.34] 
 Psychological Factors   
Other Mental Health 
Conditions 
           
 
Yes 
      
2.60 [2.45,2.76] *** 2.51 [2.36,2.66] *** 
 
No Reference 
                                                            (continued) 
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Appendix B:  Adjusted Risk Ratios and 95% Confidence Intervals from Complementary Log-Log Regression on Newly-diagnosed 
Depression among Medicaid Beneficiaries with Type 2 Diabetes Mellitus, Multistate Medicaid Claims 2000-2007 
    Model 1 Model 2 Model 3 Model 4 
    ARR 95% CI Sig ARR 95% CI Sig ARR 95% CI Sig ARR 95% CI Sig 
Medication Use   
Oral Antidiabetic Drugs 
(OADs) 
           
 
1   OAD 
      
0.89 [0.80,0.98] * 0.91 [0.82,1.01] 
 
 
2   OADs 
      
0.94 [0.85,1.04] 
 
0.96 [0.86,1.06] 
 
 
3+ OADs Reference 
 
No OAD 
      
0.94 [0.85,1.04] 
 
0.97 [0.88,1.08] 
 Insulin Use 
            
 
Yes 
      
1.03 [0.97,1.09] 
 
1.01 [0.96,1.07] 
 
 
No Reference 
Polypharmacy 
            
 
Yes 
      
1.06 [1.01,1.13] * 0.98 [0.92,1.04] 
 
 
No Reference 
Healthcare Seeking Behavior   
Inpatient Hospitalization 
           
 
Yes 
      
1.20 [1.13,1.27] *** 1.19 [1.12,1.26] *** 
 
No Reference 
Outpatient Visits 
            
 
1st  Q Reference 
 
2nd Q 
      
1.56 [1.42,1.72] *** 1.61 [1.46,1.77] *** 
 
3rd Q 
      
1.92 [1.74,2.11] *** 2.02 [1.83,2.22] *** 
 
4th Q 
      
2.19 [1.99,2.41] *** 2.39 [2.16,2.64] *** 
Number of T2DM 
related office visits 
      
1.00 [1.00,1.01] *** 1.00 [1.00,1.01] *** 
Number of ER 
Visits 
      
1.07 [1.06,1.08] *** 1.07 [1.06,1.09] *** 
 (continued) 
Page 54 of 173 
 
Appendix B:  Adjusted Risk Ratios and 95% Confidence Intervals from Complementary Log-Log Regression on Newly-diagnosed 
Depression among Medicaid Beneficiaries with Type 2 Diabetes Mellitus, Multistate Medicaid Claims 2000-2007 
    Model 1 Model 2 Model 3 Model 4 
    ARR 95% CI Sig ARR 95% CI Sig ARR 95% CI Sig ARR 95% CI Sig 
Community level Access to Care   
HPSA- Mental Health Care 
           
 
Yes 
         
0.99 [0.91,1.08] 
 
 
No Reference 
Metro 
            
 
Yes 
         
1.04 [0.93,1.17] 
 
 
No Reference 
CMHC 
            
 
Yes 
         
0.96 [0.90,1.03] 
 
 
No Reference 
FQHC 
            
 
Yes 
         
1.03 [0.94,1.12] * 
 
No Reference 
Community Resources   
Median Income 
            
 
1st  Q 
         
0.86 [0.74,1.00] * 
 
2nd Q 
         
0.91 [0.82,1.01] 
 
 
3rd Q 
         
0.90 [0.81,1.00] * 
 
4th Q Reference 
% with GT 4yr college 
education >  16%ⱡ 
           
 
Yes 
         
1.07 [0.96,1.20] 
 
 
No Reference 
   
  (continued) 
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Appendix B:  Adjusted Risk Ratios and 95% Confidence Intervals from Complementary Log-Log Regression on Newly-diagnosed 
Depression among Medicaid Beneficiaries with Type 2 Diabetes Mellitus, Multistate Medicaid Claims 2000-2007 
    Model 1 Model 2 Model 3 Model 4 
    ARR 95% CI Sig ARR 95% CI Sig ARR 95% CI Sig ARR 95% CI Sig 
% below poverty level GT 
11.1%
ⱡⱡ
 
           
 
Yes 
         
1.04 [0.93,1.16] 
 
 
No Reference 
State 
            
 
Illinois 
         
0.81 [0.75,0.88] 
 
 
New York Reference 
  Texas                   0.73 [0.66,0.81]   
Cohort 
            
 
2000-2001 Reference 
 
2001-2002 
   
1.08 [0.99,1.19] 
 
1.04 [0.94,1.14] 
 
1.04 [0.93,1.15] 
 
 
2002-2003 
   
1.19 [1.08,1.31] *** 1.12 [1.02,1.23] * 1.09 [0.98,1.23] 
 
 
2003-2004 
   
1.01 [0.92,1.11] 
 
0.92 [0.84,1.02] 
 
0.91 [0.82,1.01] 
 
 
2004-2005 
   
0.83 [0.76,0.92] *** 0.79 [0.71,0.86] *** 0.78 [0.70,0.86] *** 
 
2005-2006 
   
0.73 [0.67,0.81] *** 0.67 [0.61,0.74] *** 0.63 [0.56,0.71] *** 
 
2006-2007 
   
0.41 [0.37,0.45] *** 0.38 [0.34,0.42] *** 0.35 [0.31,0.40] *** 
                            
Note: Asterisks indicate statistical significances are based on complementary log-log regressions with concordant conditions as reference group for independent 
variable. ***P < 0.001; **.001 ≤ P < .01; *.01 ≤ P < .05. 
 
T2DM: type 2 diabetes mellitus; HPSA: health professional shortage area; CMHC: Community Mental Health Clinic; FQHC: Federally qualified health clinic 
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CHAPTER 3: Types of Coexisting Chronic Physical Conditions and Treatment for 
Depression among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-
diagnosed Depression 
 
INTRODUCTION 
Coexisting Depression among Individuals with Type 2 Diabetes Mellitus (T2DM) 
 
Presence of depression among individuals with type 2 Diabetes Mellitus (T2DM) serves 
as a prototype example of Agency of Healthcare Research and Quality (AHRQ)‟s definition of a 
complex patient who has “two or more chronic conditions where each condition may influence 
the care of the other condition(s) through limitations of life expectancy, interactions between 
drug therapies, difficulties in establishing adequate care coordination, and/or direct 
contraindications to therapy for one condition by other conditions ” [1]. Depression has 
considerable adverse impact on both psychological well-being and T2DM related outcomes. 
Coexisting depression among individuals with type 2 diabetes mellitus (T2DM) is significantly 
associated with adverse T2DM related outcomes such as poor processes of care (glycated 
hemoglobin i.e. A1C testing, LDL testing and eye examination)[2], non-adherence to the T2DM 
treatment regimens [3-8] and poor foot care [7, 9-11].  
Treatment for Depression among Individuals with T2DM  
 
Randomized clinical trials have been conducted to examine the effect of antidepressant 
treatment for depression among individuals with T2DM and coexisting depression.   These trials 
have evaluated reduction in depressive symptoms, remission from depression, and T2DM-realted 
outcomes. As compared to placebo, eight weeks of treatment with nortriptyline resulted in a 
significant reduction in depressive symptoms (reduction in Beck‟s Depression Inventory score: -
10.2 vs -5.8, p = .03).  However,  among 28 individuals with coexisting T2DM and depression, 
randomized double-blind placebo-controlled trial found that glycemic control worsened among 
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individuals who were treated with  nortriptyline [12]. As compared to placebo, eight weeks of 
treatment with fluoxetine resulted in reduction in depressive symptoms (reduction in BDI score: 
-14.0 vs. -8.8, P = 0.03) among sixty patients with diabetes (did not distinguish between type 1 
and type 2). This trial did not report any  significant differences in glycemic control between 
placebo and treatment groups [13].  Another randomized placebo-controlled double-blind 
maintenance treatment trial that included individuals who responded to open label sertraline 
treatment, found that as compared to placebo, individuals who continued treatment with 
sertraline had significantly lower risk of depression recurrence (hazard ratio = 0.51; 95% CI, 
0.31-0.85; P = .02); again  no significant differences were observed for glycemic control [14]. 
Double blind treatment with paroxetine as compared to placebo, conducted among 49 mildly 
depressed individuals, recruited from an outpatient setting in Finland, showed significant 
improvements in quality of life (mean difference  in SF-36 score: 11.0 points, p = 0.039) as well 
as glycemic control (mean difference in HbA1C: 0.59% units, p = 0.018) at 3 months, but the 
effect did not persist at 6 months [15]. Treatment of depression among 51 individuals with 10 
weeks of cognitive behavioral therapy has been shown to result in more remission rates as 
compared to control group that received no specific antidepressant treatment (85% in CBT group 
vs 27% in control group); HbA1C levels at 6 month after follow-up though significantly lower in 
CBT group (9.5% compared with 10.9% in control; P = 0.03), was above the widely accepted 
9% cut-off for uncontrolled HbA1C in both treatment and control groups [16]. Therefore, it may 
be concluded that depression treatment may be beneficial for favorable depression related 
outcomes; however, evidence for T2DM related outcomes is inconclusive. These findings 
suggest that among individuals with coexisting T2DM and depression, depression treatment may 
be favored to reduce depressive symptoms.  
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Depression Treatment Patterns among Individuals with T2DM 
 
Only a few studies have examined rates of depression treatment in real-world practice 
settings among individuals with T2DM and coexisting depression.  Findings from the handful of 
studies indicate that depression among individuals with T2DM is undertreated;  for example, 
Katon and colleagues found that in a study that included both elderly and non-elderly 
participants (mean age 59 years), only 43% of with diagnosed depression and T2DM received 
treatment with 1 or more antidepressants and only 6.7% received at least 4 psychotherapy 
sessions during a follow-up period of  12-months [17]. A study among veteran clinic users 
examined guideline consistent depression treatment within 6 months after diagnosis. This study 
found that only 51% of individuals with T2DM and newly-diagnosed depression received any 
antidepressant treatment [18]. Another study, also among veterans, but restricted to women with 
newly-diagnosed depression and T2DM, coronary artery disease or hypertension found that 54% 
of those with T2DM only used antidepressants alone and 28% used psychotherapy [19].  
Some studies have compared depression treatment rates among individuals with and 
without T2DM. The rates of depression treatment for those with T2DM were parsed from these 
studies and are reported below. A study using Medicaid claims data files from Alabama, 
Georgia, New Jersey, and Wisconsin reported that among Medicaid enrollees with depression, 
those with diabetes had higher rates of antidepressant treatment (78%). A nationally 
representative study of non-institutionalized US population aged 16 years or older that examined 
the association of treatment modality for depression and burden of comorbid chronic conditions 
using the Medical Expenditure Panel Survey data, reported that while among individuals with 
diabetes (did not distinguish between type 1 and type 2) and depression, 21% did not receive any 
treatment, about 58% were treated with antidepressants alone and 14% were treated with both 
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antidepressants and psychotherapy [20]. Another study that used the MedStat MarketScan 
Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits 
databases, found that 93% of individuals with diabetes (did not distinguish between type 1 and 
type 2) and depression were using antidepressants, selective serotonin reuptake inhibitors being 
the most prescribed class (64%) [21]. Therefore, among individuals with T2DM rates of 
depression treatment with antidepressants in the reviewed literature varied from a moderate rate 
of 43% to as high as 93%; only one study examined depression treatment rates with 
psychotherapy. 
Depression Treatment among Individuals with Coexisting Chronic Physical Conditions 
 
 Although not specific to T2DM, treatment for depression has been shown to “compete”, 
often unsuccessfully among individuals with multiple coexisting chronic physical conditions [22, 
23]. For example, one study found that among 240 individuals with 5 or more depressive 
symptoms, number of other chronic coexisting chronic physical conditions was inversely 
associated with the attention given to depression in a physician office visit [22]. Using a sample 
of 92 participants from the same study, it was found that only 17% of individuals completed 
depression treatment and additionally, severity of other coexisting chronic physical conditions 
reduced the odds of initiating depression treatment even among patients who were enthusiastic 
about depression treatment [24]. Therefore, these studies indicate that those with multiple 
chronic conditions are less likely to be treated for depression suggesting that depression 
treatment among those with T2DM and coexisting chronic physical conditions may be under-
treated. However, other existing studies have indicate that competing demands do not affect 
depression treatment among individuals with multiple coexisting chronic conditions [25-28]. For 
example, a study using 2007 National Health and Nutrition Examination Survey from found that 
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individuals with multiple chronic physical conditions were as likely as those with single 
condition to report depression treatment [28]. With such conflicting results in previous studies, 
depression treatment rates among those with T2DM and other multiple coexisting chronic 
physical conditions remains to be explored.  
Depression Treatment among Individuals with T2DM and Coexisting Chronic Physical 
conditions  
A handful of studies already mentioned above, have indirectly examined the association 
between types of coexisting chronic physical conditions and depression treatment patterns 
among individuals with T2DM. However, coexisting chronic physical conditions in these studies 
were measured using either comorbidity indices [18, 29] or number of coexisting conditions 
[19]. Two of these studies found that the number of coexisting chronic condition variable or the 
comorbidity index variable was not significantly associated with receipt of depression treatment 
[18, 19]. On the contrary, in the study among Medicaid beneficiaries with T2DM by 
Sambamoorthi et al.,[29]  it was reported that individuals with higher burden from coexisting 
conditions, were more likely to receive antidepressants compared to those with no burden from 
coexisting conditions. However, since these studies used comorbidity indices or number of 
chronic condition variable in their analyses, there is an existing knowledge gap regarding how 
different types of coexisting conditions may effect depression treatment among individuals with 
T2DM and coexisting chronic physical conditions. 
Adequate Depression Treatment 
 Guidelines for depression treatment  suggest that during the first four months after 
depression diagnosis, those with depression should be treated for at least 84 days  with 
antidepressants [1, 30] and/or at least 8 sessions of psychotherapy [31].  Adequate depression 
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treatment either with antidepressants or psychotherapy has both been found to be associated with 
improvements in depression symptoms [32], whereas, early discontinuation of depression 
treatment, specifically with antidepressants has been found to be associated with high risk of 
relapse [33, 34]. 
Among individuals who received depression treatment, the duration of treatment has been 
found to be often inadequate. An analysis of the National Comorbidity Survey Replication 
reported that in the US, among individuals with major depression and who received treatment, 
only 10% got adequate treatment [35]. Another study that analyzed Medicaid managed care data 
from a large Mid-Atlantic state in the US, found that, 30% of enrollees received adequate 
antidepressant treatment, 63% of enrollees received adequate psychotherapy defined as four or 
more psychotherapy visits.  
Adequate Depression Treatment among Individuals with T2DM and Coexisting Chronic 
Physical conditions 
 Similarly, individuals with T2DM and coexisting depression do not receive adequate 
depression treatment. For example, Katon et al found that among individuals with diabetes and 
depression, who were enrolled in a private health maintenance organization, 31% received 
adequate antidepressant treatment and only 6.7% received four or more sessions of 
psychotherapy [17]. The study by Tiwari et al., among veterans with T2DM and newly-
diagnosed depression also found that only 31% received adequate antidepressant treatment [18]. 
This study controlled for Charlson Comorbidity Index (CCI) in their logistic regression model 
for examining the odds of receiving adequate depression treatment. The odds ratio for the CCI 
variable was not statistically significant, suggesting that coexisting conditions was not associated 
with receipt of adequate depression treatment among veterans with T2DM. Treatment with 
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psychotherapy was not examined in this study.  As depression treatment often competes with 
treatment for other conditions, it is possible that even those who start depression treatment may 
not get the “adequate” treatment as per guidelines for depression treatment. However, to the best 
of the authors‟ knowledge no study has examined whether different types of coexisting chronic 
physical conditions are associated with receiving adequate depression treatment among 
individuals with T2DM and depression. 
Need for the Study 
The existing literature on patterns of depression treatment among individuals with 
diabetes have focused primarily on antidepressant treatment even though guideline consistent 
depression treatment includes both psychotherapy and antidepressant treatment [36]. One of 
these studies has used self-reported information to identify medical conditions and medication 
use [20]. Additionally, these studies have often controlled  for comorbidity indices such as 
Charlson comorbidity index [18, 29] or for number of comorbidities [19, 20] or have not 
considered impact of comorbidities at all [37]. By only controlling for comorbidity numbers or 
indices, one cannot conclude whether the types of coexisting chronic physical conditions are 
associated receipt of depression treatment with antidepressants only, psychotherapy only, both or 
receiving no treatment at all. Examining this association is especially important as often 
treatment for depression is not given priority in presence of multiple coexisting chronic 
conditions [22, 23]. Therefore this study aimed to analyze the association between types of 
coexisting chronic physical conditions and receipt of depression treatment with antidepressants 
only, psychotherapy only, both or receiving no treatment at all. 
Additionally, the current knowledge on receipt of “adequate” depression treatment by 
types of coexisting chronic physical conditions among individuals with T2DM is very limited. 
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Adequate depression treatment is one of the quality measures included in National Committee 
for Quality Assurance's (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS). 
These quality measures are used by various health plans including Medicaid and other 
organizations in the US for the purpose of accreditation, accountability and quality improvement.   
Therefore, it is essential to examine whether among individuals with T2DM, risk of not receiving 
adequate depression treatment varies by types of coexisting chronic physical conditions. This 
study also attempted to analyze the association between types of coexisting chronic physical 
conditions and receipt of adequate depression treatment among Medicaid enrollees with T2DM 
and newly-diagnosed depression.  
The study population included Medicaid enrollees. Medicaid is a major payer for non-
elderly adults in the US and it accounts for 68% of federal spending [38]. Traditionally, 
Medicaid has been a primary source of health insurance for those with low socioeconomic status, 
which incidentally is a risk factor for developing depression [39]. Additionally, it has been 
estimated that, 27% of the African-Americans population in the US receive their health insurance 
from Medicaid from Medicaid [40]. African-Americans with major depression have been 
reported to have inadequate depression treatment [41]. Additionally, individuals with diabetes 
are disproportionately covered by Medicaid, 80% of Medicaid beneficiaries with diabetes suffer 
from a coexisting chronic physical condition and  20% of Medicaid enrollees are diagnosed with 
depression [27, 28]. Based on these statistics, it can be seen that Medicaid data provides a rich 
opportunity to conduct research on treatment of depression among individuals with T2DM, 
depression and coexisting T2DM.  
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RESEARCH AIM AND HYPOTHESIS 
Aim 2: Objective 1.1: Examine the association between types of coexisting chronic physical 
conditions and depression treatment (antidepressants only, psychotherapy only, both 
antidepressants and psychotherapy and none), after adjusting for other covariates among non-
elderly (18-64 years) fee-for-service Medicaid beneficiaries with T2DM and newly-diagnosed 
depression, 
Aim2: Hypothesis 1.1: As compared to individuals with discordant conditions only, those with 
concordant conditions would be less likely to receive treatment with antidepressants.   
Aim 2: Objective 1.2: Evaluate the association between types of coexisting chronic physical 
conditions and receipt of adequate depression treatment (yes, no), after adjusting for other 
covariates among non-elderly (18-64 years) fee-for-service Medicaid beneficiaries with T2DM 
and newly-diagnosed depression who received either antidepressants or psychotherapy. 
Aim2: Hypothesis 1.2: As compared to individuals with discordant conditions only, those with 
dominant conditions would be less likely to receive adequate depression treatment. 
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CONCEPTUAL FRAMEWORK 
 
The conceptual framework used was based on a modified version of a behavioral model 
on use of health services, widely known as the Andersen Behavioral Model (ABM) [42].  The 
ABM posits that utilization of health services varies as a function of 1) each individual‟s unique 
predisposition for using services (predisposing factors); 2) the means available to each individual 
for obtaining services (enabling factors); 3) each individual‟s level of need; 4) personal health 
practices; and 5) the external environment. The model is presented below. The behavioral health 
model is very flexible and was easily adapted to analyze the relationship between types of 
coexisting chronic physical conditions and depression treatment. 
 
Aim 2 – Dependent Variable: 
Depression Treatment Categories 
Adequate Depression Treatment 
 
 
 
 
 
 
Predisposing factors: 
 Gender, age, race/ethnicity  
 
Enabling factors:  
Medicaid Eligibility 
Need Factors:  
Types of coexisting physical conditions, Other 
Mental Health Conditions, Number of chronic 
conditions  
External Environment:  
e.g. County level social determinants of health 
County Median Income, State, % with college 
education and % below poverty level and 
Community level  healthcare infrastructure e.g. 
presence of CMHC, FQHC in a county 
 
 
Personal Health Practices: 
 e.g Health care Seeking Behavior: Medication use, 
use of inpatient and emergency room services 
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METHODS 
Study Design 
A retrospective cohort study design was used for this study. Individuals with T2DM and 
newly-diagnosed depression formed the cohort. The date of newly-diagnosed depression was 
considered as the “index” date. Baseline period was defined as twelve months prior to the index 
date. All the independent variables were identified during the baseline period. Individuals were 
followed for a period of 4 months following the index date to examine receipt and depression 
treatment. This study selected a 4-month follow up period based on the Healthcare Effectiveness 
Data and Information Set (HEDIS) definition for acute phase of depression treatment [43]. The 
HEDIS measures antidepressant medication use in the acute phase as 114 days from the date of 
newly-diagnosed depression i.e. index date [43].  
Data Sources 
Medicaid analytic extract (MAX) files: 
 MAX files are prepared and produced by the Centers for Medicare and Medicaid 
Services. The MAX files comprise of enrollment (“personal summary”), inpatient claims, other 
therapy medical claims, and pharmacy claims files of Medicaid beneficiaries. These files were 
linked by beneficiaries‟ unique identification number. The person summary file provides 
information on eligibility, demographics, managed care enrollment, a utilization summary and 
Medicaid payments. The other files contain information on a variety of factors associated with 
service provided such as date of service, diagnosis or medication codes associated with the 
service provided and total amount paid by Medicaid for each service used. This study used 9 
years Medicaid data (2000-2008) from three states: New York (NY), Texas (TX), Illinois (IL). It 
Studies using data that is nationally representative of US population have observed that over the 
years rates of depression treatment with antidepressants had increased, while rate of treatment 
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with psychotherapy decreased in the time period between 1998-2007 [44]. To ensure that enough 
sample sizes were available for all depression treatment categories, multiple years of claims data 
were thus combined in this study. 
Area Health Resource File (AHRF): 
 The AHRF is national county-level health resource information provided by the U.S. 
Department of Health and Human Services, Health Resources and Services Administration [45]. 
The dataset contains more than 6,000 variables providing county level information on health 
facilities, health professions, resource scarcity, health status, economic activity, health training 
programs, and socioeconomic and environmental characteristics [45]. The AHRF file was linked 
with Medicaid data using the Federal Information Processing Standard (FIPS) county codes. 
County-level social determinants of health such as median income, percentage below poverty 
level in a county and county-level healthcare infrastructure such as federally qualified healthcare 
clinics, health professional shortage area and others (explained in the section on independent 
variables)  were derived from this file. 
Identification of the Study Cohort 
Medicaid Beneficiaries with T2DM: 
 Individuals with T2DM in a calendar year were identified as those with at least one 
inpatient visit or two or more physician outpatient visits (which were at least 30 days apart) with 
a primary or secondary diagnosis of T2DM identified by International Classification of 
Diagnosis Codes 9th Revision (ICD-9-CM) codes: 250.x0 or 250.x2. The study population 
comprised of all individuals with (1) a diagnosis of T2DM (2) no diagnosis for depression and 
(3) no antidepressant medication use, in the calendar year.  
Medicaid Beneficiaries with Newly-diagnosed Depression:  
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Medicaid beneficiaries with T2DM and who were depression free were followed in the 
subsequent calendar year to identify newly-diagnosed depression. Individuals with at least one 
outpatient visit or an inpatient admission with a primary or secondary diagnosis of  depression in 
the subsequent calendar year were identified as having a newly-diagnosed depression [46]. 
Depression was identified using ICD9 CM codes: 296.2 (major depressive disorder, single 
episode), 296.3 (major depressive disorder, recurrent episode), 311 (depression not elsewhere 
classified), 309.1 (prolonged depressive reaction), 300.4 (neurotic depression) and 298.0 
(depressive type psychosis) [19, 29]. The first observed date of outpatient visit or inpatient 
discharge with diagnosis of depression was the “index date.” Therefore, individual classified as 
having a newly-diagnosed depression had no history of depression diagnosis or antidepressant 
use for at least a period of 365 days prior to the index date. It has to be noted that previous 
studies have used a 120 day depression free period to define new episode of depression [18]. 
However, to minimize misclassification of an episodic manifestation of chronic depression 
(where depression symptoms last for two or more years) as new episode of depression, the longer 
look-back period of 365 days was used. 
Individuals were excluded from the study cohort if they (1) did not have a diagnosis of at 
least one coexisting chronic physical conditions (identified by ICD-9-CM codes included in the 
appendix) during the baseline period (2) did not have continuous fee-for-service Medicaid 
eligibility during the observation period;(3) were enrolled in Medicare managed care at any point 
during the observation period; (4) died during the study period; and (5) did not use inpatient or 
outpatient Medicaid services during the study period. 
Dependent Variables 
Depression Treatment during the Acute Phase:  
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Depression treatment consisted of pharmacotherapy with antidepressants and 
psychotherapy.  Antidepressant Use: Antidepressants were identified using National Drug Codes 
(NDC) and included selective serotonin reuptake inhibitors, selective norepinephrine reuptake 
(inhibitors), tricyclic antidepressants, monoamine oxidase inhibitors, mirtazapine and bupropion. 
Psychotherapy Use: Psychotherapy was identified using Current Procedural Terminology (CPT) 
codes. The following psychotherapy types were identified: (i) psychotherapy diagnostic 
interview (90801, 90802) (ii) individual psychotherapy [individual psychotherapy 20-30 min 
(90804, 90816, 90805, 90817), 45-50 min (90806, 90818, 90807, 90819), 75-80 min (90808, 
90821, 90809, 90822); interactive individual psychotherapy 20-30 min (90810, 90823, 90811, 
90824), 45-50 min (90812, 90826, 90813, 90827), 75-80 min (90814, 90828, 90815, 90829)] 
(iii) other psychotherapy [family psychotherapy (90846, 90847, 90849), group psychotherapy 
(90853), interactive group psychotherapy(90857)][47]. 
Depression treatment during the four months of follow-up after newly-diagnosed 
depression was classified as: (1) Antidepressants only: These individuals received at least one 
prescription for antidepressant, but no psychotherapy visit during the follow-up.; (2) 
Psychotherapy only: These individuals received at least one psychotherapy visit, but no 
prescription for antidepressant drugs during the four months of follow-up. (3) Both 
antidepressants and psychotherapy: These individuals received a minimum of one prescription 
for antidepressants and one psychotherapy visit (4) No treatment: These individuals received 
neither a prescription for antidepressants nor a psychotherapy visit. 
Adequate Depression Treatment during the Acute Phase:  
Adequate antidepressant treatment: Among individuals who received depression treatment with 
antidepressants, adequate treatment was defined using the HEDIS criteria. The HEDIS defines 
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adequate antidepressant treatment as receiving 84 or more days of prescription for any 
antidepressant drug during the first 114 days following the index date of depression diagnosis. 
Based on this definition, individuals with antidepressant prescription during 70% of the follow-
up days (84/114*100=0.71) were considered as receiving adequate treatment with 
antidepressants [1, 30]   
Adequate psychotherapy treatment: Among individuals who received depression treatment with 
psychotherapy, receipt of adequate treatment  was defined as receiving at least 8 sessions (the 
minimum length of evidence based psychotherapy depression treatment and anxiety disorders) 
[31, 48] during the 120 days of follow-up. 
Individuals who received either adequate antidepressant treatment or adequate 
psychotherapy were defined as having adequate depression treatment. Individuals who did not 
have adequate antidepressant treatment and who did not have adequate psychotherapy treatment 
were considered as not having adequate depression treatment.  
Independent Variables 
Key Independent Variable: Types of Coexisting Chronic Physical Conditions:  
Based on the theory that coexisting conditions had an impact on the medical care, self-
management, and healthcare outcomes of an individual with T2DM, Piette and Kerr developed a  
framework that classified coexisting conditions among individuals with T2DM into dominant 
(conditions whose severity eclipses all other conditions‟ management plans such as metastatic 
cancer), concordant (conditions that overlap with T2DM in their pathophysiology and 
management plans such as cardiovascular diseases) or discordant (conditions with unrelated 
pathophysiology or management plans such as musculoskeletal disorders) [49].  
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Following this framework, it may be assumed that presence of dominant, concordant and 
discordant conditions among individuals with T2DM and newly-diagnosed depression may 
affect the choice of depression treatment. Therefore, following a hierarchy defined in a previous 
study using this framework [50], forty four physical conditions commonly coexisting with 
T2DM were categorized into:  1) dominant; 2) concordant only, 3) discordant only and 4) both 
concordant and discordant conditions. Dominant conditions were given priority because such 
conditions eclipse the management of other health conditions. Concordant and discordant 
conditions were thus defined only among those without dominant conditions. These conditions 
were identified using ICD-9-CM codes and are presented in Appendix A. 
Other independent variables:  
Other independent variables were chosen based on Andersen‟s Behavioral Model. These 
variables were: 
Predisposing Factors: The variables included were: demographics (gender, age, race/ethnicity 
[Whites, African Americans, Hispanics or other races]). 
Enabling Factors:  The enabling factors were defined using Medicaid eligibility status such as 
eligibility due to poverty (yes/no), medical needs (yes/no) and waiver (yes/no). 
Need Factors: The variables included were clinical characteristics such as presence of other 
mental health conditions and number of conditions during baseline. The other mental health 
conditions included bipolar disorder, schizophrenia, post-traumatic stress disorder, and alcohol 
and drug abuse. 
Personal Health Practices: As an individual‟s propensity to seek treatment may influence receipt 
of depression treatment, the study controlled for healthcare seeking behavior by controlling for 
baseline healthcare utilization characteristics such as number of emergency room visits in 180 
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days prior to new-onset depression, inpatient hospitalization, number of oral antidiabetic 
medication classes and insulin use as identified by NDC codes, presence of polypharmacy 
identified by use of 6 or more drug classes in the 90 days prior to new-onset depression, number 
of outpatient visits measured in quartiles;  
External Environment: External environment variables included state of residence, community 
level access healthcare infrastructure and community level social determinants of health 
variables. Community level access healthcare infrastructure variables included presence of 
community mental health clinic (CMHC) and federally qualified health clinic (FQHC) in a 
county, whether county of residence was designated as Health Professional Shortage area 
(HPSA) and density of social workers in a county. Community level social determinants of 
health variables were defined as external environment variables. The variables included were 
urban/rural status of a county, median income in the county and whether percent below poverty 
level and percent with college education in the county were greater than national average based 
on US census estimates [51, 52].  
Statistical Analysis 
Unadjusted Analyses: 
 Descriptive analysis was conducted using frequency, mean and standard errors. Chi-
square tests were used to examine the unadjusted association between types of coexisting chronic 
physical conditions and depression treatment. The association between types of coexisting 
chronic physical conditions and depression treatment were also examined within each category 
of the independent variables and statistical significance of the associations were assessed using 
the chi-square tests.   Same set of statistical analyses were performed to examine the factors 
associated with adequate depression treatment. 
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Adjusted Analyses: 
Multinomial logistic regression analyses were used to examine adjusted association 
between types of coexisting conditions and depression treatment after controlling for the other 
independent variables. Adjusted logistic regression analyses were used to examine adjusted 
association between types of coexisting conditions and adequate depression treatment after 
controlling for predisposing, enabling, need, personal health practices and external environment 
variables. Given that prescription of antidepressants is contraindicated in some concordant and 
dominant conditions included in the study, in all regression analyses “discordant conditions 
only” group was used as the reference group.  Statistical Analytic Software (SAS 9.3) was used 
for all analyses. 
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RESULTS 
Characteristics of the Study Population 
 The study population consisted of 5,837 non-elderly adults Medicaid fee-for-service 
beneficiaries with T2DM and newly-diagnosed depression who were not enrolled in Medicare 
and alive during the study period (Table 1). In the study population 67% were females, 39.7% 
were in the 55-64 years, 30.2% were African-Americans, 36.5% used polypharmacy and 49.9% 
had baseline inpatient hospitalizations; based on county of residence characteristics majority 
lived in area designated as metro (89.2%), HPSA for mental health (83.5%), areas with FQHCs 
(82.4%) and percentage of persons with income below poverty level greater than national 
average (88.5%). Details on the description of the study population are presented in Table 1. 
Study Population Characteristics by Types of Coexisting Chronic Physical Conditions 
The description of the study population by types of coexisting chronic physical condition 
categories are also presented in Table 1. In the study population, 14.7% had dominant 
conditions; 27.0%, 15.4%, and 43.0% of the study population had concordant only, discordant 
only, and both concordant and discordant conditions respectively. Significant group differences 
in types of coexisting conditions were observed for all the other independent variables included 
in the study. A higher proportion of individuals with dominant conditions were older i.e.55-64 
years (18.7% vs 9% in 18-44 years age-group), males (18.4% vs 12.9% in females), had presence 
of other mental health conditions (18.6% vs 12.6% with absence of other mental health 
conditions), inpatient hospitalizations (21.3% vs 8.2% in those without) and higher number of 
outpatient visits (22.9% in 4
th
 vs 6.1% in 1
st
 quartile). Table 1 presents the description of the 
study population characteristics by types of coexisting conditions. 
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 Depression Treatment: Percentages 
 In the study population, 57.3% received any depression treatment; 27.6% received 
treatment with antidepressants only, 18.1% received treatment with psychotherapy only and 
11.6% received treatment with both antidepressants and psychotherapy, 42.7% did not receive 
any treatment. 
Unadjusted Associations between Types of Coexisting Chronic Physical Conditions and 
Depression Treatment Categories 
A  significantly lower percentage of individuals with dominant conditions (20.2%) and 
concordant conditions only (27.9%)  had treatment with antidepressants only as compared to 
those with discordant conditions only (33.1%); a significantly higher percentage of individuals in  
dominant conditions (27.9%) and concordant conditions only (17.2%) received treatment with 
psychotherapy only as compared to individuals with discordant conditions only (13.4%). Similar 
relationships were observed when types of coexisting conditions and depression treatment were 
examined for each subgroup of the categorical independent variables. For example, among 
women 20.8% and 31.2% in the dominant and concordant conditions only groups were treated 
with only antidepressants as compared to 34.1% in discordant conditions only group; 23.4% and 
13.2% in the dominant conditions and concordant conditions only groups were treated with 
psychotherapy only as compared to 11.6% in discordant only group. Percentages of individuals 
receiving treatment with antidepressants only, psychotherapy only and both antidepressants and 
psychotherapy for each category of types of coexisting conditions are presented in Table 2; 
results for no treatment group are not presented in tabular form, but can be furnished on request. 
Adjusted Associations between Types of Coexisting Chronic Physical Conditions and 
Depression Treatment Categories 
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The associations observed in unadjusted analyses, remained in adjusted analyses. In 
adjusted analyses using multinomial logistic regression, the reference group for the dependent 
variable was “No depression treatment”.  The reference group for types of coexisting chronic 
physical conditions was “discordant condition only”.  The results from the multinomial logistic 
regression revealed that as compared to individuals with discordant conditions only, those with 
dominant conditions (AOR: 0.77; 95% Confidence Interval (CI): 0.59, 0.99; p<0.05) and those 
with concordant conditions only (Adjusted Odds Ratio (AOR): 0.80; 95% CI: 0.65, 0.98; 
p<0.05) were less likely to receive depression treatment with antidepressants only.  In 
comparison to those with discordant conditions only, treatment of depression with psychotherapy 
was more likely among individuals with dominant conditions (AOR: 1.61; 95% CI: 1.21, 1.15; 
p<.01) and concordant conditions only: AOR: 1.32; 95% CI: 1.01, 1.72; p<.05). There was no 
statistically significant association between types of coexisting chronic physical conditions and 
receipt of both antidepressant and psychotherapy treatment. The results are presented in Table 3. 
Adequate Depression Treatment 
Descriptive, Unadjusted and Adjusted Associations with Types of Coexisting Chronic Physical 
Conditions: 
Among those who received depression treatment (N=3,347), 32.5% received adequate 
treatment either with antidepressants or psychotherapy. Bivariate chi-square and multivariate 
logistic regression analyses did not show any significant associations between types of coexisting 
conditions and adequate depression treatment.  
Other Independent Variables Associated with Adequate Depression Treatment  
From multivariate analyses, it was observed that Whites as compared to African 
Americans (AOR: 1.44; 95% CI:1.17, 1.78;p<0.001), 1 OAD (AOR:1.40; 95% CI:1.05, 1.88; 
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p<0.05)  and 2 OADs (AOR:1.45; 95% CI:1.08, 1.95; p<0.05)  users as compared to users of 
3+OADs and those with number of outpatient visits in the fourth quartile as compared to first 
quartile (AOR:1.79; 95% CI:1.39, 2.31; p<0.001)   were more likely to get adequate depression 
treatment. (Results not presented in tabular form). 
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DISCUSSION 
  This study examined the association between types of coexisting conditions and 
depression treatment, after adjusting for other predisposing, enabling, need, personal health 
practices and external environment factors, among non-elderly fee-for-service Medicaid 
Enrollees from multiple states who had T2DM and newly-diagnosed depression.  
Depression treatment rates found in this study I somewhat lower than those found in the T2DM 
population. Less than 40% of the study population in this received treatment with 
antidepressants. Though not specific to individuals with T2DM, Marcus et al., reported that 
among individuals with depression, antidepressant and psychotherapy treatment rates in a 
nationally representative sample of the US population in 2007 were 75% and 43% respectively.  
The antidepressant treatment rates among individuals with newly-diagnosed depression and 
T2DM have been found to vary between 93% [21]to 43% [17]. Therefore, antidepressant 
treatment rates in this study were low as compared to other studies. 
Nearly, 30% of the study population received psychotherapy. Psychotherapy treatment 
rate in nationally representative US sample was 43% in 2007 [44]. Among those with T2DM, 
psychotherapy rates have been found to be 28% in veterans‟ population. Therefore, 
psychotherapy treatment rates may be comparable to other studies. However, still 43% of 
individuals did not receive any depression treatment.  Additionally, only 33% of those were 
treated, got adequate depression treatment. 
It was observed among individuals with T2DM, those with coexisting conditions that 
were either related to T2DM pathophysiology or management i.e. concordant conditions only or 
those with potentially life threatening conditions i.e. dominant conditions were less likely to get 
prescribed antidepressants and more likely to avail psychotherapy as compared to individuals 
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with T2DM and other coexisting conditions that were unrelated to T2DM in terms of 
pathophysiology or management plans i.e. discordant conditions.  
 This study found that among individuals with T2DM and newly-diagnosed depression, 
those with concordant conditions only were less likely to receive treatment with antidepressants 
only and more likely to receive treatment with psychotherapy only. These results are not 
surprising given that antidepressants have not yet proven to be highly efficacious for treating 
depression in presence of concordant conditions such as heart disease [53] [54] [55]. It has been 
reported that 15%-25% of individuals with heart disease and depression who were initiated on 
antidepressants, discontinue their treatment because of adverse events [56]. The American Heart 
Association suggests that if antidepressant treatment is initiated among individuals with heart 
disease, then these individuals should be closely monitored to ensure medication compliance and 
to detect and manage any adverse event [57]. Given that presence of T2DM itself is associated 
with high cardiovascular event risk [58], physicians may avoid prescribing antidepressants to 
individuals with T2DM and concordant conditions such as heart disease . On the other hand, 
treating depression with psychotherapy such as cognitive behavioral therapy among individuals 
with heart disease have been shown to be effective in individuals not getting treat treatment with 
antidepressants; the ENRICHD trial showed that 12-16 sessions of CBT over 12 weeks help in 
achieving remission from moderate to severe depression [59].  
 Individuals with dominant conditions as compared to those with discordant conditions 
only were more likely to receive depression treatment with only psychotherapy.  This may be 
due to the proven  beneficial effects of  treating depression with psychotherapy among 
individuals with dominant conditions[60]. For example, a meta-analysis of six randomized 
clinical trials found that compared to treatment as usual, psychotherapies such as supportive-
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expressive group therapy, cognitive behavioral therapy, and problem-solving therapy, had 
significant clinical benefits in reducing depressive symptoms among individuals with advanced 
cancer [61]. Psychotherapy such as cognitive behavioral therapy has also proven to be beneficial 
for individuals with end stage renal disease [62]. The effectiveness of antidepressants for 
depression treatment in patients with terminal illness such as cancer and end stage renal disease 
remains inconclusive. Additionally, as it may take four to eight weeks to evaluate effectiveness 
of antidepressants, physicians may be reluctant in initiating treatment with antidepressants in 
individuals with limited life expectancy [63, 64]. Furthermore, the use of antidepressants for 
depression treatment in presence of neurological conditions such as dementia [65], Parkinson‟s 
[66] and epilepsy [67] (which were also included under definition for dominant conditions) have 
not been shown to be clinically effective in improving quality of life, and functional and 
cognitive outcomes  and sometimes[68] even in reducing depression symptoms [65].  
 This study additionally examined  the association between types of coexisting conditions 
and adequate depression treatment among those who were treated for depression after adjusting 
for predisposing, enabling, need, personal health practices and external environment variables; 
however, no statistically significant associations between adequate depression treatment and 
types of coexisting chronic physical conditions were observed.  Previous research, although not 
specific to T2DM, a study using data on veterans also observed similar relationships [69]. This 
study reported that among veterans with coexisting depression and multiple chronic conditions 
(cardiovascular/cerebrovascular diseases, arthritis, peptic ulcer, diabetes, respiratory diseases, 
substance/alcohol abuse and cancer), there were no significant associations between coexisting 
chronic illnesses and adequate antidepressant treatment [69].   
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Implications 
Individuals with both physical (i.e. T2DM, coexisting chronic physical conditions) and 
mental health (i.e. depression) often have complex health care needs which may not be fully met 
in traditionally short (often channeled in to 15 minute time slots) primary care visits [70]. To 
provide quality care to such individuals, healthcare teams with expertise in providing both 
physical and mental health care may be more appropriate. Evidence from randomized clinical 
trials have shown that collaborative care among individuals with depression and T2DM, 
significantly improved the depressive symptom score and HbA1c level, compared with control 
conditions [71]. However, even in collaborative care settings, the selection of the healthcare team 
is important. Meta-regression analysis of randomized clinical trials on collaborative care for 
depression treatment have shown that characteristics of the intervention provided such as 
whether case managers were regularly supervised by psychiatrists and the mental health 
background of case managers had more favorable effect on outcomes [72]. Therefore, such 
carefully selected teams with backgrounds in both physical and mental health care delivery may 
improve quality of depression treatment. The novel healthcare delivery models such as 
Accountable Care Organizations (ACO) and Patient Centered Medical Home (PCMH) created 
under the 2010 Patient Protection and Affordable Care Act, provide options for such integrated 
care models. Future research may focus on quality of depression treatment provided to 
individuals with both physical and mental health conditions in such settings.   
Strengths and limitations  
 The current study has many advantages. The use of administrative claims data with dates 
of services enabled us to follow a cohort of patients with T2DM over time.  Medicaid claims also 
enabled us to capture the healthcare experiences of Medicaid beneficiaries across a variety of 
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providers in different locations. The presence of diagnoses enabled identification of T2DM, 
depression and other physical and mental health conditions. The study used a comprehensive list 
of independent variables by merging Medicaid claims data with the county-level data from the 
ARF. A pragmatic practice-based theoretical framework was used to identify the numerous 
coexisting chronic physical conditions into manageable and clinically meaningful categories. 
This was the first study to examine whether depression treatment patterns among individuals 
with T2DM varied by coexisting chronic physical conditions with similar or different 
management and/or pathophysiology from that of T2DM.   
However, the study also has some limitations. As administrative claims data can only 
identify diseases through diagnosis codes, there is the potential for underestimating depression 
prevalence or incidence because of under-coding of depression. Identifying depression is one of 
the more difficult problems in administrative data research and perfection may not be attainable. 
However, claims data contain physician/psychologist diagnoses of depression and offer a 
particularly attractive alternative to the substantial cost and complications associated with 
prospective surveys supplemented with medical record data. Additionally, this study included 
only filled prescriptions and it is not known whether the antidepressants were actually used. This 
study did not include alternative forms of treatment for depression. The study included fee-for-
service Medicaid beneficiaries enrolled three states, thus results might not be generalizable to 
other populations. 
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CONCLUSIONS 
Types of coexisting conditions were associated with depression treatment categories 
among non-elderly adult fee-for-service Medicaid beneficiaries; however once treatment was 
received, whether the individual obtains adequate treatment is not associated with coexisting 
conditions. The study findings suggest that management for other chronic physical conditions 
may compete with treatment for depression. Future studies that adjust for physician factors may 
need to be conducted to explore the management priorities. The findings from this study needs to 
be replicated in the general population.  
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TABLES & APPENDICES 
Table 1: Description of the Study Population by Types of Coexisting Chronic Physical Conditions  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 - 2008 
    
All Dominant Concordant 
Only 
Discordant 
Only 
Both 
Concordant & 
Discordant Sig 
    N % N % N % N % N %   
  5,837  858 14.7 1,576 27.0 896 15.4 2,507 43.0  
  
Predisposing Factors 
Age 
           
*** 
 
18-44 years 1,448 24.8 131 9.0 470 32.5 273 18.9 574 39.6 
 
 
45-54 years 2,072 35.5 294 14.2 500 24.1 339 16.4 939 45.3 
 
 
55-64 years 2,317 39.7 433 18.7 606 26.2 284 12.3 994 42.9 
 Sex 
           
*** 
 
Female 3,911 67.0 504 12.9 1,036 26.5 656 16.8 1,715 43.9 
 
 
Male 1,926 33.0 354 18.4 540 28.0 240 12.5 792 41.1 
 Race 
           
* 
 
Whites 1,564 26.8 229 14.6 413 26.4 265 16.9 657 42.0 
 
 
African 
Americans 1,765 30.2 271 15.4 432 24.5 266 15.1 796 45.1 
 
 
Others 2,508 43.0 358 14.3 731 29.1 365 14.6 1,054 42.0 
 
  
Need Factors 
Other Mental Health Conditions 
         
*** 
 
Yes 2,022 34.6 377 18.6 506 25.0 308 15.2 831 41.1 
 
 
No 3,815 65.4 481 12.6 1,070 28.0 588 15.4 1,676 43.9 
 
  
Enabling Factors 
Medicaid Eligibility-Cash 
Assistance 
         
** 
 
Yes 5,031 86.2 752 14.9 1,331 26.5 750 14.9 2,198 43.7 
 
 
No 806 13.8 106 13.2 245 30.4 146 18.1 309 38.3 
 Medicaid Eligibility-Medical Need 
         
** 
 
Yes 732 12.5 126 17.2 214 29.2 118 16.1 274 37.4 
 
 
No 5,105 87.5 732 14.3 1,362 26.7 778 15.2 2,233 43.7 
 Medicaid Eligibility-Waiver 
         
* 
 
Yes 359 6.2 41 11.4 105 29.2 72 20.1 141 39.3 
 
 
No 5,478 93.8 817 14.9 1,471 26.9 824 15.0 2,366 43.2 
 
  
Personal Health Practices 
Oral Antidiabetic Drugs (OADs) 
         
*** 
 
1   OAD 1,660 28.4 203 12.2 458 27.6 291 17.5 708 42.7 
 
 
2   OADs 1,343 23.0 164 12.2 376 28.0 230 17.1 573 42.7 
 
 
3+ OADs 490 8.4 41 8.4 167 34.1 69 14.1 213 43.5 
 
 
No OAD 2,344 40.2 450 19.2 575 24.5 306 13.1 1,013 43.2 
 Insulin Use 
          
*** 
 
Yes 2,055 35.2 321 15.6 572 27.8 158 7.7 1,004 48.9 
 
 
No 3,782 64.8 537 14.2 1,004 26.5 738 19.5 1,503 39.7 
 Polypharmacy 
          
*** 
 
Yes 2,128 36.5 345 16.2 385 18.1 315 14.8 1,083 50.9 
 
 
No 3,709 63.5 513 13.8 1,191 32.1 581 15.7 1,424 38.4 
 Inpatient Hospitalization 
         
*** 
 
Yes 2,910 49.9 619 21.3 586 20.1 251 8.6 1,454 50.0 
 
 
No 2,927 50.1 239 8.2 990 33.8 645 22.0 1,053 36.0 
           
         continued 
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Table 1: Description of the Study Population by Types of Coexisting Chronic Physical Conditions  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 - 2008 
    
All Dominant Concordant 
Only 
Discordant 
Only 
Both 
Concordant & 
Discordant Sig 
    N % N % N % N % N %   
  5,837  858 14.7 1,576 27.0 896 15.4 2,507 43.0  
Outpatient Visits 
          
*** 
 
1st  Q 1,534 26.3 94 6.1 644 42.0 322 21.0 474 30.9 
 
 
2nd Q 1,331 22.8 166 12.5 382 28.7 229 17.2 554 41.6 
 
 
3rd Q 1,534 26.3 269 17.5 308 20.1 194 12.6 763 49.7 
 
 
4th Q 1,438 24.6 329 22.9 242 16.8 151 10.5 716 49.8 
 
  
Mean + SE Mean + SE Mean + SE Mean + SE Mean + SE 
 Number of T2DM 
related office visits 6.97+0.12 7.85+0.3 6.48+0.4 5.34+0.4 7.56+0.4 
 Number of ER Visits 1.23+0.03 1.68+0.1 0.68+0.1 0.78+0.1 1.58+0.1 
 
  
External Environment 
State 
           
*** 
 
Illinois 1,602 27.4 226 14.1 414 25.8 268 16.7 694 43.3 
 
 
New York 2,830 48.5 459 16.2 790 27.9 443 15.7 1,138 40.2 
 
 
Texas 1,405 24.1 173 12.3 372 26.5 185 13.2 675 48.0 
 HPSA- Mental Health Care 
         
* 
 
Yes 4,871 83.5 741 15.2 1,324 27.2 736 15.1 2,070 42.5 
 
 
No 966 16.5 117 12.1 252 26.1 160 16.6 437 45.2 
 Metro 
           
*** 
 
Yes 5,207 89.2 796 15.3 1,413 27.1 783 15.0 2,215 42.5 
 
 
No 630 10.8 62 9.8 163 25.9 113 17.9 292 46.3 
 CMHC 
            
 
Yes 2,786 47.7 410 14.7 760 27.3 415 14.9 1,201 43.1 
 
 
No 3,051 52.3 448 14.7 816 26.7 481 15.8 1,306 42.8 
 FQHC 
           
** 
 
Yes 4,810 82.4 739 15.4 1,311 27.3 727 15.1 2,033 42.3 
 
 
No 1,027 17.6 119 11.6 265 25.8 169 16.5 474 46.2 
 Median Income 
          
* 
 
1st  Q 1,444 24.7 176 12.2 387 26.8 213 14.8 668 46.3 
 
 
2nd Q 1,484 25.4 215 14.5 397 26.8 258 17.4 614 41.4 
 
 
3rd Q 1,588 27.2 251 15.8 434 27.3 241 15.2 662 41.7 
 
 
4th Q 1,321 22.6 216 16.4 358 27.1 184 13.9 563 42.6 
 % with GT 4yr college education >  16%
ⱡⱡ
 
        
** 
 
Yes 4,857 83.2 742 15.3 1,312 27.0 761 15.7 2,042 42.0 
 
 
No 980 16.8 116 11.8 264 26.9 135 13.8 465 47.4 
 % below poverty level GT 11.1%
ⱡⱡⱡ
 
          
 
Yes 5,166 88.5 768 14.9 1,397 27.0 785 15.2 2,216 42.9 
 
 
No 671 11.5 90 13.4 179 26.7 111 16.5 291 43.4 
 
  
Mean + SE Mean + SE Mean + SE Mean + SE Mean + SE 
 Density of Social 
Workers in the County 3.0+0.02 2.89+0.1 3.23+0.1 3.00+0.1 3.03+0.1 
                           
 
Note: Study sample comprised of individuals with type 2 diabetes mellitus aged 18-64 years and with at least one coexisting 
dominant, concordant or  discordant chronic physical condition and who were alive, not dually eligible for Medicare and 
continuously enrolled in fee-for-service Medicaid for at least 24 months( N=5,837); includes Medicaid data from three states: 
Illinois, Texas, New York 
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Asterisks (*) represent significant differences in study population characteristics and  coexisting chronic physical conditions 
categories i.e. Concordant Only, Discordant Only, Both Concordant and Discordant and Dominant, derived from chi-square 
statistics and univariate ordinary least square regressions (indicated by ⱡ) ***P<.001; **.001 ≤ P < .01; *.01 ≤ P < .05. 
ⱡ Both Concordant and Discordant 
ⱡⱡ 16% Cut off was chosen based on 2000 Census Education attainment results 
ⱡⱡⱡ 11.1% Cut off was chosen based on 1999 Census Poverty levels  
AA: African American; Q: Quartile; HPSA: Health Professional Shortage Area; CMHC: Community Mental Health 
Clinic; FQHC: Federally qualified health clinic; GT: Greater Than; 
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Table 2: Percentages of Depression Treatment by Types of Coexisting Chronic Physical Conditions  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 - 2008 
  
  
Antidepressants only Psychotherapy only Both Antidepressants & Psychotherapy 
 
 
  Dominant 
Concordant  
Only 
Discordant  
Only Both¥  Dominant 
Concordant  
Only 
Discordant  
Only Both¥  Dominant 
Concordant  
Only 
Discordant  
Only Both¥    
    % % % % % % % % % % % % Sig 
ALL 20.2 27.9 33.1 28.0 27.9 17.2 13.4 17.1 12.5 11.8 11.0 11.4 *** 
  
Predisposing Factors 
 Age 
             
 
18-44 years 21.4 26.4 29.3 26.3 26.0 16.6 14.7 17.9 13.0 12.6 12.5 13.2 
 
 
45-54 years 22.1 25.6 33.6 27.7 24.8 20.4 13.6 16.1 12.9 13.2 10.6 12.7 ** 
 
55-64 years 18.5 30.9 36.3 29.3 30.5 15.0 12.0 17.5 12.0 10.1 10.2 9.2 *** 
Sex 
             
 
Female 20.8 31.2 34.1 29.8 23.4 13.2 11.6 14.5 14.3 12.5 11.6 11.5 *** 
 
Male 19.2 21.5 30.4 24.1 34.2 24.8 18.3 22.7 9.9 10.6 9.6 11.1 *** 
Race 
             
 
Whites 21 32.7 36.2 30.9 25.8 18.9 12.1 15.7 18.3 12.3 10.6 13.9 *** 
 
African 
American 13.7 23.1 25.6 24.2 33.9 23.1 16.9 20.1 11.1 10 13.2 10.7 *** 
 
Others 24.6 27.9 36.4 29.0 24.6 12.7 11.8 15.7 9.8 12.6 9.9 10.4 *** 
  
Need Factors 
 Other Mental Health Conditions 
          
 
Yes 13.5 16.8 21.8 19.9 36.6 29.1 25.3 26.4 11.9 9.3 10.1 11.9 ** 
 
No 25.4 33.1 39.1 32.0 21.0 11.6 7.1 12.5 12.9 13 11.6 11.2 *** 
  
Enabling Factors 
 Medicaid Eligibility-Cash Assistance 
           
 
Yes 19.3 25.8 31.2 27.0 27.7 17.7 14.0 17.4 12.8 11.6 11.6 11.0 *** 
 
No 26.4 39.2 43.2 35.0 29.2 14.3 10.3 14.6 10.4 13.1 8.2 14.6 ** 
            
         continued 
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Table 2: Percentages of Depression Treatment by Types of Coexisting Chronic Physical Conditions  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 - 2008 
  
  
Antidepressants only Psychotherapy only Both Antidepressants & Psychotherapy 
 
 
  Dominant 
Concordant  
Only 
Discordant  
Only Both¥  Dominant 
Concordant  
Only 
Discordant  
Only Both¥  Dominant 
Concordant  
Only 
Discordant  
Only Both¥    
    % % % % % % % % % % % % Sig 
Medicaid Eligibility-Medical Need 
           
 
Yes 17.5 29.4 30.5 27.4 38.9 21.0 18.6 21.5 10.3 18.7 12.7 18.6 ** 
 
No 20.6 27.6 33.5 28.1 26.0 16.6 12.6 16.5 12.8 10.7 10.8 10.5 *** 
Medicaid Eligibility- Waiver 
           
 
Yes 22.0 45.7 52.8 36.9 24.4 8.6 2.8 11.3 12.2 6.7 4.2 7.8 ** 
 
No 20.1 27 31.4 28 28.0 18 14.3 17 12.5 12 11.7 12 *** 
  
Personal Health Practices 
 Number of Oral Antidiabetic Drugs (OADs) Classes 
         
 
1 24.1 28.6 34.4 28.8 19.7 13.8 13.7 15.3 20.7 12.2 9.3 10.6 *** 
 
2 29.9 29.8 33.9 32.6 20.7 13.3 12.2 13.1 7.3 9.8 10.4 12.7 
 
 
3+ 31.7 28.7 39.1 34.7 17.1 16.8 7.2 15.0 9.8 15 18.8 11.7 
 
 
None 13.8 25.7 30.1 23.4 35.1 22.6 15.4 21.0 10.9 11.8 11.4 11.2 *** 
Insulin Use 
             
 
Yes 24 33.0 33.5 28.6 19.9 14.0 12.0 14.9 15.6 14 12.0 12.9 
 
 
No 17.9 24.9 33.1 27.6 32.6 19.0 13.7 18.5 10.6 10.6 10.8 10.4 *** 
Polypharmacy 
            
 
Yes 23.8 29.6 32.7 32.7 24.3 15.3 14.6 13.9 13.6 11.7 11.7 12.8 *** 
 
No 17.7 27.3 33.4 24.4 30.2 17.8 12.7 19.5 11.7 11.8 10.7 10.3 *** 
Inpatient Hospitalization 
           
 
Yes 18.4 22.9 23.9 24.8 29.4 22.2 21.9 19.9 13.7 14.2 12.4 11.6 *** 
 
No 24.7 30.8 36.7 32.4 23.8 14.2 10.1 13.2 9.2 10.4 10.5 11.1 *** 
               
               
            continued 
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Table 2: Percentages of Depression Treatment by Types of Coexisting Chronic Physical Conditions  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 - 2008 
  
  
Antidepressants only Psychotherapy only Both Antidepressants & Psychotherapy 
 
 
  Dominant 
Concordant  
Only 
Discordant  
Only Both¥  Dominant 
Concordant  
Only 
Discordant  
Only Both¥  Dominant 
Concordant  
Only 
Discordant  
Only Both¥    
    % % % % % % % % % % % % Sig 
Outpatient Visits 
            
 
1st  Q 34 32.1 36.3 34.0 17.0 11.8 11.2 12.0 9.6 12.3 12.4 11.8 
 
 
2nd Q 21.7 25.9 35.4 31.9 21.7 18.3 10.9 14.1 10.8 12.3 9.6 10.6 * 
 
3rd  Q 21.2 25.6 32.5 28.2 30.5 20.1 11.9 17.4 13.8 10.4 11.9 9.4 *** 
 
4th  Q 14.6 22.3 23.8 20.8 31.9 26.0 23.8 22.3 13.1 11.6 9.3 13.8 * 
  
External Environment 
 State 
             
 
Illinois 24.3 28.3 27.6 28.8 28.8 20.3 16.8 20.3 15.5 15.7 17.2 15.9 
 
 
New York 18.1 30.5 38.1 32.1 30.9 14.7 10.2 15.1 7.8 6.3 6.1 6.1 *** 
 
Texas 20.2 21.8 29.2 20.3 18.5 19.1 16.2 17.0 20.8 19.1 14.1 15.9 
 HPSA- Mental Health 
         
 
Yes 19.7 27.3 31.3 27.6 28.7 17.4 14.4 17.5 12.1 11.7 11.3 11.3 *** 
 
No 23.1 31.0 41.9 29.7 22.2 16.3 8.8 14.9 14.5 12.3 10.0 11.9 * 
Metro 
             
 
Yes 19.2 27.0 31.7 28.1 29.4 17.6 13.8 18.2 12.3 12 11.6 11.5 *** 
 
No 32.3 35.6 43.4 27.1 8.1 13.5 10.6 8.2 14.5 9.8 7.1 11.0 * 
CMHC 
             
 
Yes 21.2 26.3 31.3 27.8 27.1 17.5 15.4 19.5 16.6 15.7 14.9 14.1 *** 
 
No 19.2 29.3 34.7 28.2 28.6 16.9 11.6 14.9 8.7 8.2 7.7 9.0 *** 
FQHC 
             
 
Yes 19.4 27.1 31.2 28.1 29.5 17.5 14.4 18.0 12.2 12 11.6 11.6 *** 
 
No 25.2 31.7 41.4 27.4 17.6 15.8 8.9 13.3 14.3 10.9 8.9 10.8 * 
             
          continued 
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Table 2: Percentages of Depression Treatment by Types of Coexisting Chronic Physical Conditions  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 - 2008 
  
  
Antidepressants only Psychotherapy only Both Antidepressants & Psychotherapy 
 
 
  Dominant 
Concordant  
Only 
Discordant  
Only Both¥  Dominant 
Concordant  
Only 
Discordant  
Only Both¥  Dominant 
Concordant  
Only 
Discordant  
Only Both¥    
    % % % % % % % % % % % % Sig 
Median Income 
            
 
1st  Q 24.4 30.2 37.1 22.9 15.3 16.0 11.7 15.0 15.3 15.8 10.8 14.7 ** 
 
2nd Q 19.1 28.0 34.5 30.8 27.4 16.6 12.8 16.6 11.6 11.6 9.3 10.1 *** 
 
3rd  Q 22.7 29.5 32.4 32.6 27.9 17.1 14.5 16.5 9.6 9 12.4 9.7 ** 
 
4th  Q 14.8 23.2 27.7 25.6 38.4 19.3 14.7 20.8 14.4 11.2 12.0 11.0 *** 
% with GT 4yr college education >  16%
ⱡⱡ
 
        
 
 
Yes 19.1 26.9 31.4 28.5 30.6 17.9 14.3 18.3 11.6 10.9 11.4 11.1 *** 
 
No 26.7 32.6 43.0 25.8 10.3 13.6 8.1 11.8 18.1 16.3 8.9 12.9 ** 
% below poverty level GT 11.1%
ⱡⱡⱡ
 
         
 
 
Yes 19.8 26.8 32.4 27.5 28.4 17.5 13.9 17.3 11.6 11.7 11.3 11.7 *** 
 
No 23.3 36.3 38.7 32.0 23.3 15.1 9.9 15.5 20.0 12.8 9.0 9.3 * 
                              
 
Note: Study sample comprised of individuals with type 2 diabetes mellitus aged 18-64 years and with at least one co-existing dominant, concordant or discordant chronic 
physical condition and who were alive, not dually eligible for Medicare and continuously enrolled in fee-for-service Medicaid for at least 24 months( N=5,837); includes 
Medicaid data from three states: Illinois, Texas, New York 
Asterisks(*) represent  significant differences in depression treatment categories i.e. antidepressants only, psychotherapy only, both antidepressants and psychotherapy 
and no treatment by coexisting chronic physical conditions categories i.e. Dominant, Concordant Only, Discordant Only and Both Concordant and Discordant for each 
of the categorical independent variable subgroups 
***P < .001; **.001 ≤ P < .01; *.01 ≤ P < .05. 
ⱡ Both Concordant and Discordant 
ⱡⱡ 16% Cut off was chosen based on 2000 Census Education attainment results 
ⱡⱡⱡ 11.1% Cut off was chosen based on 1999 Census Poverty levels  
Q: Quartile; HPSA: Health Professional Shortage Area; CMHC: Community Mental Health Clinic; FQHC: Federally qualified health clinic; GT: Greater Than;  
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Table 3: Odds Ratios and Adjusted Odds Ratio and 95% Confidence Intervals  
of Types of Co-existing Chronic Physical Conditions  
from Multinomial Logistic Regression on Depression Treatment Categories  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 – 2008 
    
Antidepressants Only Psychotherapy Only Both Antidepressants & 
Psychotherapy 
    OR 95% CI Sig OR 95% CI Sig OR 95% CI Sig 
  
Model 1: Adjusted for Types of Co-existing Chronic Physical Conditions 
 
Dominant 0.65 0.51 ,  0.83 *** 2.23 1.72 ,  2.91 *** 1.21 0.89 ,  1.65 
 
 
Concordant Only 0.83 0.68 ,  1.00 
 
1.26 0.98 ,  1.62 
 
1.05 0.80 ,  1.38 
 
 
Discordant Only Reference Reference Reference 
 
Both
ⱡ 
 0.82 0.69 ,  0.98 * 1.24 0.98 ,  1.57 
 
1.01 0.78 ,  1.30 
 
  AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
  
Model 2: Adjusted for Model I +  Predisposing (gender, age, race/ethnicity), 
Need Factors (other mental health conditions, number of  conditions),  
Enabling Factors (Medicaid Eligibility Categories-Poverty, Medical Need, Waiver) 
Personal health practices (number of ER and  outpatient visits, inpatient hospitalization, 
number of OAD classes, insulin use and polypharmacy) 
 
Dominant 0.77 0.60 , 1.00 * 1.61  1.21, 2.15 ** 1.14 0.82 ,  1.60 
 
 
Concordant Only 0.81 0.67 , 1.00 * 1.31 1.01 ,  1.70 * 1.03 0.78 ,  1.38 
 
 
Discordant Only Reference Reference Reference 
 
Both
ⱡ 
 0.88 0.73 , 1.07 
 
1.12 0.87 ,  1.44 
 
0.87 0.66 ,  1.14 
 
  
Model 3: Adjusted for Model 1+Model 2+ External environment characteristics  
(whether county of residence had a CMHC, FQHC,  
was HPSA for mental health, density of social workers rural/urban status of county, 
median income in the county, whether percent below poverty level and percent with 
college education greater than national average) 
 
Dominant 0.77 0.59 , 0.99 * 1.60 1.20 , 2.13 ** 1.11 0.79 , 1.55 
 
 
Concordant Only 0.80 0.65 , 0.98 * 1.32 1.01 , 1.72 * 1.01 0.76 ,  1.35 
 
 
Discordant Only Reference Reference Reference 
 
Both
ⱡ 
 0.87 0.72 , 1.05 
 
1.14 0.88 , 1.46 
 
0.86 0.65 ,  1.13 
                       
 
Note: Study sample comprised of individuals with type 2 diabetes mellitus aged 18-64 years and with at least one co-
existing concordant, discordant or dominant chronic physical condition and who were alive, not dually eligible for Medicare 
and continuously enrolled in fee-for-service Medicaid for at least 24 months( N=5,837); includes Medicaid data from three 
states: Illinois, Texas, New York 
Asterisks (*) indicate statistical significance are based on multinomial logistic regression with discordant conditions 
as reference group for independent variable and no antidepressant treatment i.e. none as reference group for 
dependent variable.  
***P<0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P <0.05. 
ⱡ Both Concordant and Discordant 
ER: Emergency Room; OAD: Oral Antidiabetic Drugs; HPSA: Health Professional Shortage Area; CMHC: 
Community Mental Health Clinic; FQHC: Federally qualified health clinic 
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Appendix A : ICD-9-CM Codes for Identifying  Types of Coexisting chronic physical Conditions  
Conditions ICD-9-CM Codes 
Concordant conditions 
 
 
Coronary Artery Disease 410,4100,4101,4102,4103,4104,4105,4106,4107,4108,4109,411,4110,
4111,4118,41181,41189,412,413,4130,4131,4139,414,4140,41400,414
01,41402,41403,41404,41405, 4141,41410,41411, 41419,4148,4149 
 
Congestive Heart Failure 40201,40211,40291,40401,40411,40491,428,4280,4281,4289 
 
Arrhythmia 423,4230,4231,4232,4238,4239,42731 
 
Stroke 431,43301,43311,43321,43331,43381,43391,43401,43411,43491,435,
4350,4351,4352,4353,4358,4359,438,4380,4381,43811,43812,4382,43
83,4384,4385,43850,4385,43852,43853,4388,43881, 
43882,43889,4389 
 
Peripheral Vascular Disease 2507,4402,44020,44021,44022,44023,44024,44029,4408,4409,4422,4
423,443,4430, 4431,4438,44381, 44389,4439,44422,44481 
 
Peripheral Vascular Disease-gangrene 7854 
 
Renal  
Chronic Renal Failure 
Chronic Pathophysiology 
40311,40391,40412,40413,40492,40493, 585,586,587, 
2741,27410,27411,27419, 
40310,40390,40410,40411,40490,40491, 
581,5810,5811,5812,5813,5818,5819, 
582,5820,5821,5822,5824,5828,58281,58289,5829,583,5830,5831,583
2,5834,5836, 
5837, 5838,58381,58389,5839,  5900,59000,59001,5936,5939, 
75312,75313,75314 
 
Diabetic Nephropathy 2504,25040,25041,25042,25043 
 
Acute Renal Failure and Disease 
 
40300,40301,40400,40401,40402,40403,40501,4533,584,5845,5846,5
847,5848,5849, 
580,5800,5804,5808,58081,58089,5809,5901,59010,59011,5902,5903,
5908,59080, 
59081,59381,866,8660,86600,86601,86602,86603,8661,86610,86611,
86612,86613 
 
Retinopathy 
(excludes advanced retinopathy, blindness) 
3620,36201,25050,25051,25052,25053 
 
Ulcer 700,68110,68111,6827,7071,73076,73077 
 
Other Diabetes Related Complications 
Uncontrolled Diabetes 
Short Term Diabetes 
25002,25003,25010,25011,25012,25013,25020,25021,25022,25023,25
030,25031, 
25032,25033 
Discordant Conditions  
 
Gastro Intestinal Tract Related Disorders: 
GERD/Esophagitis 
Peptic ulcers 
Inflammatory Bowel Disease 
Diverticulitis 
Gall Bladder disease and stone 
Viral hepatitis 
5301,5302,5303,53081,531,532,533,534,555,556,56211,56213,574 
575,576,070 
 
Chronic Obstructive Pulmonary Disease 490,491,492,493,495,496,500,501,502,503,504,505,5064  
 
Gout 274,712 
 
Hip problem 71905,71915,71925,71935,71945,71955,71965,71975,71985,71995,72
65,73314,73315,73342,820 
 
Low back pain 720,7213,72142,72210,72252,72273,72283, 
72293,72402,7242,7243,7244,7245,7246,7247,7248,7249 
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Appendix A : ICD-9-CM Codes for Identifying  Types of Coexisting chronic physical Conditions  
Conditions ICD-9-CM Codes 
 
Osteoarthritis  715 
 
Other Arthritis 716 
 
Rheumatoid arthritis  714 
 
Connective tissue rheumatological disease 7100,7101,7104,725 
 Blindness Single Eye 3696,3697,3698,3699 
Dominant Conditions  
 
End Stage Renal Disease E8791,V51,V56,V560,V5631,V5632,V568 
 
End Stage Liver Disease 5722,5723,5724,5728,4560,4561, 4562,45620,45621, 571 
 
Blindness Both Eyes/ Advanced Retinopathy 36202,3690,3691,3692,3693,3694 
 
Cancer 140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,1
56,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,17
2,174,175,176,177,178,179,180,181,182,183,184,186,187,188,189,190
,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,
207,208 
 
Pre-dementia Cognitive Impairment 294 ,2941, 29283, 2949 ,33183,78093,438,3330,3334,3315 
 
Dementia and Related Conditions 2900,29010,29011,29012,29013,2902,29021,2903,29040,29041,29042
,29043,2912, 
29410,29411,2948,3310,3311,3312,3317,33182,33189,3319,3320,046
1,0463,0941, 
29282,3109 
 
Multiple Sclerosis  340 
 
Hemiplegia Hemiparesis and Paraplegia 342,3441 
 
Parkinson‟s Disease  332 
 
Muscular dystrophy 359 
 
Spinal cord injury 80600,80601,80602,80603,80604,80605,80606,80607,80608,80609,80
61, 9520, 
 34400,34401,34402,34403,34404,34409 
 
Epilepsy 345 
 
Gastropareis  5363 
 
AIDS 042 
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Appendix B: Odds Ratios and Adjusted Odds Ratio and 95% Confidence Intervals  
of All Independent Variables from Multinomial Logistic Regression on Depression Treatment Categories 
Results presented for Antidepressants Only  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 – 2008 
  
Antidepressants Only 
Characteristics OR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Types of Coexisting Chronic Physical Conditions 
       
 
Dominant 0.65 [ 0.51 ,  0.83] *** 0.77 [ 0.60 ,  1.00] * 0.77 [ 0.59 ,  0.99] * 
 
Concordant Only 0.83 [ 0.68 ,  1.00] 
 
0.81 [ 0.67 ,  1.00] * 0.80 [ 0.65 ,  0.98] * 
 
Discordant Only 
         
 
Both 0.82 [ 0.69 ,  0.98] * 0.88 [ 0.73 ,  1.07] 0.87 [ 0.72 ,  1.05] 
 Age 
          
 
18-44 years 
         
 
 45-54 years 
   
1.04 [ 0.87 ,  1.23] 1.05 [ 0.88 ,  1.25] 
 
 
55-64 years 
   
1.03 [ 0.87 ,  1.22] 1.06 [ 0.89 ,  1.26] 
 Female 
          
 
Female 
   
1.17 [ 1.01 ,  1.34] * 1.14 [ 0.99 ,  1.32] 
 
 
Male 
         Race 
          
 
White   
   
1.63 [ 1.37 ,  1.95] *** 1.47 [ 1.21 ,  1.78] *** 
 
African American 
        
 
Others  
   
1.33 [ 1.13 ,  1.57] *** 1.30 [ 1.10 ,  1.53] ** 
Other Mental Health Conditions 
        
 
Yes 
   
0.63 [ 0.54 ,  0.73] *** 0.65 [ 0.55 ,  0.75] *** 
 
No 
         Medicaid Eligibility-Poverty 
         
 
Yes  
   
0.63 [ 0.47 ,  0.83] ** 0.61 [ 0.46 ,  0.81] *** 
 
No 
         Medicaid Eligibility-Medical Needs 
        
 
Yes  
   
0.89 [ 0.68 ,  1.17] 0.87 [ 0.66 ,  1.14] 
 
 
No 
         Medicaid Eligibility-Waiver 
         
 
Yes  
   
1.21 [ 0.87 ,  1.70] 1.14 [ 0.81 ,  1.60] 
 
 
No 
         Oral Antidiabetic Drugs (OADs) 
        
 
1 OAD 
   
0.83 [ 0.65 ,  1.06] 0.82 [ 0.64 ,  1.05] 
 
 
2 OAD 
   
0.89 [ 0.70 ,  1.15] 0.89 [ 0.69 ,  1.14] 
 
 
3 OAD 
         
 
No OAD 
   
0.73 [ 0.57 ,  0.94] * 0.73 [ 0.57 ,  0.94] * 
           
           
         (continued) 
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Appendix B: Odds Ratios and Adjusted Odds Ratio and 95% Confidence Intervals  
of All Independent Variables from Multinomial Logistic Regression on Depression Treatment Categories 
Results presented for Antidepressants Only  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 – 2008 
  
Antidepressants Only 
Characteristics OR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Insulin Use 
         
 
Yes 
   
1.21 [ 1.05 ,  1.39] ** 1.21 [ 1.05 ,  1.39] ** 
 
No 
         Polypharmacy 
         
 
Yes 
   
1.24 [ 1.07 ,  1.44] ** 1.25 [ 1.08 ,  1.46] ** 
 
No 
         Inpatient Hospitalization 
         
 
Yes 
   
0.89 [ 0.77 ,  1.03] 0.90 [ 0.77 ,  1.04] 
 
 
No 
         Outpatient Visits 
         
 
1st Quartile 
         
 
2nd Quartile 
   
0.87 [ 0.73 ,  1.05] 0.88 [ 0.73 ,  1.05] 
 
 
3rd Quartile 
   
0.87 [ 0.72 ,  1.05] 0.87 [ 0.72 ,  1.06] 
 
 
4th Quartile 
   
0.71 [ 0.57 ,  0.89] ** 0.72 [ 0.57 ,  0.90] ** 
Number of T2DM Related Office Visits 
  
1.00 [ 1.00 ,  1.01] 1.00 [ 1.00 ,  1.01] 
 Number of ER Visits 
   
0.99 [ 0.95 ,  1.02] 0.99 [ 0.96 ,  1.02] 
            
State 
          
 
Illinois 
         
 
New York 
   
0.85 [ 0.71 ,  1.02] 0.98 [ 0.77 ,  1.26] 
 
 
Texas 
   
0.66 [ 0.53 ,  0.83] *** 0.52 [ 0.39 ,  0.69] *** 
HPSA-Mental Health 
         
 
Yes 
      
0.95 [ 0.76 ,  1.18] 
 
 
No 
         Metro 
          
 
Yes 
      
1.35 [ 0.99 ,  1.83] 
 
 
No 
         CMHC 
          
 
Yes 
      
1.01 [ 0.84 ,  1.21] 
 
 
No 
         FQHC 
          
 
Yes 
      
1.03 [ 0.82 ,  1.28] 
 
 
No 
                   
        continued 
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Appendix B: Odds Ratios and Adjusted Odds Ratio and 95% Confidence Intervals  
of All Independent Variables from Multinomial Logistic Regression on Depression Treatment Categories 
Results presented for Antidepressants Only  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 – 2008 
  
Antidepressants Only 
Characteristics OR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Density Social Workers 
      
0.90 [ 0.83 ,  0.99] * 
Median Household Income 
         
 
1 st Quartile 
      
1.18 [ 0.81 ,  1.71] 
 
 
2nd Quartile 
      
1.07 [ 0.82 ,  1.41] 
 
 
3rd Quartile 
      
1.17 [ 0.89 ,  1.53] 
 
 
4th Quartile 
         % with GT 4yr college education >  16%ⱡ 
        
 
Yes 
         
 
No 
      
0.79 [ 0.61 ,  1.03] 
 
% below poverty level GT 11.1%
ⱡⱡ
 
        
 
Yes 
      
0.94 [ 0.70 ,  1.27] 
 
 
No 
      
0.92 [ 0.71 ,  1.19] 
                       
Asterisks (*) indicate statistical significance are based on multinomial logistic regression with discordant conditions 
as reference group for independent variable and no antidepressant treatment i.e. none as reference group for 
dependent variable.  
***P<0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P <0.05. 
ⱡⱡ 16% Cut off was chosen based on 2000 Census Education attainment results 
ⱡⱡⱡ 11.1% Cut off was chosen based on 1999 Census Poverty levels  
HPSA: Health Professional Shortage Area; CMHC: Community Mental Health Clinic; FQHC: Federally qualified 
health clinic; 
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Appendix C: Odds Ratios and Adjusted Odds Ratio and 95% Confidence Intervals  
of All Independent Variables from Multinomial Logistic Regression on Depression Treatment Categories 
Results presented for Psychotherapy Only  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 – 2008 
  
Psychotherapy Only 
Characteristics OR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Types of Coexisting Chronic Physical Conditions 
       
 
Dominant 2.23 [ 1.72 ,  2.91] *** 1.61 [ 1.21 ,  2.15] ** 1.60 [ 1.20 ,  2.13] ** 
 
Concordant Only 1.26 [ 0.98 ,  1.62] 
 
1.31 [ 1.01 ,  1.70] * 1.32 [ 1.01 ,  1.72] * 
 
Discordant Only 
         
 
Both 1.24 [ 0.98 ,  1.57] 
 
1.12 [ 0.87 ,  1.44] 
 
1.14 [ 0.88 ,  1.46] 
 Age 
          
 
18-44 years 
         
 
 45-54 years 
   
1.09 [ 0.89 ,  1.33] 
 
1.06 [ 0.86 ,  1.30] 
 
 
55-64 years 
   
1.25 [ 1.02 ,  1.52] * 1.20 [ 0.98 ,  1.47] 
 Female 
          
 
Female 
   
0.63 [ 0.54 ,  0.74] *** 0.65 [ 0.56 ,  0.76] *** 
 
Male 
         Race 
          
 
White   
   
0.90 [ 0.74 ,  1.10] 
 
1.13 [ 0.91 ,  1.39] 
 
 
African American 
        
 
Others  
   
0.86 [ 0.71 ,  1.04] 
 
0.90 [ 0.74 ,  1.09] 
 Other Mental Health Conditions 
        
 
Yes 
   
1.99 [ 1.70 ,  2.34] *** 1.93 [ 1.64 ,  2.28] *** 
 
No 
         Medicaid Eligibility-Poverty 
         
 
Yes  
   
1.16 [ 0.85 ,  1.59] 
 
1.17 [ 0.85 ,  1.60] 
 
 
No 
         Medicaid Eligibility-Medical Needs 
        
 
Yes  
   
1.64 [ 1.25 ,  2.15] *** 1.64 [ 1.24 ,  2.17] *** 
 
No 
         Medicaid Eligibility-Waiver 
         
 
Yes  
   
0.67 [ 0.43 ,  1.05] 
 
0.69 [ 0.44 ,  1.07] 
 
 
No 
         Oral Antidiabetic Drugs (OADs) 
        
 
1 OAD 
   
0.85 [ 0.62 ,  1.17] 
 
0.87 [ 0.63 ,  1.20] 
 
 
2 OAD 
   
0.81 [ 0.59 ,  1.13] 
 
0.82 [ 0.59 ,  1.14] 
 
 
3 OAD 
         
 
No OAD 
   
1.32 [ 0.97 ,  1.80] 
 
1.34 [ 0.98 ,  1.83] 
           
          
        (continued) 
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Appendix C: Odds Ratios and Adjusted Odds Ratio and 95% Confidence Intervals  
of All Independent Variables from Multinomial Logistic Regression on Depression Treatment Categories 
Results presented for Psychotherapy Only  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 – 2008 
  
Psychotherapy Only 
Characteristics OR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Insulin Use 
         
 
Yes 
   
0.72 [ 0.61 ,  0.86] *** 0.74 [ 0.62 ,  0.88] *** 
 
No 
         Polypharmacy 
         
 
Yes 
   
0.84 [ 0.70 ,  1.01] 
 
0.84 [ 0.70 ,  1.00] 
 
 
No 
         Inpatient Hospitalization 
         
 
Yes 
   
1.26 [ 1.07 ,  1.50] ** 1.25 [ 1.05 ,  1.48] * 
 
No 
         Outpatient Visits 
         
 
1st Quartile 
         
 
2nd Quartile 
   
1.24 [ 0.97 ,  1.57] 
 
1.21 [ 0.95 ,  1.54] 
 
 
3rd Quartile 
   
1.56 [ 1.23 ,  1.99] *** 1.56 [ 1.22 ,  1.98] *** 
 
4th Quartile 
   
1.93 [ 1.50 ,  2.48] *** 1.91 [ 1.48 ,  2.47] *** 
Number of T2DM Related Office Visits 
  
1.00 [ 0.99 ,  1.01] 
 
1.00 [ 0.99 ,  1.01] 
 Number of ER Visits 
   
0.97 [ 0.94 ,  1.00] 
 
0.97 [ 0.94 ,  1.00] * 
State           
 Illinois          
 New York    0.53 [ 0.43 ,  0.65] *** 0.47 [ 0.35 ,  0.64] *** 
 Texas    0.74 [ 0.58 ,  0.94] * 1.24 [ 0.88 ,  1.76]  
HPSA-Mental Health 
         
 
Yes 
      
1.00 [ 0.76 ,  1.32] 
 
 
No 
         Metro 
          
 
Yes 
      
1.14 [ 0.76 ,  1.71] 
 
 
No 
         CMHC 
          
 
Yes 
      
1.17 [ 0.94 ,  1.46] 
 
 
No 
         FQHC 
          
 
Yes 
      
1.19 [ 0.91 ,  1.57] 
 
 
No 
                   
          
        continued 
         
         
Page 105 of 173 
 
Appendix C: Odds Ratios and Adjusted Odds Ratio and 95% Confidence Intervals  
of All Independent Variables from Multinomial Logistic Regression on Depression Treatment Categories 
Results presented for Psychotherapy Only  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 – 2008 
  
Psychotherapy Only 
Characteristics OR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Density Social Workers 
      
1.14 [ 1.01 ,  1.28] * 
Median Household Income 
         
 
1st Quartile 
      
1.14 [ 0.75 ,  1.74] 
 
 
2nd Quartile 
      
1.12 [ 0.81 ,  1.53] 
 
 
3rd Quartile 
      
1.18 [ 0.86 ,  1.61] 
 
 
4th Quartile 
         % with GT 4yr college education >  16%ⱡ 
        
 
Yes 
         
 
No 
      
1.80 [ 1.30 ,  2.51] *** 
% below poverty level GT 11.1%
ⱡⱡ
 
        
 
Yes 
      
0.98 [ 0.68 ,  1.42] 
 
 
No 
      
1.38 [ 0.97 ,  1.96] 
                       
Asterisks (*) indicate statistical significance are based on multinomial logistic regression with discordant conditions 
as reference group for independent variable and no antidepressant treatment i.e. none as reference group for 
dependent variable.  
***P<0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P <0.05. 
ⱡⱡ 16% Cut off was chosen based on 2000 Census Education attainment results 
ⱡⱡⱡ 11.1% Cut off was chosen based on 1999 Census Poverty levels  
HPSA: Health Professional Shortage Area; CMHC: Community Mental Health Clinic; FQHC: Federally qualified 
health clinic; 
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Appendix D: Odds Ratios and Adjusted Odds Ratio and 95% Confidence Intervals  
of All Independent Variables from Multinomial Logistic Regression on Depression Treatment Categories 
Results presented for Both Antidepressants and Psychotherapy 
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 – 2008 
  
Both Antidepressants &Psychotherapy 
Characteristics OR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Types of Coexisting Chronic Physical Conditions 
      
 
Dominant 1.21 [ 0.89 ,  1.65] 
 
1.14 [ 0.82 ,  1.60] 
 
1.11 [ 0.79 ,  1.55] 
 
 
Concordant Only 1.05 [ 0.80 ,  1.38] 
 
1.03 [ 0.78 ,  1.38] 
 
1.01 [ 0.76 ,  1.35] 
 
 
Discordant Only 
         
 
Both 1.01 [ 0.78 ,  1.30] 
 
0.87 [ 0.66 ,  1.14] 
 
0.86 [ 0.65 ,  1.13] 
 Age 
          
 
18-44 years 
         
 
 45-54 years 
   
1.07 [ 0.86 ,  1.34] 
 
1.04 [ 0.83 ,  1.31] 
 
 
55-64 years 
   
0.85 [ 0.67 ,  1.07] 
 
0.82 [ 0.65 ,  1.04] 
 Female 
          
 
Female 
   
1.02 [ 0.84 ,  1.24] 
 
1.05 [ 0.86 ,  1.27] 
 
 
Male 
         Race 
          
 
White   
   
1.45 [ 1.15 ,  1.83] ** 1.85 [ 1.44 ,  2.38] *** 
 
African American 
        
 
Others  
   
1.21 [ 0.96 ,  1.52] 
 
1.21 [ 0.96 ,  1.53] 
 Other Mental Health Conditions
        
 
Yes 
   
0.96 [ 0.79 ,  1.17] 
 
0.95 [ 0.78 ,  1.16] 
 
 
No 
         Medicaid Eligibility-Poverty 
         
 
Yes  
   
1.00 [ 0.71 ,  1.42] 
 
0.98 [ 0.69 ,  1.39] 
 
 
No 
         Medicaid Eligibility-Medical Needs 
       
 
Yes  
   
1.61 [ 1.18 ,  2.21] ** 1.63 [ 1.18 ,  2.24] ** 
 
No 
         Medicaid Eligibility-Waiver 
         
 
Yes  
   
1.32 [ 0.79 ,  2.21] 
 
1.23 [ 0.73 ,  2.07] 
 
 
No 
         Oral Antidiabetic Drugs (OADs) 
        
 
1 OAD 
   
0.67 [ 0.48 ,  0.93] * 0.66 [ 0.47 ,  0.92] * 
 
2 OAD 
   
0.65 [ 0.46 ,  0.91] * 0.64 [ 0.45 ,  0.90] ** 
 
3 OAD 
         
 
No OAD 
   
0.61 [ 0.44 ,  0.85] ** 0.61 [ 0.44 ,  0.86] ** 
Insulin Use 
         
 
Yes 
   
1.22 [ 1.01 ,  1.48] * 1.26 [ 1.04 ,  1.52] * 
 
No 
         Polypharmacy 
         
 
Yes 
   
1.34 [ 1.09 ,  1.64] ** 1.35 [ 1.10 ,  1.66] ** 
 
No 
         Inpatient Hospitalization 
         
 
Yes 
   
1.18 [ 0.97 ,  1.44] 
 
1.16 [ 0.95 ,  1.42] 
 
 
No 
         
        continued 
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Appendix D: Odds Ratios and Adjusted Odds Ratio and 95% Confidence Intervals  
of All Independent Variables from Multinomial Logistic Regression on Depression Treatment Categories 
Results presented for Both Antidepressants and Psychotherapy 
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 – 2008 
  
Both Antidepressants &Psychotherapy 
Characteristics OR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
          
          
Outpatient Visits 
         
 
1st Quartile 
         
 
2nd Quartile 
   
0.96 [ 0.74 ,  1.24] 
 
0.96 [ 0.74 ,  1.24] 
 
 
3rd Quartile 
   
0.94 [ 0.72 ,  1.23] 
 
0.93 [ 0.71 ,  1.23] 
 
 
4th Quartile 
   
1.19 [ 0.89 ,  1.59] 
 
1.17 [ 0.87 ,  1.57] 
 Number of T2DM Related Office Visits 
 
1.00 [ 0.99 ,  1.01] 
 
1.00 [ 0.99 ,  1.01] 
 Number of ER Visits 
   
1.00 [ 0.97 ,  1.03] 
 
1.00 [ 0.97 ,  1.04] 
 State 
          
 
Illinois 
         
 
New York 
   
0.32 [ 0.25 ,  0.42] *** 0.35 [ 0.25 ,  0.50] *** 
 
Texas 
   
1.05 [ 0.81 ,  1.37] 
 
1.56 [ 1.08 ,  2.25] * 
HPSA-Mental Health 
         
 
Yes 
      
0.99 [ 0.74 ,  1.33] 
 
 
No 
         Metro 
          
 
Yes 
      
1.25 [ 0.82 ,  1.90] 
 
 
No 
         CMHC 
          
 
Yes 
      
1.42 [ 1.12 ,  1.81] ** 
 
No 
         FQHC 
          
 
Yes 
      
1.38 [ 1.02 ,  1.85] * 
 
No 
         Density Social Workers 
      
1.05 [ 0.93 ,  1.19] 
 Median Household Income 
         
 
1st Quartile 
      
0.91 [ 0.57 ,  1.44] 
 
 
2nd Quartile 
      
0.89 [ 0.62 ,  1.27] 
 
 
3rd Quartile 
      
0.94 [ 0.66 ,  1.35] 
 
 
4th Quartile 
         % with GT 4yr college education >  16%ⱡ 
       
 
Yes 
         
 
No 
      
1.17 [ 0.84 ,  1.63] 
 % below poverty level GT 11.1%
ⱡⱡ
 
        
 
Yes 
      
1.04 [ 0.69 ,  1.57] 
 
 
No 
      
1.02 [ 0.71 ,  1.47] 
               
Asterisks (*) indicate statistical significance are based on multinomial logistic regression with discordant conditions 
as reference group for independent variable and no antidepressant treatment i.e. none as reference group for 
dependent variable.  
***P<0.001; **0.001 ≤ P < 0.01; *0.01 ≤ P <0.05. 
ⱡⱡ 16% Cut off was chosen based on 2000 Census Education attainment results 
ⱡⱡⱡ 11.1% Cut off was chosen based on 1999 Census Poverty levels  
HPSA: Health Professional Shortage Area; CMHC: Community Mental Health Clinic; FQHC: Federally qualified 
health clinic; 
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CHAPTER 4: Treatment for Depression and Healthcare Expenditures among Medicaid 
Beneficiaries with Type 2 Diabetes Mellitus and Newly-Diagnosed Depression 
Introduction 
Type 2 Diabetes Mellitus (T2DM), Depression and Healthcare Expenditures  
 
Individuals with coexisting type 2 diabetes mellitus (T2DM) and depression use more 
healthcare services such as inpatient [1], outpatient [2, 3] and prescription drug use [2, 3], report 
higher total [1, 3, 4] as well as T2DM-related medical care expenditures, as compared 
individuals with T2DM and no depression [5]. Research with Medical Expenditure Panel Survey, 
a nationally representative data of the United States‟ population has shown that among 
individuals with diabetes, those with coexisting depression could have mean total annual 
healthcare expenditures 4.5 times higher ($247,000,000) compared to those without depression 
($55,000,000) [3]. An analysis of West Virginia state Medicaid data (1997-2002) showed that 
among enrollees with T2DM, those with depression had 65% higher healthcare expenditures as 
compared to those without depression [6]. Therefore, presence of depression is associated with 
substantially high healthcare expenditures among individuals with T2DM. However, in general, 
recovery from depression following depression treatment has been shown to be associated with 
lower subsequent healthcare utilization and expenditures [7]. 
Treatment for Depression and Healthcare Expenditures among Individuals with T2DM 
 
  Randomized clinical trials that have studied whether among individuals with both 
depression and T2DM, depression treatment delivered in primary care based collaborative care 
settings (where both depression and T2DM is managed with the help of coordinated healthcare 
teams comprising of primary care physicians, nurses and other specialists) results in reduction of 
healthcare expenditures as compared to usual care. The Improving Mood-Promoting Access to 
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Collaborative (IMPACT) randomized controlled trial included 418 individuals aged 60 years or 
older, of them 204 received the collaborative care intervention and 214 were randomized to usual 
care; this study found that at the end of 24 months the intervention group had $896 lower 
expenditures as compared to the usual care group [8]. The Pathways study [9, 10] was also a 
randomized controlled trial which was carried out in 9 primary care settings across Washington 
and Idaho; the participants were members of a mixed model health plan. The intervention 
provided was a 12 month stepped-care depression management program delivered via primary 
care physicians, registered nurses who received training in problem solving therapy for 
depression and psychiatrists. Depression treatment for intervention group (mean age 58 years) in 
step 1 started with antidepressant drugs or psychotherapy, in case of no response to treatment in 
step 1, treatment modality was adjusted in step 2, e.g. those treated with antidepressants in step 
1, were given psychotherapy in step 2, in case of no response to treatment in step 2, treatment in 
step 3 involved referral to specialist; the control group (mean age 57 years) was given usual care. 
Total healthcare expenditures reported at the end of 2-year and 5-year periods were found to be 
lower in the intervention group as compared to control group: 2 year mean (SD) in intervention 
vs control group were $21,148 ($27 548) vs $22, 258 ($35,607) [9] and 5 year mean(SD) in 
intervention vs control group were  49,254 (50,773) vs 49,254 (50,773) [10]. 
Studies examining the association between depression treatment with healthcare 
expenditures among individuals with coexisting T2DM and depression are very limited. So, 
evidence from studies examining the association between depression treatment and healthcare 
expenditures among individuals with other chronic conditions is discussed. Using administrative 
claims data, one study showed that among individuals with dyslipidemia, T2DM and coronary 
artery disease, either in combination or alone, antidepressant medication adherence improved 
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adherence to coexisting disease medications and thus reduced one-year healthcare expenditures 
[11]. On the contrary, one study carried out with real world data from Medicare Current 
Beneficiary Survey (MCBS),found that among beneficiaries with coexisting depression and 
chronic diseases such as  arthritis, diabetes, respiratory diseases including asthma, chronic 
obstructive pulmonary disease, heart disease, hypertension, osteoporosis, and stroke, those 
receiving depression treatment had higher inpatient, medical provider and prescription drug 
expenditures [12]; however, this study was restricted to the elderly population.  
While randomized controlled trials have demonstrated that depression treatment 
delivered in collaborative care settings reduced expenditures among individuals with T2DM and 
coexisting depression, studies conducted using real world observational data have reported 
inconsistent findings. However these studies were not specific to T2DM population and included 
special populations such as elderly. Therefore, it remains to be established whether depression 
treatment with antidepressants and psychotherapy, alone or in combination, are associated with 
reductions in healthcare expenditures, among individuals with T2DM. Based on evidence from 
depression care delivered in collaborative care settings, one may infer that combined 
antidepressants and psychotherapy may reduce healthcare expenditures. 
The Relationship between Depression Treatment and Healthcare Expenditures by Coexisting 
Chronic Physical Conditions 
Virtually, there are no existing studies using real world data that are specific to 
populations with coexisting T2DM and depression which have examined the association between 
depression treatment and healthcare expenditures; therefore there is no knowledge on whether 
this association varies by types of coexisting chronic physical conditions. Findings from 
unpublished studies conducted by the authors of this study, have revealed that among individuals 
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with T2DM, the risk of having newly-diagnosed depression and treatment received by those with 
newly-diagnosed depression varied by types of coexisting chronic physical conditions. 
Therefore, it is highly plausible that healthcare expenditures following depression treatment may 
also be associated with coexisting chronic physical conditions. With majority of adults (88.6%) 
with T2DM in the US having at least one chronic condition and 15% having reported four or 
more chronic conditions [13], presence of other coexisting chronic physical conditions among 
individuals with T2DM is a norm rather than an exception. Therefore, in absence of any related 
literature it is important to examine whether the relationship between depression treatment and 
expenditures vary by types of coexisting chronic physical conditions.  
Need for the study 
 As explained above there is a significant gap in the literature on whether depression 
treatment can reduce healthcare expenditures among individuals with T2DM. To the best of the 
authors‟ knowledge, no study has examined whether the association between depression 
treatment and healthcare expenditures among individuals with T2DM vary by types of coexisting 
chronic physical conditions.  
It is particularly important to study this association in non-elderly population given that, 
in recent years, the prevalence of multiple coexisting chronic conditions, which has traditionally 
been thought of as a problem in the elderly population, has been increasing among non-elderly 
adults [14, 15]. In the US, among adults participating in the national health interview survey and 
in the age group 45-64 years, the prevalence of multiple coexisting chronic conditions has been 
increasing and has grown from 24.5% in 2004 to 28.1% in 2010 [16]. As risk of depression 
increases with increasing number of coexisting chronic physical conditions [17], there is a need 
to evaluate the impact of type of depression treatment on healthcare expenditures and whether 
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this relationship vary by types of coexisting chronic physical conditions among non-elderly 
adults aged 18-64 years. 
In the US, state Medicaid plans are a major provider of health insurance among non-
elderly adults. As of 2010, 27% of US adults, 20-64 years of age were covered by Medicaid, 
outlaying 68% of the federal spending [18]. Adults with diabetes are disproportionately covered 
by Medicaid and four out of five Medicaid beneficiaries with diabetes suffer from a coexisting 
chronic physical condition. It has been reported that among adults enrolled in Medicaid, those 
with diabetes spend more than 2.5 times compared to those without diabetes [19]. Twenty 
percent of Medicaid enrollees suffer from depression [20, 21].According to Agency of 
Healthcare Research and Quality 2011 statistical brief, mood disorders which includes 
depression ranks top most among the ten conditions for 30 day readmission in Medicaid resulting 
in 41,600 readmissions and costing $286 million [22]. Depression is also a major driver for poor 
health outcomes and future healthcare expenditures in T2DM [23]. Given such compelling 
statistics, it is apparent that Medicaid data provides a rich opportunity to conduct research of 
both depression and T2DM, and can lead to important findings that might influence clinical 
practice and policy. Therefore, among the high risk population of Medicaid enrollees with 
T2DM, it is necessary to delineate the relationship between depression treatment and healthcare 
expenditures and understand how types of coexisting chronic physical conditions impact this 
association. 
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RESEARCH OBJECTIVES AND HYPOTHESES 
 
Aim 3.1: Among non-elderly Medicaid beneficiaries with T2DM and newly-diagnosed 
depression, examine the association depression treatment categories and total and T2DM-related 
healthcare care expenditures.  
Hypothesis 3.1: As compared to those with no depression treatment, those with depression 
treatment with only antidepressants, only psychotherapy or both, will have negative associations 
with total and T2DM-related healthcare expenditures as compared no depression treatment. 
Aim 3.2: Among non-elderly Medicaid beneficiaries with T2DM and newly-diagnosed 
depression, examine whether the association between depression treatment and total and T2DM-
related medical care expenditures vary by types of coexisting chronic physical conditions.  
Hypothesis 3.2.1: As compared to no depression treatment, treatment within both 
antidepressants and psychotherapy will reduce total and T2DM related healthcare expenditures 
across all conditions.  
Hypothesis 3.2.2: Depression treatment with only antidepressants will not be associated with 
T2DM related healthcare expenditures among those with concordant conditions only.  
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CONCEPTUAL FRAMEWORK 
 
The basic framework used in this study was a hybrid of the expanded behavioral model 
on use of health services, widely known as the Andersen behavioral model (ABM) [24].  The 
ABM posits that utilization of health services varies as a function of 1) each individual‟s unique 
predisposition for using services (predisposing factors); 2) the means available to each individual 
for obtaining services (enabling factors); 3) each individual‟s level of need; 4) personal health 
practices; and 5) the external environment (figure 1). The behavioral health model is very 
flexible and was easily adapted to analyze the relationship between depression treatment and 
types of coexisting chronic physical conditions and the association between depression treatment 
and healthcare expenditures.  
 
 
Aim 3 – Dependent Variables: 
Total Healthcare Expenditure 
T2DM-Related Healthcare Expenditure 
 
 
 
 
 
Predisposing factors: 
 Gender, age, race/ethnicity  
 
Enabling factors:  
Medicaid Eligibility 
Need Factors:  
Types of coexisting physical conditions, Other Mental 
Health Conditions, Number of chronic conditions  
External Environment:  
e.g. County level social determinants of health County 
Median Income, State, % with college education and % 
below poverty level and Community level  healthcare 
infrastructure e.g. presence of CMHC, FQHC in a 
county 
 
 
Personal Health Practices: 
 e.g Health care Seeking Behavior: Medication use, use 
of inpatient and emergency room services 
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METHODS 
Study Design 
 
A retrospective longitudinal study repeated measures cohort design was used. The study 
cohort included individuals with T2DM and newly-diagnosed depression. “Index date” was 
defined as the first date of depression diagnosis and baseline and follow-up periods were 
respectively defined as 12 months prior and subsequent to this index date. Inpatient, outpatient 
and prescription drug expenditures were identified at the end of each month of follow-up.  
Therefore, each individual included in the study cohort had 12 observations. Appropriate 
statistical models were used to account for such repeated measures design. Independent measures 
design, which often use aggregate expenditures at the end of follow-up period, do not capture the 
variation in healthcare expenditures at different time points of follow-up. The repeated measures 
analysis helped in capturing healthcare expenditures both during and after the acute phase of 
depression treatment.   
Data Source 
Medicaid analytic extract (MAX) files:  
The MAX files are prepared and produced by the Centers for Medicare and Medicaid 
Services. Person-level data such as eligibility, demographics, managed care enrollment, a 
utilization summary and Medicaid payments for enrollees are provided in the enrollment 
(“personal summary”) file. Information on International Classification of Diseases 9th revision 
(ICD-9-CM codes) of conditions diagnosed, healthcare service utilizations and charges paid by 
Medicaid for the services can be extracted from inpatient, other therapy files. The pharmacy file 
provides information on variables such as national drug code (NDC) of medications used and 
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amount paid by Medicaid for the medication claims. This study used Medicaid data from 2000-
2008 data from three states: New York (NY), Texas (TX), Illinois (IL). 
Area Health Resource File (AHRF):  
The AHRF is national county-level health resource information provided by the U.S. 
Department of Health and Human Services (2011) that provides information on more than 6,000 
variables county level variables such as characteristics of  health facilities, number and type of 
health professionals in a county, rural-urban status, resource scarcity, health status, economic 
activity, health training programs, and socioeconomic and environmental characteristics [25]. 
The Federal Information Processing Standard (FIPS) county codes which are available both in 
the AHRF file and the personal summary file of the MAX data, were used to link the two files.  
Identification of T2DM and Newly-diagnosed Depression Cohort 
 
Three state Medicaid data from 2000-2008 was used to identify seven longitudinal 
cohorts: 2000-02, 2001-03, 2002-04, 2003-05, 2004-06,2005-07, 2006-08. 
Medicaid Beneficiaries with T2DM:  
Medicaid enrollees with at least one inpatient visit or two or more physician outpatient 
visits which were at least 30 days apart, with a primary or secondary diagnosis of ICD-9-CM 
codes: 250.x0 or 250.x2 during a calendar year, were identified as having T2DM. Medicaid 
beneficiaries with T2DM who had a diagnosis of depression or antidepressant medication use 
during the calendar year were excluded. 
Medicaid Beneficiaries with Newly-diagnosed Depression:  
The eligible study population was followed into the subsequent calendar year to identify 
newly-diagnosed depression. Enrollees with at least one outpatient physician visit or an inpatient 
admission with a primary or secondary diagnosis of  depression in the following calendar year 
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were classified as having a newly-diagnosed depression [26]. Depression was identified using 
ICD9 CM codes: 296.2 (major depressive disorder, single episode), 296.3 (major depressive 
disorder, recurrent episode), 311 (depression not elsewhere classified), 309.1 (prolonged 
depressive reaction), 300.4 (neurotic depression) and 298.0 (depressive type psychosis). These 
ICD-9-CM codes are extensively used by health plans to identify depression [27] and have also 
been used in previous literature that have studied depression in Medicaid enrollees [28-30]. 
Those with no newly-diagnosed depression were excluded from the study cohort. The first 
observed date of outpatient visit or inpatient discharge with diagnosis of depression was the 
“index date”; 365 days prior to the index date was required to be free of any depression diagnosis 
or antidepressant medication. One may note that other studies have 120 day depression free 
period to define newly-diagnosed depression [31]. However, the 365 day look-back period was 
used with the intent to minimize misclassification of an episodic manifestation of chronic 
depression (where depression symptoms last for two or more years) as newly-diagnosed 
depression.  
 Additional exclusion criteria were (1) not having a diagnosis of at least one chronic 
physical condition (identified by ICD-9-CM codes included in the appendix) in the baseline 
period (2) no continuous fee-for-service Medicaid eligibility and (3) enrollment in Medicare at 
any point during the observation period; (4) died during the study period and (5) did not use 
inpatient or outpatient Medicaid services during the study period. 
 Dependent Variables 
 
Total Healthcare Expenditures:  
Total healthcare expenditure per person included in the study cohort was defined as the 
total dollar amount that Medicaid paid for inpatient, outpatient and pharmacy claims. Total 
Page 119 of 173 
 
healthcare expenditures were identified at the end of each month of follow-up during the 12 
month follow-up period. The total healthcare expenditures were adjusted by the medical 
component of the Consumer Price Index (CPI) and expressed in the 2008 constant dollars. After 
assessing the skewness and kurtosis properties and linearity through qq-plots, the total health 
expenditures were log transformed and used as dependent variable. 
T2DM-Related Healthcare Expenditures:  
T2DM-related healthcare expenditure per person included in the study cohort were 
defined as the total dollar amount that Medicaid paid for inpatient and outpatient claims with a 
diagnosis of T2DM. The T2DM-related healthcare expenditures were also identified on a 
monthly basis during the 12 month follow-up period. Similar to total healthcare expenditures, the 
T2DM-related expenditures were also adjusted by the medical component of the CPI and 
expressed in the 2008 constant dollars and were log transformed.  
Independent Variables 
 
Key Independent Variables: 
Depression treatment during the acute phase: The first four months following the newly-
diagnosed depression is known as the acute phase of depression treatment. The acute phase is 
used to set treatment goals, assess risk of suicide, decide on using psychotherapy and/or 
appropriate antidepressant, enhance adherence and monitor response [32]. The initial treatment 
choice may influence the effectiveness of depression treatment and therefore may also be 
associated with healthcare expenditures over time.  
Depression treatment in the acute phase could be provided with only antidepressants or 
only psychotherapy or both. Antidepressant Use: The national drug codes available in the 
prescription drug use file of MAX data were used to identify antidepressant drug classes: 
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selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, tricyclic 
antidepressants, monoamine oxidase inhibitors and other (mirtazapine and bupropion). 
Psychotherapy Use:  The use of psychotherapy was identified with Current Procedural 
Terminology (CPT) codes. The following psychotherapy types were used: (i) psychotherapy 
diagnostic interview (90801, 90802) (ii) individual psychotherapy [individual psychotherapy 20-
30 min (90804, 90816, 90805, 90817), 45-50 min (90806, 90818, 90807, 90819), 75-80 min 
(90808, 90821, 90809, 90822); interactive individual psychotherapy 20-30 min (90810, 90823, 
90811, 90824), 45-50 min (90812, 90826, 90813, 90827), 75-80 min (90814, 90828, 90815, 
90829)] (iii) other psychotherapy [family psychotherapy (90846, 90847, 90849), group 
psychotherapy (90853), interactive group psychotherapy(90857)][33].    
Depression treatment in the acute phase was categorized as treatment with: (1) Only 
Antidepressants: These individuals received at least one prescription for antidepressant, but no 
psychotherapy visit during the acute phase of depression treatment were considered as being 
treated with only antidepressants; (2) Only Psychotherapy: Those who received at least one 
psychotherapy office visit, but no prescription for antidepressant drugs during the acute phase 
were considered as being treated with only psychotherapy. (3) Both Antidepressants and 
Psychotherapy: Those who received a minimum of one prescription for antidepressants and one 
psychotherapy visit during the first120 days following newly-diagnosed depression were 
considered as being treated with both antidepressants and psychotherapy (4) No treatment: These 
individuals received no prescriptions for antidepressants and no psychotherapy office visit during 
the acute phase. 
Types of Coexisting Chronic Physical Conditions (Need Factor used in ABM): 
Page 121 of 173 
 
As other physical conditions coexisting with T2DM often impact the medical care, self-
management, and healthcare outcomes of an individual with T2DM, Piette and Kerr developed a 
framework that classified coexisting conditions among individuals with T2DM into categories 
based on similarities and differences from T2DM pathophysiology and management. The 
categories of conditions that might coexist with T2DM were defined as: dominant (conditions 
whose severity eclipses all other conditions‟ management plans such as metastatic cancer), 
concordant (conditions that overlap with T2DM in their pathophysiology and management plans 
such as cardiovascular diseases) or discordant (conditions with unrelated pathophysiology or 
management plans such as musculoskeletal disorders) [34].  
 Following this framework, one may assume that presence of such coexisting conditions 
among individuals with T2DM and newly-diagnosed depression may also affect the management 
of depression and therefore response to depression treatment. Therefore, based on this theoretical 
framework, forty-four different types of coexisting chronic physical conditions a list of which 
along with the ICD-9-CM codes used to identify the conditions is presented in Appendix A, were 
used to define types of coexisting chronic physical conditions. A hierarchical classification was 
followed [23]; dominant conditions were given priority because such conditions often take 
precedence over the management of other health conditions. Only among those without 
dominant conditions, concordant and discordant conditions were identified. The types of 
coexisting chronic physical conditions were classified as: 1) Dominant conditions 2) Concordant 
only, 3) Discordant only and 4) Both concordant and discordant.  
Other independent variables:  
Based on the Andersen‟s Behavioral Model, the other independent variables included in 
the study were: 
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Predisposing Factors: The included variables were: demographics (gender, age, race/ethnicity 
[Whites, African Americans, Hispanics or other races]). 
Enabling Factors: Using Medicaid eligibility status the enabling factors included were: 
eligibility due to poverty (yes/no), medical needs (yes/no) and waiver (yes/no). 
Need Factors: The variables included were clinical characteristics such as presence of other 
mental health conditions and number of conditions during baseline. The other mental health 
conditions included bipolar disorder, schizophrenia, post-traumatic stress disorder, and alcohol 
and drug abuse. 
Personal Health Practices: As an individual‟s propensity to seek treatment may influence 
healthcare utilizations and thereby expenditure, therefore the study controlled for healthcare 
seeking behavior by controlling for baseline healthcare utilization characteristics such as number 
of emergency room visits in 180 days prior to new-onset depression, inpatient hospitalization, 
number of oral antidiabetic medication classes and insulin use as identified by NDC codes, 
presence of polypharmacy identified by use of 6 or more drug classes in the 90 days prior to 
new-onset depression, number of outpatient visits measured in quartiles and total baseline 
healthcare expenditures  
External Environment: External environment variables included state of residence, community 
level access healthcare infrastructure and community level social determinants of health 
variables. Community level access healthcare infrastructure variables included presence of 
community mental health clinic (CMHC) and federally qualified health clinic (FQHC) in a 
county, whether county of residence was designated as Health Professional Shortage area 
(HPSA) and density of social workers in a county. The social determinants of health variables 
included were urban/rural status of a county, median income in the county and whether percent 
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below poverty level and percent with college education in the county were greater than national 
average based on US census estimates [35, 36].  
Other variables: After response to depression treatment is achieved in the acute phase, treatment 
for depression may be continued for another 4 to 9 months of continuation phase treatment [37]. 
Therefore, it may be plausible that some individuals received depression treatment with 
antidepressants and/or psychotherapy during entire length of follow-up and some did not. To 
control for such variation, the statistical models additionally controlled for antidepressant 
treatment at each month of follow-up: This was defined as a dichotomous (yes/no) variable, 
which indicated whether an individual received antidepressant prescription during each month of 
the follow-up; psychotherapy treatment at each month of follow-up: A categorical (yes/no) 
variable that indicated whether an individual received outpatient psychotherapy during each 
month of the follow-up. year of observation: As data from multiple years forming seven 
different panels (2000-2002, 2001-2003, 2002-2004, 2003-2005, 2004-2006, 2005-2007, 2006-
2008) were used, a variable indicating the particular  cohort the observation came from was also 
included. 
Statistical Analyses 
Bivariate Analyses: 
Unadjusted analyses using descriptive statistics, including frequency, percentage, mean, 
and standard errors were conducted. Chi-square analyses were used to examine unadjusted 
differences in baseline characteristics and types of coexisting chronic physical conditions. Chi-
square analyses were used to examine unadjusted differences in types of coexisting chronic 
physical conditions and depression treatment. 
Analyses with repeated measures:  
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As healthcare expenditures were aggregated for each month of follow-up, 12 
observations were available for each individual. Due to repeated measures of healthcare 
expenditures, the observations were not independent. Because standard regression techniques 
assume that individual observations are independent, they cannot be applied to data with 
repeated measures. More appropriate models are those that account, for such dependence.   
Therefore, the multivariable analyses consisted of linear mixed effects models. These models 
account for correlated error terms of observations from same person.  
Linear mixed model analyses were conducted to assess the association between 
depression treatment categories during the acute phase and total and T2DM-related healthcare 
expenditures. The statistical model included the key independent variable i.e. depression 
treatment categories during the acute phase, types of coexisting chronic physical conditions, and 
predisposing, enabling, need, personal health practices (health seeking behavior), external 
environment characteristics and other variables (antidepressant treatment at each month of 
follow-up, psychotherapy treatment at each month of follow-up, year of observation) . 
Additionally, separate linear mixed model regressions for each type of coexisting chronic 
physical conditions were conducted to examine whether the association between depression 
treatment and total and T2DM-related healthcare expenditures vary by types of coexisting 
chronic physical conditions.  
Observed Selection Bias: Adjusting for inverse probability weighting technique (IPTW) 
Depression treatment is a choice variable and observed differences in individual as 
characteristics of the study population can influence this choice. To account for such observed 
differences the inverse probability weighting technique (IPTW) was used. The IPTW gives 
weight to each individual based on the inverse of their propensity to use a particular type of 
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depression treatment. Thus individuals who have lower propensity are up-weighted and those 
with higher propensity are down weighted. This helps to balance the probability of treatment 
across the treatment groups. In order to account for the differences in group sizes of the 
treatment groups, the weights were further stabilized by dividing them with sample size of each 
group.   
For easier interpretation of log transformed expenditure variables, percentage changes in 
total and T2DM-related expenditures for depression treatment categories were calculated by 
subtracting one (depression treatment being categorical) from exponentiated beta coefficients 
and multiplying this number by 100. All analyses were conducted using Statistical Analysis 
Software (SAS 9.3). 
Secondary Analysis 
It has been observed the individuals with depression often do not get adequately treated 
owing to various clinician and patient related factors such as short duration of treatment and non-
compliance to medication use [38]. However, adequate depression treatment has been found to 
be associated with lesser increase in healthcare expenditures from pre-depression to post- 
depression time periods as compared those not adequately treated, especially in presence of other 
coexisting chronic conditions [39]. Therefore, this study additionally examined whether adequate 
depression treatment in the acute phase was associated with healthcare expenditures in this study 
population. Results of this analysis are presented in Appendix B.  
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RESULTS 
 
Description of the Study Population 
 The study population consisted of 5,295 non-elderly fee-for-service Medicaid 
beneficiaries with T2DM and newly-diagnosed depression. Description of the study population is 
presented in Table 1. In the study population, 36.3% were aged 45-54 years and 38.5% were 
older adults aged between 55 and 64 years, 67.3% were females; 26.8% were Whites and 30.1% 
were African Americans and 43% belonged to other races; majority of the counties of residence 
were metro areas (89.1%), however, 83.2% of counties were designated as shortage area for 
mental health professionals and 51.1% of counties did not have a CMHC. 
Description of the Study Population by Types of Coexisting Chronic Physical conditions 
 Table 1 also presents a description of the study population by types of coexisting chronic 
physical conditions. In the study population, 14.2% had dominant conditions, 27.3% had 
concordant conditions only, 15.8% had discordant conditions only and 42.8% had both 
concordant and discordant conditions. All individual baseline characteristics and majority of the 
county level characteristics differed significantly among the types of coexisting chronic physical 
conditions groups. For example, a greater proportion of individuals with dominant conditions 
were older i.e.55-64 years (17.4% vs 9.1% in 18-44 years age-group), males (18.3% vs 12.3% 
females), had presence of other mental health conditions (18.6% vs 11.6% with absence of other 
mental health conditions), inpatient hospitalizations (20.5% vs 8.1% in those without) and higher 
number of outpatient visits (22.7% in 4th vs 6.1% in 1st quartile). For the external environment 
characteristics, presence of a CMHC in the county and percentage of the county population 
below the national poverty level of 11.1% were the two variables that did not significantly differ 
among the types of coexisting chronic physical condition subgroups. 
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Unadjusted Association between Types of Coexisting Chronic Physical Conditions and 
Depression Treatment Categories  
During the acute phase, 27.3% had treatment with only antidepressants, 18.1% had 
treatment with only psychotherapy, 11.4% had treatment with both antidepressants and 
psychotherapy and 43.2% of the study population had no depression treatment. Unadjusted chi-
square analyses revealed that depression treatment during the acute phase varied significantly (P-
value <0.001) among the types of coexisting chronic physical conditions subgroups. A  
significantly lower percentage of individuals with dominant conditions (19.1%) and concordant 
conditions only (27.3%)  had treatment with only antidepressants as compared to those with 
discordant conditions only (32.7%); a significantly higher percentage of individuals in  dominant 
conditions (28.2%) and concordant conditions only (17.2%) received treatment with only 
psychotherapy  as compared to individuals with discordant conditions only (14.0%); treatment 
with both antidepressants and psychotherapy was received by 12.6% with  dominant conditions, 
11.2% with concordant conditions only, 10.7% with discordant conditions only and 11.4% with 
both concordant and discordant conditions. The percentages with no depression treatment were 
40.1% for those with dominant conditions, 44.3% for individuals with concordant conditions 
only, 42.6% for individuals with discordant conditions only and 43.8% for individuals with both 
concordant and discordant conditions. Results are not presented in tabular form. 
Mean Monthly Healthcare Expenditures for Depression Treatment Categories 
 Total Healthcare Expenditures: The mean total healthcare expenditures for 12 months 
after diagnosis of depression were $30,590 for those treated with only antidepressants, $35,099 
for those treated with only with psychotherapy, $33,032 for those treated with both 
antidepressants and psychotherapy and $34,041 for those receiving no depression treatment. The 
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mean monthly expenditures across all depression treatment categories decreased over time. For 
example, in the antidepressant only group, the mean expenditure reduced from $4,729 at the end 
of Month 1 to $2,497 at the end of Month 12; for the only psychotherapy  group the reduction 
from Month 1 to Month 12 was $6,172 to $2,621; for those with both antidepressant and 
psychotherapy treat the mean expenditures reduced from $5,473 (Month 1) to $2,327 (Month 12) 
and among those with no treatment the total healthcare expenditures reduced from $5291 (Month 
1)  to $2,689 (Month 12).  
T2DM-related Healthcare Expenditures: The mean total healthcare expenditures for 12 
months after diagnosis of depression were $13,642 for those treated with only antidepressants, 
$15,654 for those treated with only psychotherapy, $15,726 for those treated with both 
antidepressants and psychotherapy and $14,801 for those receiving no depression treatment. 
Similar to the reductions observed in total healthcare expenditures over each month, the 
reduction  in T2DM-related healthcare expenditures from Month 1 to Month 12 was $2,848 to 
$895 for only antidepressants, $3,419 to $1,013 for only psychotherapy , $3176 to $768 for those 
treated with both antidepressants and psychotherapy and $3,305 to $1,065 for those received no 
depression treatment. Whether the mean monthly expenditures  
The total and T2DM-related healthcare expenditures aggregated at ends of Months1-4, 
Months 5-8 and Months 7-12 are presented in Figure1.  
Mean Monthly Healthcare Expenditures for Depression Treatment Categories:  by Types of 
Coexisting Chronic Physical Conditions 
Total Healthcare Expenditures: Total healthcare expenditures reduced with in each 
subgroup of types of coexisting chronic physical conditions. 
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T2DM-related Healthcare Expenditures: Similarly, The T2DM-related healthcare 
expenditures also reduced with in each subgroup of types of coexisting chronic physical 
conditions.   
Total and T2DM-related healthcare expenditures aggregated at ends of Months1-4, 
Months 5-8 and Months 9-12 by each subgroup of types of coexisting chronic physical 
conditions are presented in Figure 2. 
Adjusted Association between Depression Treatment Categories during the Acute Phase and 
Healthcare Expenditures 
 Total Healthcare Expenditures: Linear mixed model regression analyses were 
conducted to examine the association between depression treatment categories and log 
transformed total and T2DM-related healthcare expenditures. In Model 1, which did not include 
the interaction term between depression treatment categories and types of coexisting chronic 
physical condition, it was found that, as compared to no treatment, all other types of treatment 
was associated with reduction in total healthcare expenditures. As compared to no depression 
treatment, depression treatment with only antidepressants was associated with 17% (beta: -0.18; 
SE: 0.04) reduction in total healthcare expenditures, treatment with only psychotherapy was 
associated with 22% (beta: -0.25; SE: 0.05) reduction in total healthcare expenditures and 
treatment with both antidepressants and psychotherapy was associated with 28% (beta: -0.33; 
SE: 0.06) reductions in total healthcare expenditures.  
 T2DM-related Healthcare Expenditures: Treatment with only antidepressants was not 
significantly associated with reduced log transformed T2DM-related expenditures as compared 
to no depression treatment. However, treatment with psychotherapy and both antidepressants and 
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psychotherapy was associated with 28% and 18% reduction in  T2DM-related expenditures as 
compared to no depression treatment.  
The results are presented in Table 3. 
Adjusted Association between Depression Treatment Categories during the Acute Phase and 
Healthcare Expenditures by Types of Coexisting Chronic Physical Conditions 
Total Healthcare Expenditures: Treatment with only antidepressants was associated 
with 21% (beta: -0.24; SE: 0.18) reductions in total healthcare expenditures among those with 
concordant conditions only and by 18% (beta: -0.20; SE: 0.09) among those with discordant 
conditions only. Depression treatment with only psychotherapy was associated with 48% (beta: -
0.65; SE: 0.12) reductions in total healthcare expenditures among those with dominant 
conditions and 21% (beta: -0.23; SE: 0.07) reductions in total healthcare expenditures among 
those with both concordant and discordant conditions. Treatment with both antidepressants and 
psychotherapy was associated with reductions in total healthcare expenditures among all types of 
coexisting chronic physical condition groups.     
T2DM-related Healthcare Expenditures: Associations with reduced T2DM-related 
healthcare expenditures were not observed with treatment by only antidepressants. Treatment 
with only psychotherapy was associated with 41% (beta:-0.53; SE: 0.14) reduction in T2DM-
related healthcare expenditures among those with dominant conditions and 34% (beta:-0.41; SE: 
10) reduction in T2DM-related healthcare expenditures among individuals with both concordant 
and discordant conditions. Treatment with both antidepressants and psychotherapy was 
associated with 27% (beta:-0.32; SE: 0.13) reduction in T2DM-related healthcare expenditures 
among those with concordant conditions only.  
Table 4 presents the beta-coefficients and standard errors 
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DISCUSSION 
 This study examined the association between depression treatment categories and total 
and T2DM-related healthcare expenditures and further assessed whether this association varied 
by types of coexisting chronic physical conditions among non-elderly Medicaid beneficiaries 
with T2DM and newly-diagnosed depression. Multiple unique significant findings were 
observed.  
Depression Treatment Categories during the Acute Phase and Healthcare Expenditures 
 In this study population, 43%, or 4 in 10 i.e individuals with T2DM and newly 
diagnosed depression did not receive any treatment for depression. 
  However, it was observed that as compared to not receiving treatment for 
depression, any modality of depression treatment reduced both total healthcare 
expenditures.  
 With regards to T2DM-related expenditures, the modality of depression treatment 
was important; treating depression with only antidepressants did not reduce 
T2DM-related healthcare expenditures. 
Total Healthcare Expenditures: The study findings indicate that treating depression is 
associated with a reductions in total healthcare expenditure. There are some plausible 
explanations for such an observed association between depression treatment and reduced 
healthcare expenditures. Randomized Clinical trials which have examined the association of 
depression treatment with pharmacotherapy i.e. antidepressants and/or psychotherapy have found 
that depression treatment with antidepressants reduced depressive symptoms among individuals 
with T2DM and depression [40-47] and depression treatment with psychotherapy such as 
cognitive behavioral therapy was also effective in reducing depression symptoms [48-50]. 
Therefore, treating depression may reduce healthcare expenditures by providing relief from 
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depressive symptoms by reducing mental-health related expenditures. Additionally, individuals 
with depression have been shown to have high utilizations of healthcare services [51, 52] and 
also there is evidence that coexisting depression worsens of other medical conditions by its 
adverse effect of medication adherence [53] and self-care regimens [54]. Treatment of 
depression may result in subsequent relief from symptoms and therefore, may result in reduced 
healthcare service utilizations, improved adherence of other chronic disease medications and 
better self-care, thereby, reducing healthcare expenditures.  
T2DM-related Healthcare Expenditures: An interesting finding was that, depression 
treatment with only antidepressants did not reduce T2DM-related healthcare expenditures. This 
finding can be explained by the fact that among individuals with T2DM and depression, clinical 
trials of depression treatment with only antidepressants did not provide conclusive evidence of 
better T2DM related outcomes such as glycemic control [55]. Furthermore, among adults with 
T2DM, depression treatment with antidepressants can increase cardiovascular morbidity and 
mortality [56, 57]. Therefore, among individuals with T2DM, treatment with antidepressants 
may not be a suitable option for reducing T2DM-related expenditures.  
However, depression treatments modalities which included which psychotherapy was a 
component of treatment was associated with reductions in T2DM-related healthcare 
expenditures. This finding is comparable to the limited evidence from previous research. For 
example, Lustman et al., showed that treatment of depression among 51 individuals with T2DM 
and depression, 10 weeks of cognitive behavioral therapy was not significantly associated with 
reduced glycated hemoglobin (A1C) levels in the intervention group at 6 month after follow-up 
(intervention vs control: 9.5% vs 10.9% ; P = 0.03). No study in real-world setting has examined 
the effects of treating depression with both antidepressants and psychotherapy. However, 
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evidence from randomized controlled trials of collaborative care which includes often depression 
treatment with antidepressants as well as psychotherapy (either initiated together or in a stepped 
care approach based on response to initial treatment) have shown significant reductions in A1C 
levels in intervention as compared to control group [58]. Such evidence, supports this study 
findings that treatment of depression with psychotherapy can reduce T2DM-related expenditures. 
Depression Treatment Categories during the Acute Phase and Healthcare Expenditures: By 
Types of Coexisting Chronic Physical Conditions 
 Across all types of co-existing conditions treatment for depression with 
combination therapy (i.e. antidepressants and psychotherapy) was associated with 
reduced total healthcare expenditures. 
 The relationships between other depression treatment categories and total 
healthcare expenditures varied by types of coexisting chronic physical conditions.   
 For some conditions treatment for depression with only antidepressants reduced 
total healthcare expenditures.  These were: concordant conditions only and 
discordant conditions only  
 For other conditions, treatment for depression with only psychotherapy reduced 
total healthcare expenditures:  these conditions were: dominant conditions and 
both concordant and discordant conditions.  
 The associations between depression treatment categories and T2DM-related 
expenditures varied by types of co-existing chronic conditions.   For some 
conditions psychotherapy reduced T2DM-related expenditures: these were 
dominant conditions and both concordant and discordant conditions; for 
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concordant only condition combined antidepressants and psychotherapy reduced 
T2DM-related expenditures.  
Taken together these findings highlight the importance of combined antidepressants and 
psychotherapy as the best alternative to reducing total healthcare expenditures among individuals 
with T2DM and newly diagnosed depression. Several studies, including multiple randomized 
clinical trials [59-61] and meta-analyses [62, 63] have shown that, among individuals with 
depression, combined treatment with both pharmacotherapy and psychotherapy significantly 
reduces depression symptoms and dropout rates. Treatment with both antidepressants and 
psychotherapy has also been found to found to have long term benefits in terms of preventing 
relapse [67] and increasing depression treatment adherence [68-70]. Therefore, by improving 
depression related outcomes, treatment with both antidepressants and psychotherapy may help to 
reduce total healthcare expenditures.  
However, if physicians or patients prefer treatment either with antidepressants or 
psychotherapy alone, then the choice of treatment need to be prioritized based on type of 
coexisting chronic physical condition. Depression treatment with only psychotherapy reduced 
total healthcare expenditures among those with high burden of coexisting conditions such as 
those with dominant conditions and also individuals with both concordant and discordant 
conditions; additionally, it also needs to be noted that, treatment with only psychotherapy also 
reduced T2DM-related healthcare expenditures among these individuals. Individuals with 
dominant and those with both concordant and discordant conditions may have higher disease 
burden and treating depression in such patients can be challenging. A previous study has shown 
that principles of certain types of psychotherapy, such as cognitive behavioral therapy may help 
in managing aspects of chronic physical conditions such as pain [64, 65]. Pain management is an 
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integral part of dominant conditions such as cancer and multiple sclerosis. Presence of both 
concordant and discordant conditions, for example, coexisting neuropathy and rheumatoid 
arthritis, may also result in exacerbated pain. Psychotherapy such as cognitive behavioral therapy 
has also been proven to be beneficial for management of pain [66, 67]. Treatment with 
psychotherapy, in such cases, may result in more holistic treatment and better outcomes as seen 
by reduced healthcare expenditures as compared to treatment with only antidepressants. 
Implications 
The study findings have significant health policy implications. In this study expenditures 
over a one year period were examined among Medicaid beneficiaries with newly-diagnosed 
depression. Therefore, this could be viewed as expenditures following a new episode of 
depression in a high risk group of Medicaid beneficiaries with T2DM and coexisting conditions. 
In general, the study results indicated that depression treatment is associated with reduced 
healthcare expenditures, however the association varies by types of coexisting chronic physical 
conditions. Such results have important implications in the context of new payment models such 
as the “bundled payment” where providers or facilities are paid a single payment for all services 
in relation to treating a condition or provide a treatment. The results of this study indicated the 
some types of depression treatment is no better than not treating depression at all, in terms of 
association with reduced healthcare expenditure. For example, depression treatment with only 
antidepressants in presence of dominant conditions is not associated with reduced healthcare 
expenditures. Therefore, among individuals with T2DM and coexisting dominant conditions, 
physicians may not want to initiate treatment for newly-diagnosed depression with 
antidepressants, under the bundled payment systems.  
The findings also have implications for improving quality of care initiatives such as 
Medicare Shared Savings Program (MSSP). The MSSP [68] use expenditure patterns of 
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Medicare beneficiaries in the past three years to set expenditures “benchmarks”, using risk 
adjustment models. These benchmarks are used to establish savings and share the cost-reduction 
with the CMS. [69] Although, the MSSP is specific to Medicare, many state Medicaid agencies 
are using the MSSP as one of the models for building their accountable care organization (ACO) 
programs. The study results have implications with regards to such “benchmarking” approaches. 
Response to depression treatment in terms of economic benefits varied by types of coexisting 
conditions present. Therefore, total healthcare expenditures among Medicaid beneficiaries with 
T2DM and newly-diagnosed depression and coexisting conditions may vary both by types of co-
existing conditions and types of depression treatment received. Therefore, while setting 
benchmarks for individuals with T2DM, newly-diagnosed depression and other coexisting 
chronic physical conditions, one will need to risk adjust for type of coexisting conditions and 
types of depression treatment categories. .     
The study findings further suggests that economic benefits of depression treatment may 
be more achievable in integrated care settings where physical and mental healthcare are 
delivered in tandem and treatment of depression is adjusted as per individual response. The 2010 
Patient Protection and Affordable Care Act aims to promote such integrated care through patient 
centered medical homes (PCMH). For managing treatment of mental health conditions such as 
depression, the PCMH model promotes coordinated care among primary care physicians, a 
mental healthcare specialist and a care manager [70]. As care is integrated, primary care 
physicians can monitor the overall health and can easily consult and refer with mental healthcare 
specialists and thus provide more holistic care to individuals with both depression and multiple 
coexisting chronic physical conditions [70]. As of 2013, 43 of 50 states of US had adopted 
policies to promote PCMH [71]. Therefore, in coming years, studies need to be conducted to 
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assess depression treatment patterns and associated long term expenditures among individuals 
with coexisting depression and multiple chronic physical conditions.  
Strengths and Limitations 
 There are several strengths of this study. Medicaid claims data from multiple years of 
three states were used in this study. There are several advantages to using such administrative 
data. A large cohort of patients could be efficiently followed for a long period of time across a 
variety of providers. The study included adults with T2DM, newly-diagnosed depression and 
coexisting chronic physical conditions, such populations with multiple conditions are often 
ignored in clinical trials of depression treatment. The economic consequences of depression 
treatment were observed in real world settings instead of the controlled environment of clinical 
trials. The use of a repeated measures design allowed for studying the association between 
depression treatments and healthcare expenditure over time, instead of aggregating expenditures 
at the end of follow-up. To the best of the authors‟ knowledge such a design has yet not been 
adopted by any other study in this area. Since the association between depression treatments and 
healthcare expenditures adjusted for inverse probability treatment weights, selection bias due to 
differences in observed characteristics in the depression treatment groups could be controlled in 
the analyses.  
However, the study has some limitations. As administrative claims data can only identify 
diseases through diagnosis codes, a limitation using such kind of data for studies with 
depression, is the potential for underestimating newly-diagnosed depression owing to 
undiagnosed depression and under-coding of depression. Identifying depression is one of the 
more difficult problems in administrative data research and perfection may not be attainable. 
However, the use of diagnoses codes that are recommended by HEDIS and extensively used by 
health plans in order to identify depression claims and the ability to identify  physician/ 
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psychologist diagnoses of depression offer a particularly attractive alternative to the substantial 
expenditure and complications associated with prospective surveys supplemented with medical 
record data. Additionally, T2DM and other coexisting chronic physical conditions were also 
identified using diagnosis codes in medical claims. Incomplete or erroneous records submitted 
by healthcare providers, limited clinical detail in the ICD-9-CM codes and inaccurate 
demographic information might limit the accuracy of administrative data. Perceived general and 
mental health status variables were not available due to nature of the dataset and thus could not 
be controlled for in the analyses. These variables may impact choice of depression treatment and 
expenditures. Duration of T2DM and coexisting chronic conditions may influence healthcare 
utilization and consequently expenditures, however as these variables were not available and 
were not adjusted for in regression analyses. The study included fee-for-service Medicaid 
beneficiaries enrolled in three states, thus results might not be generalizable to Medicaid 
population. Additionally, though differences in observed characteristics among depression 
treatment groups were controlled by using IPTW, there may be unobserved differences between 
the depression treatment groups which were not examined in this study.   
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CONCLUSION 
 Among non-elderly adults with T2DM and newly diagnosed depression, compared to no 
depression treatment, treating depression can produce cost-savings to Medicaid.  Treating 
depression with combined antidepressants and psychotherapy may be the best alternative to 
achieve consistent reduction in expenditures across all types of coexisting chronic physical 
conditions. For specific modalities of depression treatment (i.e. antidepressant only or 
psychotherapy only), cost-reductions will depend on the types of coexisting chronic physical 
conditions. 
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TABLES, FIGURES & APPENDICES 
Table 1: Description of the Study Population by Types of Coexisting Chronic Physical Conditions  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 - 2008 
    All Dominant 
Concordant 
Only 
Discordant 
Only 
Both 
Concordant 
& 
Discordant 
Sig 
    N % N % N % N % N %   
All 
 
5,295 
 
753 14.2 1,444 27.3 834 15.8 2,264 42.8 *** 
  
Predisposing Factors 
Age 
           
 
18-44 1,335 25.2 122 9.1 426 31.9 256 19.2 531 39.8 
 
 
45-54 1,921 36.3 277 14.4 457 23.8 317 16.5 870 45.3 
 
 
55-64 2,039 38.5 354 17.4 561 27.5 261 12.8 863 42.3 
 Sex 
           
*** 
 
Female 3,565 67.3 437 12.3 949 26.6 613 17.2 1,566 43.9 
 
 
Male 1,730 32.7 316 18.3 495 28.6 221 12.8 698 40.3 
 Race 
          
** 
 
Whites 1,420 26.8 203 14.3 369 26.0 251 17.7 597 42.0 
 
 
AA 1,596 30.1 240 15.0 396 24.8 250 15.7 710 44.5 
 
 
Others 2,279 43.0 310 13.6 679 29.8 333 14.6 957 42.0 
 
  
Need Factor 
Other Mental Health Conditions 
         
*** 
 
Yes 1,877 35.4 349 18.6 476 25.4 294 15.7 758 40.4 
 
 
No 3,418 64.6 404 11.8 968 28.3 540 15.8 1,506 44.1 
 
  
Enabling Factors 
Medicaid eligibility - Poverty 
         
** 
 
Yes 4,620 87.3 1,237 26.8 708 15.3 2,014 43.6 661 14.3 
 
 
No 675 12.7 207 30.7 126 18.7 250 37.0 92 13.6 
 Medicaid eligibility - Medical Need 
        
* 
 
Yes 638 12.0 181 28.4 108 16.9 238 37.3 111 17.4 
 
 
No 4,657 88.0 1,263 27.1 726 15.6 2,026 43.5 642 13.8 
 Medicaid eligibility - Waiver 
          
 
Yes 300 5.7 89 29.7 60 20.0 114 38.0 37 12.3 
 
 
No 4,995 94.3 1,355 27.1 774 15.5 2,150 43.0 716 14.3 
 
  
Personal Health Practices 
Oral Antidiabetic Drugs (OADs) 
        
*** 
 
1 1,508 28.5 171 11.3 422 28.0 272 18.0 643 42.6 
 
 
2 1,238 23.4 144 11.6 353 28.5 214 17.3 527 42.6 
 
 
3+  450 8.5 38 8.4 156 34.7 63 14.0 193 42.9 
 
 
None 2,099 39.6 400 19.1 513 24.4 285 13.6 901 42.9 
             
          (continued) 
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Table 1: Description of the Study Population by Types of Coexisting Chronic Physical Conditions  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 - 2008 
    All Dominant 
Concordant 
Only 
Discordant 
Only 
Both 
Concordant 
& 
Discordant 
Sig 
    N % N % N % N % N %   
Insulin Use 
          
*** 
 
Yes 1,827 34.5 277 15.2 512 28.0 148 8.1 890 48.7 
 
 
No 3,468 65.5 476 13.7 932 26.9 686 19.8 1,374 39.6 
 Polypharmacy 
          
*** 
 
Yes 1,915 36.2 293 15.3 345 18.0 295 15.4 982 51.3 
 
 
No 3,380 63.8 460 13.6 1,099 32.5 539 15.9 1,282 37.9 
 Inpatient Hospitalization 
         
*** 
 
Yes 2,604 49.2 534 20.5 532 20.4 232 8.9 1,306 50.2 
 
 
No 2,691 50.8 219 8.1 912 33.9 602 22.4 958 35.6 
 Outpatient Visits 
          
*** 
 
1st  Quartile 1,392 26.3 85 6.1 588 42.2 294 21.1 425 30.5 
 
 
2nd Quartile 1,221 23.1 139 11.4 352 28.8 215 17.6 515 42.2 
 
 
3rd Quartile 1,352 25.5 227 16.8 282 20.9 180 13.3 663 49.0 
 
 
4th Quartile 1,330 25.1 302 22.7 222 16.7 145 10.9 661 49.7 
 
  
Mean + SE Mean + SE Mean + SE Mean + SE Mean + SE 
 Number of T2DM-
related office visits 
6.93±0.13 7.98±0.29  6.51±0.29  5.44±0.21 7.40±0.19 
 
Number of ER Visits 
1.18±0.03 1.65±0.11  0.66±0.04 0.78±0.05 1.51±0.05 
 
  
External Environment 
State 
          
*** 
 
Illinois 1,502 28.4 211 14.0 379 25.2 256 17.0 656 43.7 
 
 
New York 2,550 48.2 402 15.8 725 28.4 405 15.9 1,018 39.9 
 
 
Texas 1,243 23.5 140 11.3 340 27.4 173 13.9 590 47.5 
 HPSA- Mental Health 
Care 
          
* 
 
Yes 4,405 83.2 651 14.8 1,209 27.4 679 15.4 1,866 42.4 
 
 
No 890 16.8 102 11.5 235 26.4 155 17.4 398 44.7 
 Metro 
          
** 
 
Yes 4,719 89.1 698 14.8 1,291 27.4 730 15.5 2,000 42.4 
 
 
No 576 10.9 55 9.5 153 26.6 104 18.1 264 45.8 
 CMHC 
           
 
Yes 2,590 48.9 376 14.5 702 27.1 393 15.2 1,119 43.2 
 
 
No 2,705 51.1 377 13.9 742 27.4 441 16.3 1,145 42.3 
             
          (continued) 
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Table 1: Description of the Study Population by Types of Coexisting Chronic Physical Conditions  
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression  
Multi-state Medicaid Claims Database – 2000 - 2008 
    All Dominant 
Concordant 
Only 
Discordant 
Only 
Both 
Concordant 
& 
Discordant 
Sig 
    N % N % N % N % N %   
           
FQHC 
          
** 
 
Yes 4,365 82.4 651 14.9 1,199 27.5 674 15.4 1,841 42.2 
 
 
No 930 17.6 102 11.0 245 26.3 160 17.2 423 45.5 
 Median Income 
          
** 
 
1st  Quartile 1,312 24.8 145 11.1 365 27.8 204 15.5 598 45.6 
 
 
2nd Quartile 1,415 26.7 199 14.1 378 26.7 246 17.4 592 41.8 
 
 
3rd Quartile 1,235 23.3 182 14.7 345 27.9 190 15.4 518 41.9 
 
 
4th Quartile 1,333 25.2 227 17.0 356 26.7 194 14.6 556 41.7 
 % with GT 4yr college 
education >  16%
ⱡ
 
          
** 
 
Yes 4,399 83.1 656 14.9 1,197 27.2 704 16.0 1,842 41.9 
 
 
No 896 16.9 97 10.8 247 27.6 130 14.5 422 47.1 
 % below poverty level 
GT 11.1%
ⱡⱡ
 
  
753 
 
1,444 
 
834 
 
2,264 
  
 
Yes 4,692 88.6 675 14.4 1,284 27.4 732 15.6 2,001 42.6 
 
 
No 603 11.4 78 12.9 160 26.5 102 16.9 263 43.6 
 
  
Mean + SE Mean + SE Mean + SE Mean + SE Mean + SE 
 
Density of Social 
Workers 
3.01±0.02 3.27±0.06 3.02±0.04 3.02±0.06 2.91±0.04 
                           
 
 Note: Study sample comprised of adults with type 2 diabetes mellitus aged 18-64 years and with at least one 
coexisting dominant, concordant, discordant chronic physical condition and who were alive, not dually eligible for 
Medicare and continuously enrolled in fee-for-service Medicaid for at least 24 months( N=5,295); includes 
Medicaid data from three states: Illinois, Texas, New York 
Asterisks(*) represent significant differences in study population characteristics and  coexisting chronic physical 
conditions categories i.e. Dominant, Concordant Only, Discordant Only and Both Concordant and Discordant, 
derived from chi-square statistics  
***P ≤ .001; **.001 ≤ P < .01; *.01 ≤ P < .05. 
ⱡ 16% Cut off was chosen based on 2000 Census Education attainment results 
ⱡⱡ 11.1% Cut off was chosen based on 1999 Census Poverty in 18-64 year results  
 
HPSA: health professional shortage area; CMHC: Community Mental Health Clinic; FQHC: Federally qualified 
health clinic; GT: Greater Than 
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Table 2: IPTW Adjusted Association Between Depression Treatment and Healthcare Expenditures, 
Among Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression 
Multi-state Medicaid Claims Database – 2000 – 2008 (Reference Group : No Depression Treatment) 
  ALL Expenditures 
T2DM-Related  
Expenditures 
Depression 
Treatment 
Beta SE Sig 
 
Beta 
 
SE 
Sig 
Only antidepressants -0.18 0.04 *** -0.10 0.05 
 Only psychotherapy  -0.25 0.05 *** -0.33 0.06 *** 
Antidepressants and 
Psychotherapy  -0.33 0.06 *** -0.20 0.07 ** 
       
 
Model adjusted for Random effects: Random Intercept; Fixed Effects: Time in months , Depression Treatment , 
Predisposing (gender, age, race/ethnicity), Need Factors (other mental health conditions, Types of Co-existing 
Chronic Physical Conditions), Enabling Factors (Medicaid Eligibility -Poverty, Medical Need, Waiver), Personal 
health practices (number of ER and  outpatient visits, inpatient hospitalization, number of OAD classes, insulin use 
and polypharmacy, total baseline healthcare expenditures), External environment characteristics: (whether county 
of residence had a CMHC, FQHC, was HPSA for mental health, density of social workers rural/urban status of 
county, median income in the county, whether percent below poverty level and percent with college education 
greater than national average), Other variables: Antidepressant treatment during each month of follow-up, 
Psychotherapy treatment during each month of follow-up and  
All Healthcare expenditures included Inpatient, Outpatient and Prescription Drug Related Expenditures; T2DM 
Related Expenditures included Inpatient and Outpatient Expenditures due to T2DM-related diagnosis. The 
expenditures were log transformed 
Asterisks indicate statistical significance and are based on mixed effects models; none i.e. no antidepressant 
treatment i.e. none as reference group for dependent variable. ***P <.001; **.001 ≤ P < .01; *.01 ≤ P < .05. 
T2DM: Type 2 Diabetes Mellitus; depression: Major Depressive Disorder; IPTW: Inverse Probability Treatment 
Weights; SE: Standard Error 
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Table 3: IPTW Adjusted Association Between Depression Treatment and Healthcare 
Expenditures Stratified by Types of Coexisting Conditions  among  Medicaid Beneficiaries with 
Type 2 Diabetes Mellitus and Newly-diagnosed Depression, Multi-state Medicaid Claims 
Database – 2000 – 2008, (Reference Group : No Depression Treatment) 
  ALL Expenditures T2DM Related Expenditures 
Depression Treatment 
Categories 
 
Beta 
 
SE Sig 
 
Beta 
 
 
SE  
 
Sig 
 
Dominant 
Only antidepressants -0.26 0.14 
 
-0.26 0.16 
 Only psychotherapy  -0.65 0.12 *** -0.53 0.14 *** 
Antidepressants and 
Psychotherapy  -0.53 0.16 ** -0.28 0.19 
 
 
Concordant Only 
Only antidepressants -0.24 0.08 ** -0.05 0.10 
 Only psychotherapy  -0.12 0.09 
 
-0.21 0.12 
 Antidepressants and 
Psychotherapy  -0.26 0.11 * -0.32 0.13 * 
 
Discordant Only 
Only antidepressants -0.20 0.09 * -0.09 0.11 
 Only psychotherapy  -0.09 0.13 
 
-0.11 0.15 
 Antidepressants and 
Psychotherapy -0.34 0.13 * -0.11 0.16 
 
 
Both Concordant & Discordant 
Only antidepressants -0.11 0.06 
 
-0.10 0.08 
 Only psychotherapy  -0.23 0.07 *** -0.41 0.10 *** 
Antidepressants and 
Psychotherapy -0.32 0.08 *** -0.10 0.12 
        
 
Note: Model adjusted for Random effects: Random Intercept; Fixed Effects: Adjusted for: Time in months, 
Depression Treatment , Predisposing (gender, age, race/ethnicity), Need Factors (other mental health conditions, 
Types of Co-existing Chronic Physical Conditions), Enabling Factors (Medicaid Eligibility -Poverty, Medical 
Need, Waiver), Personal health practices (number of ER and  outpatient visits, inpatient hospitalization, number of 
OAD classes, insulin use and polypharmacy), External environment characteristics: (whether county of residence 
had a CMHC, FQHC, was HPSA for mental health, density of social workers rural/urban status of county, median 
income in the county, whether percent below poverty level and percent with college education greater than national 
average), Other variables: Antidepressant treatment at each month of follow-up, Psychotherapy treatment at each 
month of follow-up and Year of observation  
All Healthcare Expenditures included Inpatient, Outpatient and Prescription Drug Related Expenditures; T2DM 
Related Expenditures included Inpatient and Outpatient Expenditures due to T2DM-related diagnosis. The 
expenditures were log transformed 
 
Asterisks indicate statistical significance and are based on mixed effects models; ***P < .001; **.001 ≤ P < .01; 
*.01 ≤ P < .05. 
T2DM: Type 2 Diabetes Mellitus; depression: Major Depressive Disorder; IPTW: Inverse Probability Treatment 
Weights; SE: Standard Error 
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Figure 1: Mean IPTW adjusted Total and T2DM-Related Healthcare Expenditures during Follow-up for Medicaid Beneficiaries with 
T2DM and Newly-Diagnosed Depression 
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Figure 2: Mean IPTW adjusted Total and T2DM-Related Healthcare Expenditures during Follow-up for Medicaid Beneficiaries with 
T2DM and Newly-Diagnosed Depression: By Types of Coexisting Chronic Physical Conditions 
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Appendix A : ICD-9-CM Codes for Identifying  Types of Coexisting chronic physical Conditions 
Conditions ICD-9-CM Codes 
Concordant conditions 
 
 
Coronary Artery Disease 410,4100,4101,4102,4103,4104,4105,4106,4107,4108,4109,411,4110,
4111,4118,41181,41189,412,413,4130,4131,4139,414,4140,41400,414
01,41402,41403,41404,41405, 4141,41410,41411, 41419,4148,4149 
 
Congestive Heart Failure 40201,40211,40291,40401,40411,40491,428,4280,4281,4289 
 
Arrhythmia 423,4230,4231,4232,4238,4239,42731 
 
Stroke 431,43301,43311,43321,43331,43381,43391,43401,43411,43491,435,
4350,4351,4352,4353,4358,4359,438,4380,4381,43811,43812,4382,43
83,4384,4385,43850,4385,43852,43853,4388,43881, 
43882,43889,4389 
 
Peripheral Vascular Disease 2507,4402,44020,44021,44022,44023,44024,44029,4408,4409,4422,4
423,443,4430, 4431,4438,44381, 44389,4439,44422,44481 
 
Peripheral Vascular Disease-gangrene 7854 
 
Renal  
Chronic Renal Failure 
Chronic Pathophysiology 
40311,40391,40412,40413,40492,40493, 585,586,587, 
2741,27410,27411,27419, 
40310,40390,40410,40411,40490,40491, 
581,5810,5811,5812,5813,5818,5819, 
582,5820,5821,5822,5824,5828,58281,58289,5829,583,5830,5831,583
2,5834,5836, 
5837, 5838,58381,58389,5839,  5900,59000,59001,5936,5939, 
75312,75313,75314 
 
Diabetic Nephropathy 2504,25040,25041,25042,25043 
 
Acute Renal Failure and Disease 
 
40300,40301,40400,40401,40402,40403,40501,4533,584,5845,5846,5
847,5848,5849, 
580,5800,5804,5808,58081,58089,5809,5901,59010,59011,5902,5903,
5908,59080, 
59081,59381,866,8660,86600,86601,86602,86603,8661,86610,86611,
86612,86613 
 
Retinopathy 
(excludes advanced retinopathy, blindness) 
3620,36201,25050,25051,25052,25053 
 
Ulcer 700,68110,68111,6827,7071,73076,73077 
 
Other Diabetes Related Complications 
Uncontrolled Diabetes 
Short Term Diabetes 
25002,25003,25010,25011,25012,25013,25020,25021,25022,25023,25
030,25031, 
25032,25033 
Discordant Conditions  
 
Gastro Intestinal Tract Related Disorders: 
GERD/Esophagitis 
Peptic ulcers 
Inflammatory Bowel Disease 
Diverticulitis 
Gall Bladder disease and stone 
Viral hepatitis 
5301,5302,5303,53081,531,532,533,534,555,556,56211,56213,574 
575,576,070 
 
Chronic Obstructive Pulmonary Disease 490,491,492,493,495,496,500,501,502,503,504,505,5064  
 
Gout 274,712 
 
Hip problem 71905,71915,71925,71935,71945,71955,71965,71975,71985,71995,72
65,73314,73315,73342,820 
 
Low back pain 720,7213,72142,72210,72252,72273,72283, 
72293,72402,7242,7243,7244,7245,7246,7247,7248,7249 
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Appendix A : ICD-9-CM Codes for Identifying  Types of Coexisting chronic physical Conditions 
Conditions ICD-9-CM Codes 
 
Osteoarthritis  715 
 
Other Arthritis 716 
 
Rheumatoid arthritis  714 
 
Connective tissue rheumatological disease 7100,7101,7104,725 
 Blindness Single Eye 3696,3697,3698,3699 
Dominant Conditions  
 
End Stage Renal Disease E8791,V51,V56,V560,V5631,V5632,V568 
 
End Stage Liver Disease 5722,5723,5724,5728,4560,4561, 4562,45620,45621, 571 
 
Blindness Both Eyes/ Advanced Retinopathy 36202,3690,3691,3692,3693,3694 
 
Cancer 140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,1
56,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,17
2,174,175,176,177,178,179,180,181,182,183,184,186,187,188,189,190
,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,
207,208 
 
Pre-dementia Cognitive Impairment 294 ,2941, 29283, 2949 ,33183,78093,438,3330,3334,3315 
 
Dementia and Related Conditions 2900,29010,29011,29012,29013,2902,29021,2903,29040,29041,29042
,29043,2912, 
29410,29411,2948,3310,3311,3312,3317,33182,33189,3319,3320,046
1,0463,0941, 
29282,3109 
 
Multiple Sclerosis  340 
 
Hemiplegia Hemiparesis and Paraplegia 342,3441 
 
Parkinson‟s Disease  332 
 
Muscular dystrophy 359 
 
Spinal cord injury 80600,80601,80602,80603,80604,80605,80606,80607,80608,80609,80
61, 9520, 
 34400,34401,34402,34403,34404,34409 
 
Epilepsy 345 
 
Gastropareis  5363 
 
AIDS 042 
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Appendix B: Secondary Analysis 
 
Adequate depression Treatment during the acute phase: Among those who received depression treatment either 
with antidepressant or psychotherapy, adequate depression treatment was classified as: (1) Received Adequate 
Treatment with Antidepressants or Psychotherapy: Based on HEDIS definition adequate antidepressant treatment 
was defined as receiving 84 or more days of prescription for any antidepressant drug during the first 120 days 
following the index date of depression diagnosis [1, 2]. Those who received 8 or more sessions of psychotherapy 
office visits (the minimum length of evidence based psychotherapy treatment for depression and anxiety disorders) 
[3, 4] during the 120 days of acute phase treatment were considered as having Adequate treatment with 
psychotherapy. Those who received adequate treatment either with antidepressants or psychotherapy were 
considered as having received adequate treatment during the acute phase (2) Not Adequate depression Treatment: 
Individuals who did not receive adequate treatment either with antidepressants or psychotherapy were considered as 
not being adequately treated.  
 
Unadjusted Association between Types of Coexisting Chronic Physical Conditions and Adequate Depression 
Treatment: Over-all, 56.78% (N=3,007) of the study population received depression treatment with antidepressants 
and/or psychotherapy. Of these individuals 32.46% received adequate depression treatment; 32.2% of those with 
dominant conditions (N=451), 34.1% of those with concordant conditions (N=804), 31.7% of those discordant 
conditions (N=479) and 31.8% of those with both discordant and concordant conditions (N=1,273) received 
adequate depression treatment. Results of chi-square analysis showed that the association between types of 
coexisting chronic physical conditions and adequate depression treatment was not statistically significant. These 
results are not presented in tabular form 
 
Adjusted Association between Types of Adequate Depression Treatment and Expenditures: The linear mixed 
model regression analysis results showed that adequate depression treatment was not associated with total healthcare 
expenditures. As compared to bot adequate depression treatment, adequate depression treatment was not 
significantly associated with log transformed T2DM-related healthcare expenditures (beta coefficient: 0.27, standard 
error: 0.07; p-value <0.0001) Model 1, which did not control for interaction between adequate depression treatment 
and types of coexisting chronic physical conditions; however the significance disappeared after controlling for the 
interaction term suggesting that the association between adequate depression treatment and T2DM-related 
expenditures differed by types of coexisting chronic physical conditions.  
 
Adjusted Association between Types of Adequate Depression Treatment And Expenditures: By Coexisting 
Chronic Physical Conditions: When separate linear mixed model regressions where conducted among each 
subgroup of types of coexisting chronic physical conditions, no statistically significant association was observed 
between adequate depression treatment and log transformed total healthcare expenditures.  
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Appendix C: IPTW Adjusted Linear Mixed Model Regression on Healthcare Expenditures, Among 
Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression 
Multi-state Medicaid Claims Database – 2000 – 2008 
    
Total Healthcare 
Expenditure 
T2DM-Related Healthcare 
Expenditure 
    Beta 
Standard  
Error 
Sig Beta 
Standard  
Error 
Sig 
Time in Months -0.06 0.00 *** -0.08 0.00 *** 
Depression Treatment 
       Only antidepressants -0.18 0.04 *** -0.10 0.05 
  Only psychotherapy   -0.25 0.05 *** -0.33 0.06 *** 
 Both Antidepressants and Psychotherapy -0.33 0.06 *** -0.20 0.07 ** 
 No Treatment 
   
0.00 
  Each Month Antidepressant Treatment  
       Yes 0.77 0.02 *** 0.31 0.04 *** 
 No 0.00 
  
0.00 
  Each Month Psychotherapy Treatment  
       Yes 0.80 0.03 *** 0.71 0.05 *** 
 No 0.00 
  
0.00 
  Types of Coexisting Chronic Physical Conditions 
     
 
Concordant Only -0.01 0.05 
 
0.17 0.07 * 
 
Both Concordant & Discordant 0.01 0.05 
 
0.23 0.06 *** 
 
Dominant -0.11 0.06 
 
0.03 0.08 
 
 
Discordant Only 0.00 
  
0.00 
  Age 
       18-44 years 0.18 0.04 *** 0.07 0.05 
   45-54 years 0.13 0.04 ** 0.12 0.06 * 
 55-64 years 0.00 
  
0.00 
  Female 
       Female -0.04 0.04 
 
-0.06 0.05 
  Male 0.00 
  
0.00 
  Race 
       White   0.03 0.05 
 
-0.10 0.06 
  African American 0.01 0.04 
 
0.04 0.05 
  Others  0.00 
  
0.00 
  State 
       Illinois -0.05 0.06 
 
-0.18 0.08 * 
 New York 0.26 0.07 *** 0.31 0.09 *** 
 Texas 0.00 
  
0.00 
  Other Mental Health Conditions 
       Yes 0.19 0.04 *** 0.09 0.05 * 
 No 0.00 
  
0.00 
         
     (continued) 
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Appendix C: IPTW Adjusted Linear Mixed Model Regression on Healthcare Expenditures, Among 
Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression 
Multi-state Medicaid Claims Database – 2000 – 2008 
    
Total Healthcare 
Expenditure 
T2DM-Related Healthcare 
Expenditure 
    Beta 
Standard  
Error 
Sig Beta 
Standard  
Error 
Sig 
Medicaid Eligibility-Poverty 
       Yes  -0.16 0.07 * -0.09 0.09 
  No 0.00 
  
0.00 
  Medicaid Eligibility-Medical Needs 
       Yes  0.31 0.06 *** 0.06 0.08 
  No 0.00 
  
0.00 
  Medicaid Eligibility-Waiver 
       Yes  -0.05 0.09 
 
-0.05 0.11 
  No 0.00 
  
0.00 
  Oral Antidiabetic Drugs (OADs) 
       1 OAD 0.08 0.04 
 
0.06 0.06 
  2 OAD 0.18 0.06 ** 0.14 0.08 
  3 OAD -0.20 0.04 *** -0.12 0.05 * 
 No OAD 0.00 
  
0.00 
  Insulin Use 
       Yes 0.27 0.04 *** 0.60 0.05 *** 
 No 0.00 
  
0.00 
  Polypharmacy 
       Yes 0.47 0.04 *** -0.03 0.05 
  No 0.00 
  
0.00 
  Inpatient Hospitalization 
       Yes -0.10 0.04 * 0.23 0.05 *** 
 No 0.00 
  
0.00 
  Outpatient Visits 
       1 st Quartile 0.47 0.05 *** 0.11 0.06 
  2nd Quartile 0.85 0.05 *** 0.31 0.06 *** 
 3rd Quartile 1.20 0.06 *** 0.32 0.07 *** 
 4th Quartile 0.00 
  
0.00 
  Number of T2DM Related Office Visits 0.00 0.00 
 
0.06 0.00 *** 
Number of ER Visits 0.02 0.01 * 0.09 0.01 *** 
HPSA-Mental Health 
       Yes 0.01 0.06 
 
0.22 0.07 ** 
 No 0.00 
  
0.00 
         
     (continued) 
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Appendix C: IPTW Adjusted Linear Mixed Model Regression on Healthcare Expenditures, Among 
Medicaid Beneficiaries with Type 2 Diabetes Mellitus and Newly-diagnosed Depression 
Multi-state Medicaid Claims Database – 2000 – 2008 
    
Total Healthcare 
Expenditure 
T2DM-Related Healthcare 
Expenditure 
    Beta 
Standard  
Error 
Sig Beta 
Standard  
Error 
Sig 
Metro 
       Yes -0.05 0.08 
 
-0.03 0.10 
  No 0.00 
  
0.00 
  CMHC 
       Yes -0.07 0.04 
 
0.08 0.06 
  No 0.00 
  
0.00 
  FQHC 
     
*** 
 Yes 0.06 0.06 
 
0.27 0.07 
  No 0.00 
  
0.00 
  Density Social Workers 0.03 0.02 
 
0.06 0.03 * 
Median Household Income 
       1st Quartile -0.21 0.08 * 0.05 0.11 
  2nd Quartile -0.18 0.06 ** -0.17 0.08 * 
 3rd Quartile -0.11 0.06 
 
-0.06 0.08 
  4th Quartile 0.00 
  
0.00 
  % with GT 4yr college education >  16%ⱡ 
       Yes -0.13 0.06 * -0.40 0.08 *** 
 No 0.00 
  
0.00 
  
% below poverty level GT 11.1%
ⱡⱡ
 
       Yes -0.09 0.07 
 
-0.28 0.10 ** 
 No 0.00 
  
0.00 
  Baseline total healthcare expenditure 0.00 0.00 *** 0.00 0.00 *** 
 Year 
      
 
2000-2002 0.16 0.08 * 0.53 0.10 *** 
 
2001-2003 0.25 0.08 ** 0.61 0.10 *** 
 
2002-2004 0.23 0.08 ** 0.57 0.10 *** 
 
2003-2005 0.16 0.07 * 0.45 0.10 *** 
 
2004-2006 0.14 0.07 * 0.25 0.09 ** 
 
2005-2007 0.18 0.07 ** 0.26 0.09 ** 
 
2006-2008 0.00 
  
0.00 
                  
Note: Asterisks indicate statistical significance and are based on mixed effects models; none i.e. no antidepressant 
treatment i.e. none as reference group for dependent variable. ***P < .001; **.001 ≤ P < .01; *.01 ≤ P < .05. 
Ɨ 
Both: Both Antidepressants and Psychotherapy;
 ƗƗ
 None: Neither antidepressants nor Psychotherapy; SE: Standard 
Error 
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CHAPTER 5 
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CHAPTER 5: SUMMARY AND CONCLUSIONS 
Study Summary 
The relationship between types of physical conditions and risk of depression is poorly 
understood. It is plausible that adults with T2DM and coexisting chronic physical conditions 
with similar disease management strategies may be at a lower risk for developing depression 
compared to those with coexisting chronic physical conditions that may require contradicting 
clinical and self-management strategies. As a majority of individuals with T2DM live with 
multiple other coexisting physical conditions, it is essential to examine whether individuals with 
particular types of coexisting physical conditions are at higher risk of developing depression as 
compared to other groups. In aim 1 of this dissertation, the association of risk of newly-
diagnosed depression with types of coexisting physical conditions among adults with T2DM was 
examined. 
Types of coexisting physical conditions were identified based on forty four different 
physical conditions commonly co-occurring among individuals with T2DM. These conditions 
were identified as dominant (life threatening severe conditions whose management takes priority 
over all other coexisting conditions) conditions, concordant (conditions with management or 
pathophysiology similar to that of T2DM) and discordant (conditions with management or 
pathophysiology different from that of T2DM). The types of coexisting physical conditions were 
classified following a hierarchy.  Dominant conditions were first identified.  Among those 
without dominant conditions concordant and discordant conditions were grouped. The final 
classification consisted of: 1) dominant 2) concordant only 3) discordant only and 4) both 
concordant and discordant conditions.  
Depression treatment among adults with T2DM is challenging. Randomized clinical trials 
have proven that treating depressions helps in relieving depressive symptoms; however, the 
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effect of treating depression on T2DM outcomes is not clear [1-5].  In addition, antidepressants 
(one of the main modalities of depression treatment) have been shown to increase the risks of 
cardiovascular morbidity and mortality [6, 7]. As many adults with T2DM also have coexisting 
cardiovascular diseases, physicians may be cautious in prescribing antidepressant treatment for 
adults with T2DM and coexisting chronic physical conditions such as hypertension and heart 
disease. While there have been studies on depression treatment using collaborative care models, 
there real-world practices of managing depression among adults with T2DM is not known.  
Therefore, in aim 2 of this dissertation the association between types of coexisting chronic 
physical conditions and depression treatment among adults with T2DM and newly-diagnosed 
depression was analyzed. 
 The economic benefits of treating depression among adults with T2DM  have not been 
studied widely. While randomized controlled trials have demonstrated that depression treatment 
delivered in collaborative care settings reduced expenditures among individuals with T2DM and 
coexisting depression, studies not specific to T2DM population and conducted using real world 
observational data have reported inconsistent findings. Therefore, it remains to be established 
whether depression treatment with antidepressants and psychotherapy, alone or in combination, 
are associated with reductions in healthcare expenditures, among individuals with T2DM. 
Therefore, in aim 3 of this study, whether the relationship between depression treatment and total 
and type 2 diabetes mellitus (T2DM) -related healthcare care expenditures vary by types of 
coexisting chronic physical conditions among non-elderly adult Medicaid beneficiaries with 
T2DM and newly-diagnosed depression was examined. 
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Summary of Findings 
One in ten Medicaid beneficiaries with T2DM developed depression. The risk of 
developing depression among those with T2DM varied by types of coexisting conditions; 
Medicaid beneficiaries with T2DM and dominant conditions and those with both concordant and 
discordant conditions were at higher risk of developing newly-diagnosed depression. Four in ten 
individuals in the study population did not receive any treatment for newly-diagnosed 
depression. Individuals with coexisting chronic physical conditions with dominant conditions 
were less likely to receive depression treatment with antidepressants. However, among non-
elderly adults with T2DM and newly-diagnosed depression, compared to no depression 
treatment, treating depression produced cost-savings to Medicaid. The results indicated that 
treating depression with combined antidepressants and psychotherapy may be the best alternative 
to achieve consistent reduction in expenditures across all types of coexisting chronic physical 
conditions. For specific modalities of depression treatment cost-reductions would depend on the 
types of coexisting chronic physical conditions.  
Clinical and policy implications of the findings 
The study findings suggest that to reduce this increased risk of newly-diagnosed 
depression, those with dominant conditions and combinations of concordant and discordant 
conditions need to be under constant surveillance. However, in order for surveillance to be 
effective, in case such individuals get diagnosed with depression, appropriate treatment and 
follow-up must be provided. Future research may examine specific dominant conditions and 
combinations of concordant and discordant conditions that may result in high risk of newly 
diagnosed depression among adults with T2DM. 
The low depression treatment rates observed in this study population may suggest that 
physicians are prioritizing treatment of other coexisting conditions in this study population. 
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Individuals with both physical (i.e. T2DM, coexisting chronic physical conditions) and mental 
health (i.e. depression) often have complex health care needs which may not be fully met in 
traditionally short (often channeled in to 15 minute time slots) primary care visits [8]. Integrating 
physical and mental healthcare with carefully selected teams having backgrounds in both 
physical and mental health care delivery may improve quality of depression treatment among 
such individuals The novel healthcare delivery models such as Accountable Care Organizations 
(ACO) and Patient Centered Medical Home (PCMH) created under the 2010 Patient Protection 
and Affordable Care Act, provide options for such integrated care models. 
The study results indicated that depression treatment is associated with reduced 
healthcare expenditures; however the association varies by types of coexisting chronic physical 
conditions. Such findings have important implications with respect to new payment models for 
healthcare services such as “bundled payment” and “expenditure benchmarking”. Under bundled 
payment systems, where only a certain amount of prospective payment is made for episodes of 
care provided for a condition, while treating depression individuals with T2DM and other 
coexisting conditions,  physicians may want to refrain from initiating depression treatment types 
which were no better associated with reduced healthcare expenditures as compared to not 
providing depression treatment all. While setting expenditure benchmarks for individuals with 
T2DM, newly-diagnosed depression and other coexisting chronic physical conditions, one will 
need to risk adjust for type of coexisting conditions and types of depression treatment categories. 
Unique contribution of the study 
(1) Filled a critical knowledge gap: This study provided evidence on the extent to which 
different types of depression treatments are economically beneficial, in the presence of T2DM 
and multiple coexisting chronic physical conditions (2) Use of Medicaid Claims data, feasibility 
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of identifying treatments, longitudinal design: The use of administrative claims data with dates of 
services made it possible to follow a cohort of patients with T2DM over time and to capture the 
healthcare experiences of Medicaid beneficiaries across a variety of providers. The study used a 
comprehensive list of independent variables by merging Medicaid claims data with the county-
level data from the AHRF. (3) Use of framework to identify coexisting chronic physical 
conditions: A pragmatic practice-based theoretical framework was used to identify the numerous 
coexisting chronic physical conditions into manageable and clinically meaningful categories. (4) 
Real-world experience: This study was more in line with real world experiences of the patients, 
the effectiveness of depression treatments were examined among individuals with multiple 
coexisting chronic physical conditions, a population often not included in clinical trials [9].  
Limitations 
As administrative claims data can only identify diseases through diagnosis codes, there is 
the potential for underestimating depression prevalence or incidence because of under-coding of 
depression. Identifying depression is one of the more difficult problems in administrative data 
research and perfection may not be attainable. However, claims data contain physician/ 
psychologist diagnoses of depression and offer a particularly attractive alternative to the 
substantial cost and complications associated with prospective surveys supplemented with 
medical record data. Additionally, this study included only filled prescriptions and it is not 
known whether the antidepressants were actually used. This study did not include alternative 
forms of treatment for depression. The study included fee-for-service Medicaid beneficiaries 
enrolled three states, thus results might not be generalizable to other populations. 
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